drug,phenotype,p_value,bio_geo_group,variant,data_source
efavirenz,Metabolism/PK,P value  0.0001,Multiple groups,CYP2B6*1,research
efavirenz,Metabolism/PK,P value  0.0001,Multiple groups,CYP2B6*18,research
ivacaftor,Efficacy,P value  0.009,Unknown,rs113993960,research
codeine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
codeine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*4,research
fentanyl,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1,research
fentanyl,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1G,research
methadone,Metabolism/PK,P value  0.002,European,CYP2D6*1,research
methadone,Metabolism/PK,P value  0.002,European,CYP2D6*2,research
methadone,Metabolism/PK,P value  0.002,European,CYP2D6*2xN,research
phenytoin,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
phenytoin,Metabolism/PK,P value  0.01,East Asian,CYP2C9*3,research
atorvastatin,Metabolism/PK,P value  2.21e-6,European,rs4149056,research
atorvastatin,Metabolism/PK,P value  7.25e-16,European,rs887829,research
atorvastatin,Metabolism/PK,P value  6.18e-7,European,rs45446698,research
metronidazole,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic, Black and Middle-Eastern particicpants",CYP2A6*1A,research
metronidazole,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic, Black and Middle-Eastern particicpants",CYP2A6*2,research
metronidazole,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic, Black and Middle-Eastern particicpants",CYP2A6*9,research
metronidazole,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic, Black and Middle-Eastern particicpants",CYP2A6*17,research
aripiprazole,Metabolism/PK,P value  0.000,East Asian,rs1058164,research
aripiprazole,Metabolism/PK,P value  0.000,East Asian,rs28371699,research
aripiprazole,Metabolism/PK,P value  0.000,East Asian,CYP2D6 intermediate metabolizer,research
aripiprazole,Metabolism/PK,P value  0.000,East Asian,rs1135840,research
aripiprazole,Metabolism/PK,P value  0.000,East Asian,rs28371702,research
olanzapine,Metabolism/PK,P value  0.004,"Multiple groups, '36 Caucasians, 42 Latin-Americans and 2 Blacks'",rs34059508,research
olanzapine,Metabolism/PK,P value  0.007,"Multiple groups, '36 Caucasians, 42 Latin-Americans and 2 Blacks'",rs34059508,research
tramadol,Efficacy,P value  0.01,Unknown,CYP2D6 poor metabolizer phenotype,research
irinotecan,Dosage,P value  0.01,East Asian,UGT1A1*1,research
irinotecan,Dosage,P value  0.01,East Asian,UGT1A1*28,research
bilirubin,Metabolism/PK,P value  0.0048,East Asian,rs4124874,research
allopurinol,Efficacy,P value  0.00024,Unknown,rs2231142,research
allopurinol,Efficacy,P value  0.00073,Unknown,rs2231142,research
allopurinol,Efficacy,P value  0.001,Unknown,rs2231142,research
peginterferon alfa-2b,Efficacy,P value  7.06E-8,Multiple groups,rs8099917,research
peginterferon alfa-2b,Efficacy,P value  9.39e-4,Multiple groups,rs8099917,research
methadone,Metabolism/PK,P value  0.001,"Multiple groups, 84 participants were white.",CYP3A low activity,research
telmisartan,Metabolism/PK,P value  3.83e-22,European,UGT1A3*1,research
telmisartan,Metabolism/PK,P value  3.83e-22,European,UGT1A3*2,research
bilirubin,Other,P value  3.0E-4,Multiple groups,UGT1A1*1,research
bilirubin,Other,P value  3.0E-4,Multiple groups,UGT1A1*28,research
acetaminophen,Efficacy,P value  0.001,East Asian,rs1799971,research
SN-38,Metabolism/PK,P value  0.001,Multiple groups,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.001,Multiple groups,UGT1A1*28,research
salmeterol,Efficacy,P value  0.003,Unknown,rs1042713,research
varenicline,Efficacy,P value  0.0014,African American/Afro-Caribbean,rs16969968,research
buprenorphine,Dosage,P value  0.004,European,rs1045642,research
buprenorphine,Dosage,P value  0.007,European,rs1045642,research
SN-38,Metabolism/PK,P value  1.9E-4,Unknown,UGT1A1*1,research
SN-38,Metabolism/PK,P value  1.9E-4,Unknown,UGT1A1*28,research
efavirenz,Metabolism/PK,P value  0.01,East Asian,rs2279343,research
efavirenz,Metabolism/PK,P value  0.001,Unknown,rs2279343,research
opioids,Dosage,P value  0.008,Unknown,rs6517442,research
sufentanil,Dosage,P value  0.01,Unknown,rs1799971,research
simvastatin acid,Metabolism/PK,P value  0.0001,East Asian,rs4149056,research
atorvastatin,Metabolism/PK,P value  0.004,American,rs4149056,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*6,research
methadone,Dosage,P value  0.0001,Unknown,rs806368,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*7,research
methadone,Dosage,P value  0.0035,Unknown,rs16974799,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Black (n=12), White (n=81), South Asian (n=20), Other (n=5)",CYP3A5*1,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Black (n=12), White (n=81), South Asian (n=20), Other (n=5)",CYP3A5*3,research
tacrolimus,Dosage,P value  0.003,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*1,research
tacrolimus,Dosage,P value  0.003,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*3,research
tacrolimus,Dosage,P value  0.004,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*1,research
tacrolimus,Dosage,P value  0.004,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*3,research
tacrolimus,Dosage,P value  0.0005,"Multiple groups, Predominantly African American (67%)",CYP3A5*1,research
tacrolimus,Dosage,P value  0.0005,"Multiple groups, Predominantly African American (67%)",CYP3A5*3,research
tacrolimus,Dosage,P value  0.0005,"Multiple groups, Predominantly African American (67%)",CYP3A5*6,research
tacrolimus,Dosage,P value  0.0005,"Multiple groups, Predominantly African American (67%)",CYP3A5*7,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Predominantly African American (67%)",CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Predominantly African American (67%)",CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Predominantly African American (67%)",CYP3A5*6,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Predominantly African American (67%)",CYP3A5*7,research
simvastatin,Efficacy,P value  5e-8,Unknown,rs4149056,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs776746,research
tacrolimus,Dosage,P value  0.01,European,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
clozapine,Metabolism/PK,P value  1.677E-8,Unknown,rs28379954,research
methadone,Dosage,P value  0.0003,Unknown,rs11265549,research
methadone,Metabolism/PK,P value  0.0006,Unknown,rs11265549,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
atorvastatin,Metabolism/PK,P value  0.000,East Asian,rs4149056,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs28399499,research
warfarin,Dosage,P value  0.003,East Asian,rs1057910,research
o-desmethyltramadol,Metabolism/PK,P value  0.002,Unknown,CYP2D6 poor metabolizers and intermediate metabolizers,research
moxifloxacin,Metabolism/PK,P value  0.001,"Multiple groups, South African: 56 individuals were Black, one individual white and one individual 'colored'",UGT1A1*1,research
moxifloxacin,Metabolism/PK,P value  0.001,"Multiple groups, South African: 56 individuals were Black, one individual white and one individual 'colored'",UGT1A1*28,research
moxifloxacin,Metabolism/PK,P value  0.001,"Multiple groups, South African: 56 individuals were Black, one individual white and one individual 'colored'",UGT1A1*36,research
moxifloxacin,Metabolism/PK,P value  0.001,"Multiple groups, South African: 56 individuals were Black, one individual white and one individual 'colored'",UGT1A1*37,research
rosuvastatin,Efficacy,P value  7.7e-5,European,rs4149056,research
anastrozole,Efficacy,P value  2.82E-9,Unknown,rs1437153,research
anastrozole,Efficacy,P value  2.02E-8,Unknown,rs6981827,research
anastrozole,Efficacy,P value  2.23E-10,Unknown,rs2449598,research
peginterferon alfa-2a,Efficacy,P value  0.001,East Asian,rs12979860,research
alfentanil,Dosage,P value  0.002,Unknown,rs1799971,research
alfentanil,Dosage,P value  0.004,Unknown,rs1799971,research
alfentanil,Dosage,P value  0.009,Unknown,rs1799971,research
rosuvastatin,Metabolism/PK,P value  0.01,Unknown,rs4149056,research
warfarin,Dosage,P value  0.0001,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",CYP2C9*1,research
warfarin,Dosage,P value  0.0001,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",CYP2C9*3,research
simvastatin,Metabolism/PK,P value  9.0E-4,Unknown,CYP2C9*1,research
simvastatin,Dosage,P value  9.0E-4,Unknown,CYP2C9*1,research
simvastatin,Metabolism/PK,P value  9.0E-4,Unknown,CYP2C9*3,research
simvastatin,Dosage,P value  9.0E-4,Unknown,CYP2C9*3,research
warfarin,Metabolism/PK,P value  1.0E-4,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  1.0E-4,Unknown,CYP2C9*1,research
warfarin,Metabolism/PK,P value  1.0E-4,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  1.0E-4,Unknown,CYP2C9*3,research
rosuvastatin,Metabolism/PK,P value  0.004,East Asian,rs2231142,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Metabolism/PK,P value  1.0E-4,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  1.0E-4,Unknown,CYP2C9*1,research
warfarin,Metabolism/PK,P value  1.0E-4,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  1.0E-4,Unknown,CYP2C9*2,research
peginterferon alfa-2a,Efficacy,P value  1.37E-28,"Multiple groups, European-Americans: 871; African-Americans: 191; Hispanics: 75.",rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.002,European,rs12979860,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,Unknown,rs1057910,research
warfarin,Dosage,P value  4.0E-4,Near Eastern,rs28371686,research
peginterferon alfa-2a,Efficacy,P value  0.0029,European,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.01,European,rs12979860,research
warfarin,Dosage,P value  0.001,Near Eastern,rs9923231,research
phenprocoumon,Dosage,P value  0.0001,Unknown,rs9923231,research
acenocoumarol,Dosage,P value  0.001,Multiple groups,rs9923231,research
acenocoumarol,Dosage,P value  0.001,Multiple groups,rs9923231,research
warfarin,Dosage,P value  0.005,East Asian,rs2108622,research
fluoxetine,Efficacy,P value  0.008,European,rs7905446,research
nevirapine,Metabolism/PK,P value  0.01,Sub-Saharan African,rs3745274,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*2,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3C,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*9,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*21,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*33,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*34,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*2,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3C,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*9,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*21,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*33,research
mercaptopurine,Dosage,P value  0.0002,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*34,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*2,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3C,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*9,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*21,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*33,research
mercaptopurine,Dosage,P value  0.007,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*34,research
rosuvastatin,Metabolism/PK,P value  1e-4,East Asian,rs2231142,research
atorvastatin,Efficacy,P value  0.00001,Multiple groups,rs4149056,research
SN-38,Dosage,P value  1.0E-4,East Asian,rs4148323,research
efavirenz,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,rs36118214,research
rosuvastatin,Metabolism/PK,P value  0.001,East Asian,rs4149056,research
carfilzomib,Efficacy,P value  0.009,Unknown,rs833061,research
varenicline,Efficacy,P value  0.0019,European,rs7164594,research
tacrolimus,Metabolism/PK,P value  0.0002,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0002,Unknown,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.0003,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0003,Unknown,CYP3A5*3,research
voriconazole,Metabolism/PK,P value  0.009,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.009,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.009,East Asian,CYP2C19*3,research
voriconazole,Metabolism/PK,P value  0.009,East Asian,CYP2C19*17,research
opioids,Dosage,P value  0.009,East Asian,rs2275913,research
opioids,Efficacy,P value  0.009,East Asian,rs2275913,research
rosuvastatin,Metabolism/PK,P value  5.75e-4,East Asian,rs2231142,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs193922525,research
tacrolimus,Metabolism/PK,P value  0.0004,East Asian,rs10211,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs121909013,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*1,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*2,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*3,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*5,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*6,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*10,research
warfarin,Dosage,P value  0.0001,"Multiple groups, European-American plus African American",CYP2C9*11,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*5,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*6,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*10,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*11,research
mycophenolic acid,Metabolism/PK,P value  0.006,Unknown,rs2273697,research
mycophenolic acid,Metabolism/PK,P value  0.010,Unknown,rs2273697,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs74503330,research
bupropion,Efficacy,P value  0.0008,European,rs8109525,research
mycophenolic acid,Metabolism/PK,P value  0.008,Unknown,rs2273697,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs121908755,research
aspirin,Efficacy,P value  0.01,"Multiple groups, 59 White; 55 African American",rs4244285,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs121908757,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs121909005,research
aspirin,Efficacy,P value  0.00001,"Multiple groups, European, African American and East Asian ancestries",rs12041331,research
aspirin,Efficacy,P value  0.00001,"Multiple groups, European, African American and East Asian ancestries",rs12041331,research
aspirin,Efficacy,P value  0.00001,"Multiple groups, European, African American and East Asian ancestries",rs12041331,research
nicotine,Metabolism/PK,P value  0.002,American,CYP2A6*1A,research
nicotine,Metabolism/PK,P value  0.002,American,CYP2A6*1B1,research
tacrolimus,Dosage,P value  0.0001,East Asian,rs776746,research
fentanyl,Efficacy,P value  1E-7,Unknown,rs13093031,research
tacrolimus,Dosage,P value  0.0001,East Asian,rs776746,research
fentanyl,Efficacy,P value  2E-7,Unknown,rs6961071,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.0001,East Asian,rs776746,research
warfarin,Dosage,P value  0.0002,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",rs2108622,research
warfarin,Dosage,P value  0.0001,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",rs9923231,research
warfarin,Dosage,P value  0.0003,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",CYP2C9*1,research
warfarin,Dosage,P value  0.0003,"Multiple groups, 94% were White (all were patients at Ottawa Hospital Thrombosis Clinic).",CYP2C9*2,research
meloxicam,Metabolism/PK,P value  0.0001,Multiple groups,CYP2C9*1,research
meloxicam,Metabolism/PK,P value  0.0001,Multiple groups,CYP2C9*2,research
meloxicam,Metabolism/PK,P value  0.0001,Multiple groups,CYP2C9*3,research
warfarin,Dosage,P value  0.002,European,rs9934438,research
warfarin,Dosage,P value  0.003,Near Eastern,rs2108622,research
warfarin,Dosage,P value  0.006,East Asian,rs7294,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*17,research
warfarin,Dosage,P value  0.0015,European,CYP2C9*1,research
warfarin,Dosage,P value  0.0015,European,CYP2C9*2,research
warfarin,Dosage,P value  0.0015,European,CYP2C9*3,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,rs28365063,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,rs12233719,research
digoxin,Metabolism/PK,P value  0.01,European,rs2032582,research
ivacaftor,Efficacy,P value  0.0001,Unknown,rs113993960,research
maraviroc,Metabolism/PK,P value  0.0036,Unknown,CYP3A5 intermediate metabolizers,research
meloxicam,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*1,research
meloxicam,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*2,research
meloxicam,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*3,research
meloxicam,PD,P value  0.001,East Asian,CYP2C9*1,research
meloxicam,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
meloxicam,PD,P value  0.001,East Asian,CYP2C9*13,research
meloxicam,Metabolism/PK,P value  0.001,East Asian,CYP2C9*13,research
fentanyl,Metabolism/PK,P value  0.006,East Asian,CYP3A5*1,research
fentanyl,Metabolism/PK,P value  0.006,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  1.0E-4,European,rs2359612,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  0.01,Unknown,rs9923231,research
fenofibrate,Efficacy,P value  0.004,European,rs1417938,research
warfarin,Dosage,P value  0.00001,Multiple groups,rs9923231,research
peginterferon alfa-2b,Efficacy,P value  2.59E-7,European,rs8099917,research
mercaptopurine,Dosage,P value  0.004,Unknown,rs186364861,research
glucocorticoids,Efficacy,P value  0.009,East Asian,rs1045642,research
hydroxyurea,Efficacy,P value  0.0001,Near Eastern,rs4671393,research
opioids,Dosage,P value  0.004,Unknown,rs795484,research
hydroxyurea,Efficacy,P value  0.001,Near Eastern,rs766432,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs1799853,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs1799853,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs9923231,research
warfarin,Other,P value  0.001,Central/South Asian,rs9923231,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs9923231,research
warfarin,Other,P value  0.001,Central/South Asian,rs9923231,research
glucocorticoids,Efficacy,P value  0.001,European,rs1047303,research
glucocorticoids,Efficacy,P value  0.001,European,rs1047303,research
mercaptopurine,Dosage,P value  5.24E-9,Unknown,rs116855232,research
clonidine,Efficacy,P value  0.001,East Asian,rs5443,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs1057910,research
warfarin,Dosage,P value  0.001,Central/South Asian,rs1057910,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
warfarin,Dosage,P value  3.96e-8,"Multiple groups, mostly Caucasians",rs2288344,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
lumefantrine,Metabolism/PK,P value  0.004,Sub-Saharan African,rs8187710,research
warfarin,Dosage,P value  4.14e-8,"Multiple groups, mostly Caucasians",rs17126068,research
warfarin,Dosage,P value  8.3e-10,"Multiple groups, 98% white",rs9923231,research
warfarin,Dosage,P value  4.98e-11,"Multiple groups, mostly Caucasians",CYP2C9*1,research
warfarin,Dosage,P value  4.98e-11,"Multiple groups, mostly Caucasians",CYP2C9*2,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs11045854,research
rosuvastatin,Metabolism/PK,P value  0.001,European,rs4149056,research
warfarin,Dosage,P value  8.3e-10,"Multiple groups, 98% white",rs2359612,research
warfarin,Dosage,P value  8.3e-10,"Multiple groups, 98% white",rs2860905,research
warfarin,Dosage,P value  2.55e-05,"Multiple groups, 98% white",rs1057910,research
warfarin,Dosage,P value  1.77e-22,"Multiple groups, mostly Caucasians",CYP2C9*1,research
warfarin,Dosage,P value  1.77e-22,"Multiple groups, mostly Caucasians",CYP2C9*3,research
efavirenz,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,rs28399499,research
Vitamin B-complex,Efficacy,P value  0.001,Unknown,rs1801131,research
metformin,Efficacy,P value  0.002,Unknown,rs11868513,research
metformin,Efficacy,P value  0.008,Multiple groups,rs11868513,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs12305884,research
adrenergics,Efficacy,P value  8.8E-4,Multiple groups,rs34548976,research
rosuvastatin,Metabolism/PK,P value  0.01,Sub-Saharan African,rs12721616,research
nicotine,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,rs140471703,research
atomoxetine,Efficacy,P value  0.01,Multiple groups,rs12708954,research
metformin,Efficacy,P value  0.0002,Multiple groups,rs6719578,research
nicotine,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,rs143690364,research
azathioprine,Dosage,P value  0.0006,Unknown,TPMT*1,research
azathioprine,Efficacy,P value  0.0006,Unknown,TPMT*1,research
azathioprine,Toxicity,P value  0.0006,Unknown,TPMT*1,research
azathioprine,Dosage,P value  0.0006,Unknown,TPMT*3A,research
azathioprine,Efficacy,P value  0.0006,Unknown,TPMT*3A,research
azathioprine,Toxicity,P value  0.0006,Unknown,TPMT*3A,research
azathioprine,Dosage,P value  0.0006,Unknown,TPMT*3C,research
azathioprine,Efficacy,P value  0.0006,Unknown,TPMT*3C,research
azathioprine,Toxicity,P value  0.0006,Unknown,TPMT*3C,research
nicotine,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,rs376817657,research
warfarin,Dosage,P value  0.001,East Asian,rs41301394,research
gliclazide,Efficacy,P value  0.006,East Asian,rs2237897,research
efavirenz,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,rs3745274,research
warfarin,Dosage,P value  0.001,Unknown,rs9934438,research
rosuvastatin,Metabolism/PK,P value  0.003,Sub-Saharan African,rs8187692,research
warfarin,Dosage,P value  0.001,East Asian,rs2108622,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.0,European,CYP2C9*2,research
warfarin,Dosage,P value  0.0,European,CYP2C9*3,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*17,research
warfarin,Dosage,P value  0.003,Multiple groups,rs2108622,research
rosuvastatin,Metabolism/PK,P value  0.001,Sub-Saharan African,rs1805343,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs8187706,research
rosuvastatin,Metabolism/PK,P value  0.01,Sub-Saharan African,rs8187710,research
Beta Blocking Agents,Efficacy,P value  0.001,East Asian,rs1801253,research
ivacaftor,Efficacy,P value  0.0001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.01,Unknown,rs113993960,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs7899457,research
ethanol,Dosage,P value  0.001,Unknown,rs1799971,research
pravastatin,Metabolism/PK,P value  0.001,European,rs4149015,research
pravastatin,Efficacy,P value  0.001,European,rs4149015,research
efavirenz,Metabolism/PK,P value  0.0001,Unknown,rs3745274,research
efavirenz,Metabolism/PK,P value  0.0001,Unknown,rs3745274,research
dalcetrapib,Efficacy,P value  0.004,European,rs1967309,research
bupropion,Efficacy,P value  0.008,European,rs363225,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
ivacaftor,Efficacy,P value  0.01,Unknown,rs78655421,research
warfarin,Dosage,P value  0.005,African American/Afro-Caribbean,rs9934438,research
warfarin,Dosage,P value  0.01,European,rs9934438,research
bupropion,Efficacy,P value  0.01,European,rs8075924,research
ivacaftor,Efficacy,P value  0.001,Unknown,rs75527207,research
bupropion,Efficacy,P value  0.008,European,rs2873804,research
warfarin,Dosage,P value  0.01,European,rs8050894,research
ivacaftor,Efficacy,P value  0.0001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.0001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.0018,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.0085,Unknown,rs113993960,research
atenolol,Efficacy,P value  0.001,European,rs5443,research
atenolol,Efficacy,P value  0.001,European,rs5443,research
atenolol,Efficacy,P value  0.002,European,rs5443,research
atenolol,Efficacy,P value  0.008,European,rs5443,research
atazanavir,Metabolism/PK,P value  0.008,European,rs2472677,research
imatinib,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs776746,research
adalimumab,Efficacy,P value  0.008951,Unknown,rs1267067,research
aspirin,Efficacy,P value  0.003,Unknown,CYP2C19*1,research
aspirin,Efficacy,P value  0.003,Unknown,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.001,Near Eastern,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,Near Eastern,CYP2C19*2,research
adalimumab,Efficacy,P value  0.006627,Unknown,rs1126535,research
atenolol,Efficacy,P value  0.001,European,rs11064426,research
atenolol,Efficacy,P value  0.001,European,rs11064426,research
adalimumab,Efficacy,P value  0.003902,Unknown,rs25648,research
ivacaftor,Efficacy,P value  0.001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.005,Unknown,rs113993960,research
etanercept,Efficacy,P value  0.001,European,rs1800629,research
adalimumab,Efficacy,P value  0.003733,Unknown,rs2230926,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
atenolol,Efficacy,P value  0.001,European,rs5443,research
atenolol,Efficacy,P value  0.005,European,rs5443,research
simvastatin,Metabolism/PK,P value  0.006,Multiple groups,CYP3A4*1,research
simvastatin,Metabolism/PK,P value  0.006,Multiple groups,CYP3A4*22,research
atenolol,Efficacy,P value  0.001,European,rs2301339,research
atenolol,Efficacy,P value  0.001,European,rs2301339,research
hydrochlorothiazide,Efficacy,P value  3e-4,European,rs10995,research
atenolol,Efficacy,P value  0.001,European,rs11064426,research
atenolol,Efficacy,P value  0.004,European,rs11064426,research
ivacaftor,Efficacy,P value  0.002,European,rs75527207,research
ivacaftor,Efficacy,P value  0.006,Unknown,rs75527207,research
tacrolimus,Metabolism/PK,P value  0.0002,"Multiple groups, Caucasian and Unknown",CYP3A5*1,research
tacrolimus,Dosage,P value  0.0002,"Multiple groups, Caucasian and Unknown",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0002,"Multiple groups, Caucasian and Unknown",CYP3A5*3,research
tacrolimus,Dosage,P value  0.0002,"Multiple groups, Caucasian and Unknown",CYP3A5*3,research
enalapril,Efficacy,P value  0.003,East Asian,rs5522,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9934438,research
disulfiram,Efficacy,P value  1.0E-4,"Multiple groups, Caucasian, African American and Hispanic",rs1801133,research
warfarin,Dosage,P value  0.001,Multiple groups,rs2359612,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
ivacaftor,Efficacy,P value  0.0003,Unknown,rs113993960,research
warfarin,Metabolism/PK,P value  0.001,Unknown,CYP2C9*1,research
warfarin,Metabolism/PK,P value  0.001,Unknown,CYP2C9*2,research
warfarin,Metabolism/PK,P value  0.001,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  0.001,Multiple groups,rs7294,research
flupenthixol,Efficacy,P value  1.88E-6,"Multiple groups, 82 South African Colored (SAC), 13 Xhosa and eight Caucasian individuals",rs230493,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*1,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*2,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*3,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*1,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*2,research
omeprazole,Efficacy,P value  0.01,East Asian,CYP2C19*3,research
flupenthixol,Efficacy,P value  1.48E-4,"Multiple groups, 82 South African Colored (SAC), 13 Xhosa and eight Caucasian individuals",rs230504,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
atenolol,Efficacy,P value  0.008,European,rs699,research
pitavastatin,Metabolism/PK,P value  0.0002,Unknown,SLCO1B1*1,research
pitavastatin,Metabolism/PK,P value  0.0002,Unknown,SLCO1B1*15,research
pitavastatin,Metabolism/PK,P value  0.002,Unknown,SLCO1B1*1,research
pitavastatin,Metabolism/PK,P value  0.002,Unknown,SLCO1B1*15,research
pitavastatin,Metabolism/PK,P value  0.004,Unknown,SLCO1B1*1,research
pitavastatin,Metabolism/PK,P value  0.004,Unknown,SLCO1B1*15,research
pitavastatin,Metabolism/PK,P value  0.004,Unknown,SLCO1B1*1,research
pitavastatin,Metabolism/PK,P value  0.004,Unknown,SLCO1B1*15,research
atenolol,Efficacy,P value  0.001,European,rs5051,research
omeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*3,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*6,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*5,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Unknown,NAT2*7,research
methadone,Metabolism/PK,P value  2.24E-8,East Asian,rs17180299,research
simvastatin,Metabolism/PK,P value  0.001,Multiple groups,rs4149056,research
fluorouracil,Efficacy,P value  0.005,Unknown,rs1801265,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9923231,research
efavirenz,Metabolism/PK,P value  0.0001,Multiple groups,rs3745274,research
metformin,Efficacy,P value  2.6e-8,European,rs8192675,research
cyclosporine,Metabolism/PK,P value  0.002,Unknown,rs9282564,research
cyclosporine,Toxicity,P value  0.002,Unknown,rs9282564,research
interferon alfa-2a,Efficacy,P value  0.0001,European,rs12979860,research
acenocoumarol,Efficacy,P value  0.001,European,rs9923231,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.002,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.002,East Asian,CYP3A5*3,research
etanercept,Efficacy,P value  0.005,European,rs1800629,research
etanercept,Efficacy,P value  0.0057,European,rs1800629,research
pioglitazone,Efficacy,P value  0.010,East Asian,rs1801282,research
selective beta-2-adrenoreceptor agonists,Efficacy,P value  0.003,European,rs2781659,research
pioglitazone,Efficacy,P value  0.005,East Asian,rs17584499,research
3,Efficacy,P value  0.01,European,CYP2D6*1,research
3,Efficacy,P value  0.01,European,CYP2D6*2,research
3,Efficacy,P value  0.01,European,CYP2D6*3,research
3,Efficacy,P value  0.01,European,CYP2D6*4,research
3,Efficacy,P value  0.01,European,CYP2D6*5,research
3,Efficacy,P value  0.01,European,CYP2D6*6,research
3,Efficacy,P value  0.01,European,CYP2D6*9,research
3,Efficacy,P value  0.01,European,CYP2D6*10,research
3,Efficacy,P value  0.01,European,CYP2D6*41,research
sirolimus,Metabolism/PK,P value  0.0016,Unknown,rs1045642,research
olanzapine,Efficacy,P value  1.59E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs6688363,research
risperidone,Efficacy,P value  3.85E-08,"Multiple groups, European American, African American and 'Other' ethnicities.",rs8050896,research
cotinine,Metabolism/PK,P value  6.91E-17,European,rs16969968,research
risperidone,Efficacy,P value  2.97E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs2980976,research
cotinine,Metabolism/PK,P value  1.51E-9,European,rs7170068,research
risperidone,Efficacy,P value  3.68E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs2636697,research
interferon alfa-2a,Efficacy,P value  0.001,Near Eastern,rs12979860,research
cotinine,Metabolism/PK,P value  5.89E-10,European,rs10851907,research
cotinine,Metabolism/PK,P value  2.92E-8,European,rs57064725,research
pravastatin,Metabolism/PK,P value  2.0E-4,Unknown,rs4149015,research
cotinine,Metabolism/PK,P value  5.89E-10,European,rs77107237,research
quetiapine,Efficacy,P value  1.58E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs17742120,research
paroxetine,Efficacy,P value  0.005,European,rs7905446,research
quetiapine,Efficacy,P value  1.87E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs2164660,research
infliximab,Efficacy,P value  0.01,Unknown,rs1800629,research
risperidone,Efficacy,P value  2.25E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs711355,research
captopril,Efficacy,P value  0.005,Unknown,rs1799752,research
risperidone,Efficacy,P value  4.86E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs785423,research
adalimumab,Efficacy,P value  0.0001,Unknown,rs1800629,research
risperidone,Efficacy,P value  5.05E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs2636719,research
escitalopram,Efficacy,P value  0.008,European,rs7905446,research
adalimumab,Efficacy,P value  0.005,Unknown,rs1800629,research
risperidone,Efficacy,P value  1.98E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs7395555,research
olanzapine,Efficacy,P value  1.03E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs10170310,research
ranibizumab,Efficacy,P value  0.009,European,rs1061170,research
letrozole,Metabolism/PK,P value  0.0001,"Multiple groups, Study carried out in London, Ontario, Canada. The majority of study participants were Caucasian.",CYP2A6*1A,research
letrozole,Metabolism/PK,P value  0.0001,"Multiple groups, Study carried out in London, Ontario, Canada. The majority of study participants were Caucasian.",CYP2A6*2,research
letrozole,Metabolism/PK,P value  0.0001,"Multiple groups, Study carried out in London, Ontario, Canada. The majority of study participants were Caucasian.",CYP2A6*4A,research
letrozole,Metabolism/PK,P value  0.0001,"Multiple groups, Study carried out in London, Ontario, Canada. The majority of study participants were Caucasian.",CYP2A6*9,research
letrozole,Metabolism/PK,P value  0.0001,"Multiple groups, Study carried out in London, Ontario, Canada. The majority of study participants were Caucasian.",CYP2A6*12,research
lamotrigine,Metabolism/PK,P value  0.010,East Asian,rs2011425,research
quetiapine,Efficacy,P value  4.21E-08,"Multiple groups, European American, African American and 'Other' ethnicities.",rs17382202,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
risperidone,Efficacy,P value  4.91E-07,"Multiple groups, European American, African American and 'Other' ethnicities.",rs813676,research
mercaptopurine,Metabolism/PK,P value  2.2E-8,Multiple groups,NUDT15*1,research
mercaptopurine,Metabolism/PK,P value  2.2E-8,Multiple groups,NUDT15*2,research
mercaptopurine,Metabolism/PK,P value  2.2E-8,Multiple groups,NUDT15*3,research
mercaptopurine,Metabolism/PK,P value  2.2E-8,Multiple groups,NUDT15*5,research
mercaptopurine,Metabolism/PK,P value  7.7E-5,East Asian,NUDT15*1,research
mercaptopurine,Metabolism/PK,P value  7.7E-5,East Asian,NUDT15*2,research
mercaptopurine,Metabolism/PK,P value  7.7E-5,East Asian,NUDT15*3,research
mercaptopurine,Metabolism/PK,P value  7.7E-5,East Asian,NUDT15*5,research
mercaptopurine,Metabolism/PK,P value  2.9E-4,East Asian,NUDT15*1,research
mercaptopurine,Metabolism/PK,P value  2.9E-4,East Asian,NUDT15*2,research
mercaptopurine,Metabolism/PK,P value  2.9E-4,East Asian,NUDT15*3,research
mercaptopurine,Metabolism/PK,P value  2.9E-4,East Asian,NUDT15*5,research
methotrexate,Metabolism/PK,P value  10E-10,Unknown,rs13120400,research
paclitaxel,Efficacy,P value  0.008,East Asian,rs2227310,research
warfarin,Dosage,P value  0.001,Unknown,rs9934438,research
warfarin,Efficacy,P value  0.001,Unknown,rs9934438,research
lamotrigine,Metabolism/PK,P value  0.003,East Asian,rs7668258,research
methotrexate,Metabolism/PK,P value  10E-7,Unknown,rs13137622,research
paclitaxel,Efficacy,P value  0.01,East Asian,rs12415607,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9923231,research
methotrexate,Metabolism/PK,P value  10E-8,Unknown,rs12505410,research
benazepril,Efficacy,P value  0.007,East Asian,rs1799752,research
paclitaxel,Efficacy,P value  0.004,East Asian,rs4353229,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.0001,"Multiple groups, White European and Black African",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,"Multiple groups, White European and Black African",CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.000856,"Multiple groups, White European and Black African",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.000856,"Multiple groups, White European and Black African",CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.0027,"Multiple groups, White European and Black African",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0027,"Multiple groups, White European and Black African",CYP3A5*3,research
mercaptopurine,Dosage,P value  4.45E-8,Multiple groups,NUDT15*1,research
mercaptopurine,Dosage,P value  4.45E-8,Multiple groups,NUDT15*2,research
mercaptopurine,Dosage,P value  4.45E-8,Multiple groups,NUDT15*3,research
mercaptopurine,Dosage,P value  4.45E-8,Multiple groups,NUDT15*4,research
mercaptopurine,Dosage,P value  4.45E-8,Multiple groups,NUDT15*5,research
mercaptopurine,Dosage,P value  2.1E-5,East Asian,NUDT15*1,research
mercaptopurine,Dosage,P value  2.1E-5,East Asian,NUDT15*2,research
mercaptopurine,Dosage,P value  2.1E-5,East Asian,NUDT15*3,research
mercaptopurine,Dosage,P value  2.1E-5,East Asian,NUDT15*4,research
mercaptopurine,Dosage,P value  2.1E-5,East Asian,NUDT15*5,research
mercaptopurine,Dosage,P value  0.0054,East Asian,NUDT15*1,research
mercaptopurine,Dosage,P value  0.0054,East Asian,NUDT15*2,research
mercaptopurine,Dosage,P value  0.0054,East Asian,NUDT15*3,research
mercaptopurine,Dosage,P value  0.0054,East Asian,NUDT15*4,research
mercaptopurine,Dosage,P value  0.0054,East Asian,NUDT15*5,research
clopidogrel,Efficacy,P value  0.009,Latino,rs1045642,research
warfarin,Dosage,P value  0.01,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.01,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.01,East Asian,rs9923231,research
tacrolimus,Metabolism/PK,P value  0.005,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.005,East Asian,CYP3A5*3,research
infliximab,Efficacy,P value  0.0086,Unknown,rs1800629,research
endoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*41,research
atomoxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*10,research
benazepril,Efficacy,P value  0.003,East Asian,rs1801133,research
nevirapine,Metabolism/PK,P value  0.002,Sub-Saharan African,rs28399499,research
methotrexate,Efficacy,P value  0.002,Central/South Asian,HLA-C*06:02:01:01,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs2032582,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs2032582,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs2032582,research
lithium,Efficacy,P value  8.45E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs6942227,research
mercaptopurine,Dosage,P value  0.0001,East Asian,rs116855232,research
nevirapine,Metabolism/PK,P value  0.00011,Sub-Saharan African,rs3745274,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*1xN,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*3,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.003,Unknown,CYP2D6*6,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs1045642,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs1045642,research
amlodipine,Metabolism/PK,P value  0.01,East Asian,rs1045642,research
lithium,Efficacy,P value  9.92E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs1611259,research
lithium,Efficacy,P value  2.60E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs61123830,research
lithium,Efficacy,P value  7.21E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs59724122,research
lithium,Efficacy,P value  2.06E-4,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs7959663,research
azathioprine,Dosage,P value  6.21E-4,East Asian,rs116855232,research
nicotine,Dosage,P value  0.0001,European,rs16969968,research
lithium,Efficacy,P value  4.95E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs66486766,research
lithium,Efficacy,P value  5.27E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs7405404,research
endoxifen,Metabolism/PK,P value  0.004,Unknown,CYP2D6 poor metabolizer phenotype,research
azathioprine,Toxicity,P value  1.45E-4,East Asian,rs116855232,research
lithium,Efficacy,P value  1.34E-4,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs6728642,research
lithium,Efficacy,P value  6.33E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs7588746,research
lithium,Efficacy,P value  3.41E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs209474,research
warfarin,Dosage,P value  0.0001,Latino,rs9923231,research
warfarin,Dosage,P value  0.007,Unknown,rs9923231,research
lithium,Efficacy,P value  3.93E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs1611255,research
efavirenz,Metabolism/PK,P value  0.00002,Unknown,rs3745274,research
efavirenz,Metabolism/PK,P value  0.009,Unknown,rs3745274,research
hmg coa reductase inhibitors,Efficacy,P value  8.52e-29,Multiple groups,rs445925,research
hmg coa reductase inhibitors,Efficacy,P value  1.58e-18,Multiple groups,rs445925,research
hmg coa reductase inhibitors,Efficacy,P value  1.41e-15,Multiple groups,rs445925,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*14,research
mercaptopurine,Dosage,P value  0.002,East Asian,rs116855232,research
methotrexate,Other,P value  0.003,Central/South Asian,rs3761548,research
methotrexate,Other,P value  0.004,Central/South Asian,rs3761548,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*28,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*28,research
SN-38,Metabolism/PK,P value  0.005,European,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.005,European,UGT1A1*28,research
citalopram,Efficacy,P value  0.00025,European,CYP2C19 poor metabolizer phenotype,research
citalopram,Efficacy,P value  0.00037,European,CYP2C19 poor metabolizer phenotype,research
omeprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*3,research
lithium,Efficacy,P value  1.31E-8,"Multiple groups, European, Asian, Other",rs78015114,research
lithium,Efficacy,P value  3.31E-9,"Multiple groups, European, Asian, Other",rs74795342,research
lithium,Efficacy,P value  3.50E-9,"Multiple groups, European, Asian, Other",rs75222709,research
ibuprofen,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*1,research
ibuprofen,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*3,research
atazanavir,Metabolism/PK,P value  0.01,European,rs1045642,research
lithium,Efficacy,P value  1.37E-8,"Multiple groups, European, Asian, Other",rs79663003,research
lansoprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.0001,Unknown,CYP2C19*3,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*3,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
efavirenz,Metabolism/PK,P value  0.003,East Asian,rs2279343,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs2279343,research
ibuprofen,Metabolism/PK,P value  0.01,Multiple groups,CYP2C9*1,research
ibuprofen,Metabolism/PK,P value  0.01,Multiple groups,CYP2C9*2,research
dichloroacetic acid,Metabolism/PK,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs1046428,research
dichloroacetic acid,Other,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs1046428,research
hmg coa reductase inhibitors,Efficacy,P value  1.05e-9,Multiple groups,rs646776,research
hmg coa reductase inhibitors,Efficacy,P value  6.7e-7,Multiple groups,rs646776,research
hmg coa reductase inhibitors,Efficacy,P value  2.43e-4,Multiple groups,rs646776,research
hmg coa reductase inhibitors,Efficacy,P value  7.41e-44,Multiple groups,rs10455872,research
hmg coa reductase inhibitors,Efficacy,P value  7.14e-35,Multiple groups,rs10455872,research
hmg coa reductase inhibitors,Efficacy,P value  1.95e-11,Multiple groups,rs10455872,research
dichloroacetic acid,Metabolism/PK,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs7972,research
dichloroacetic acid,Other,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs7972,research
efavirenz,Metabolism/PK,P value  0.0004,Unknown,rs3745274,research
dichloroacetic acid,Metabolism/PK,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs7975,research
dichloroacetic acid,Other,P value  0.01,"Multiple groups, 2 Black, 1 Asian, 9 Whites",rs7975,research
methotrexate,Metabolism/PK,P value  3.97E-11,Multiple groups,rs2306283,research
methotrexate,Efficacy,P value  3.97E-11,Multiple groups,rs2306283,research
methotrexate,Toxicity,P value  3.97E-11,Multiple groups,rs2306283,research
Opioid anesthetics,Efficacy,P value  0.001,Unknown,rs1799971,research
methotrexate,Metabolism/PK,P value  5.72E-19,Multiple groups,rs4149056,research
methotrexate,Efficacy,P value  5.72E-19,Multiple groups,rs4149056,research
methotrexate,Toxicity,P value  5.72E-19,Multiple groups,rs4149056,research
methotrexate,Metabolism/PK,P value  2.01E-10,Multiple groups,rs4149056,research
methotrexate,Efficacy,P value  2.01E-10,Multiple groups,rs4149056,research
methotrexate,Toxicity,P value  2.01E-10,Multiple groups,rs4149056,research
Opioid anesthetics,Efficacy,P value  0.001,Unknown,rs2231142,research
SN-38,Metabolism/PK,P value  0.01,Unknown,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.01,Unknown,UGT1A1*28,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*13,research
rabeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
rabeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
rabeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*3,research
methadone,Metabolism/PK,P value  0.0019,Unknown,rs1045642,research
rabeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
rabeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
rabeprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
efavirenz,Metabolism/PK,P value  0.002,Latino,rs2307424,research
efavirenz,Metabolism/PK,P value  0.001,Latino,rs2307424,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*4A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*10,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*1A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*4A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*7,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*1A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*4A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*9A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*1A,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*7,research
pilocarpine,Metabolism/PK,P value  0.01,East Asian,CYP2A6*9A,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*13,research
boceprevir,Efficacy,P value  2e-4,European,rs12979860,research
omeprazole,Efficacy,P value  0.0006,Unknown,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0006,Unknown,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0006,Unknown,CYP2C19*3,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*3,research
duloxetine,Efficacy,P value  0.005,European,rs4261893,research
duloxetine,Efficacy,P value  0.006,European,rs4261893,research
duloxetine,Efficacy,P value  0.0003,European,rs2303377,research
efavirenz,Metabolism/PK,P value  0.01,East Asian,rs3745274,research
pravastatin,Metabolism/PK,P value  1.0E-4,Unknown,rs4149015,research
mercaptopurine,Dosage,P value  0.001,East Asian,rs116855232,research
mercaptopurine,Dosage,P value  0.001,East Asian,rs116855232,research
nicotine,Efficacy,P value  0.006,European,rs1799732,research
duloxetine,Efficacy,P value  1.9E-6,European,rs117986340,research
efavirenz,Metabolism/PK,P value  0.001,Latino,rs3745274,research
efavirenz,Metabolism/PK,P value  0.008,,rs3745274,research
bupropion,Efficacy,P value  0.01,European,rs1799732,research
morphine,Dosage,P value  0.0004,"Multiple groups, Chinese, Malay and Indian self-reported ethnicities.",rs1799971,research
morphine,Efficacy,P value  0.0004,"Multiple groups, Chinese, Malay and Indian self-reported ethnicities.",rs1799971,research
methotrexate,Efficacy,P value  0.007,European,rs4673993,research
efavirenz,Metabolism/PK,P value  0.0001,Latino,rs3745274,research
methylphenidate,Efficacy,P value  0.001,Unknown,rs1800544,research
quetiapine,Efficacy,P value  0.008,East Asian,rs6269,research
tacrolimus,Metabolism/PK,P value  0.001,European,rs776746,research
selective beta-2-adrenoreceptor agonists,Efficacy,P value  0.009,European,rs2239179,research
ethanol,Efficacy,P value  0.003,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
ethanol,Efficacy,P value  0.005,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
ethanol,Efficacy,P value  0.009,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs1461773,research
risperidone,Efficacy,P value  0.01,East Asian,rs3787430,research
warfarin,Metabolism/PK,P value  0.002,European,rs1057910,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",CYP2C9*1,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",CYP2C9*3,research
warfarin,Metabolism/PK,P value  0.002,European,rs1799853,research
ethanol,Efficacy,P value  0.000,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.000,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.003,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.003,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs3778148,research
rocuronium,Dosage,P value  5.302E-11,Unknown,rs7967354,research
rocuronium,Dosage,P value  0.001,Unknown,rs7967354,research
topotecan,Metabolism/PK,P value  0.0001,Unknown,rs4148157,research
quetiapine,Metabolism/PK,P value  0.0002,East Asian,rs776746,research
imatinib,Metabolism/PK,P value  0.0001,Unknown,rs683369,research
rocuronium,Dosage,P value  1.416E-10,Unknown,rs11045995,research
rocuronium,Dosage,P value  0.001,Unknown,rs11045995,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*3,research
hydrochlorothiazide,Efficacy,P value  1.43E-3,Unknown,rs177852,research
atenolol,Efficacy,P value  0.0003,European,rs1042714,research
atenolol,Efficacy,P value  0.0007,Unknown,rs1042714,research
atenolol,Efficacy,P value  0.01,European,rs1042714,research
atorvastatin,Efficacy,P value  0.001,"Multiple groups, Brazilian",rs9370867,research
hydrochlorothiazide,Efficacy,P value  3.67E-5,European,rs7553527,research
tacrolimus,Metabolism/PK,P value  0.0001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,Unknown,CYP3A5*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",rs1799853,research
disulfiram,Efficacy,P value  0.0001,"Multiple groups, 'Primarily Caucasian'",rs28363170,research
disulfiram,Efficacy,P value  0.0001,"Multiple groups, 'Primarily Caucasian'",rs28363170,research
warfarin,Dosage,P value  0.00,Central/South Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.00,Central/South Asian,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Central/South Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Central/South Asian,CYP2C9*2,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",CYP2C9*1,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",CYP2C9*2,research
peginterferon alfa-2a,Efficacy,P value  0.001,European,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.002,European,rs12979860,research
ethanol,Efficacy,P value  0.002,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs2075572,research
ethanol,Efficacy,P value  0.003,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs2075572,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs2075572,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs548646,research
ethanol,Efficacy,P value  0.005,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs548646,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs548646,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs548646,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*3,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*3,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*3,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian, African, Unknown",CYP2D6*5,research
ivacaftor,Efficacy,P value  0.005,Unknown,rs75527207,research
paroxetine,Efficacy,P value  0.009,East Asian,rs6280,research
warfarin,Dosage,P value  0.0001,East Asian,rs9332098,research
thioguanine,Metabolism/PK,P value  0.001,Unknown,TPMT*1,research
thioguanine,Metabolism/PK,P value  0.001,Unknown,TPMT*3A,research
thioguanine,Metabolism/PK,P value  0.001,Unknown,TPMT*3C,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs681243,research
ethanol,Efficacy,P value  0.006,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs681243,research
ethanol,Efficacy,P value  0.007,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs681243,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs681243,research
warfarin,Dosage,P value  0.0001,East Asian,rs9332092,research
proguanil,Metabolism/PK,P value  0.001,Oceanian,CYP2C19*1,research
proguanil,Metabolism/PK,P value  0.001,Oceanian,CYP2C19*2,research
proguanil,Metabolism/PK,P value  0.001,Oceanian,CYP2C19*3,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs267606723,research
tamoxifen-n-glucuronide,Metabolism/PK,P value  0.005,"Multiple groups, Chinese, Malay, Indian",rs2011425,research
buprenorphine,Efficacy,P value  0.008,African American/Afro-Caribbean,rs678849,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs121909041,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs648007,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs648007,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs80282562,research
exemestane,Metabolism/PK,P value  0.01,Multiple groups,CYP3A4*1,research
exemestane,Metabolism/PK,P value  0.01,Multiple groups,CYP3A4*22,research
atorvastatin,Efficacy,P value  0.009,Unknown,rs1800591,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0085,European,rs1061622,research
deferasirox,Metabolism/PK,P value  0.004,"Multiple groups, Mainly Caucasian (Italy)",rs2470890,research
citalopram,Metabolism/PK,P value  0.0001,"Multiple groups, Asian and White",CYP2C19*1,research
citalopram,Metabolism/PK,P value  0.0001,"Multiple groups, Asian and White",CYP2C19*2,research
citalopram,Metabolism/PK,P value  0.0001,"Multiple groups, Asian and White",CYP2C19*3,research
methadone,Efficacy,P value  0.001,African American/Afro-Caribbean,rs678849,research
clopidogrel,Dosage,P value  0.0005,Unknown,rs12248560,research
clopidogrel,Efficacy,P value  0.0005,Unknown,rs12248560,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs2279345,research
efavirenz,Metabolism/PK,P value  0.001,Central/South Asian,rs3745274,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*1,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*6,research
paroxetine,Efficacy,P value  6.0E-5,Multiple groups,rs6265,research
XK469,Metabolism/PK,P value  0.003,European,rs10931910,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*1,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*30,research
citalopram,Metabolism/PK,P value  0.0001,"Multiple groups, Asian and White",CYP2C19*1,research
citalopram,Metabolism/PK,P value  0.0001,"Multiple groups, Asian and White",CYP2C19*17,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*1,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2B6*29,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.001,Unknown,CYP2C19*3,research
cyclosporine,Metabolism/PK,P value  0.001,European,rs776746,research
cyclosporine,Dosage,P value  0.001,European,rs776746,research
cyclosporine,Metabolism/PK,P value  0.001,European,rs776746,research
cyclosporine,Dosage,P value  0.001,European,rs776746,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
cyclophosphamide,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
cyclosporine,Metabolism/PK,P value  0.001,European,rs776746,research
cyclosporine,Dosage,P value  0.001,European,rs776746,research
cyclosporine,Metabolism/PK,P value  0.001,Unknown,rs776746,research
cyclosporine,Dosage,P value  0.001,Unknown,rs776746,research
cyclophosphamide,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
cyclophosphamide,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
perindopril,Efficacy,P value  0.001,European,rs12050217,research
carbamazepine,Metabolism/PK,P value  0.0004,European,rs762551,research
budesonide,Efficacy,P value  1.1E-7,European,rs2392165,research
budesonide,Efficacy,P value  1.48E-7,European,rs2392165,research
haloperidol,Efficacy,P value  0.001,Unknown,rs3892097,research
haloperidol,Efficacy,P value  0.001,Unknown,rs3892097,research
cyclophosphamide,Efficacy,P value  0.0001,East Asian,rs2279343,research
epirubicin,Efficacy,P value  0.01,Unknown,rs1800566,research
epirubicin,Toxicity,P value  0.01,Unknown,rs1800566,research
warfarin,Dosage,P value  1.66E-7,African American/Afro-Caribbean,rs12777823,research
warfarin,Dosage,P value  3.0E-5,African American/Afro-Caribbean,rs12777823,research
cyclophosphamide,Efficacy,P value  0.0001,East Asian,CYP3A5*1,research
cyclophosphamide,Efficacy,P value  0.0001,East Asian,CYP3A5*3,research
fluvastatin,Efficacy,P value  0.0005,European,SLCO1B1*1A,research
fluvastatin,Efficacy,P value  0.0005,European,SLCO1B1*14,research
fluvastatin,Efficacy,P value  0.005,European,SLCO1B1*1A,research
fluvastatin,Efficacy,P value  0.005,European,SLCO1B1*14,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
warfarin,Dosage,P value  0.0003,East Asian,rs9934438,research
atorvastatin,Efficacy,P value  0.004,Unknown,rs2230806,research
perindopril,Efficacy,P value  0.001,European,rs275651,research
lamotrigine,Metabolism/PK,P value  0.005,"Custom, Non human cell line",UGT1A4*1a,research
lamotrigine,Efficacy,P value  0.005,"Custom, Non human cell line",UGT1A4*1a,research
lamotrigine,Metabolism/PK,P value  0.005,"Custom, Non human cell line",UGT1A4*2,research
lamotrigine,Efficacy,P value  0.005,"Custom, Non human cell line",UGT1A4*2,research
lamotrigine,Metabolism/PK,P value  0.005,"Custom, Non human cell line",UGT1A4*3a,research
lamotrigine,Efficacy,P value  0.005,"Custom, Non human cell line",UGT1A4*3a,research
ritonavir,Metabolism/PK,P value  0.01,"Multiple groups, 30 Caucasian, 5 African",rs4149056,research
carbamazepine,Metabolism/PK,P value  0.006,"Multiple groups, African Americans and Caucasians",rs2461817,research
ritonavir,Metabolism/PK,P value  0.007,"Multiple groups, 30 Caucasian, 5 African",rs2032582,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  6.12E-8,Latino,CYP3A5*3,research
everolimus,Metabolism/PK,P value  0.004,Unknown,rs776746,research
clopidogrel,Metabolism/PK,P value  0.0015,European,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.0015,European,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.0015,European,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.0015,European,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.0015,European,CYP2C19*8,research
clopidogrel,Efficacy,P value  0.0015,European,CYP2C19*8,research
clopidogrel,Metabolism/PK,P value  0.0015,European,CYP2C19*17,research
clopidogrel,Efficacy,P value  0.0015,European,CYP2C19*17,research
carbamazepine,Metabolism/PK,P value  0.008,"Multiple groups, African American and Caucasian.",rs3740066,research
nevirapine,Metabolism/PK,P value  0.001,Central/South Asian,rs3745274,research
captopril,Efficacy,P value  1.0E-4,East Asian,rs1799752,research
clopidogrel,Efficacy,P value  0.0001,European,rs4244285,research
methylphenidate,Efficacy,P value  0.001,"Multiple groups, European-Brazilian and African-Brazilian",rs734644,research
clopidogrel,Dosage,P value  0.01,"Multiple groups, out of an initial 40 patients(2 of whom did not complete the study), there were 35 Caucasian,2 Maori,2 Fijian Indian and 1 Chinese from the Australian New Zealand Clinical Trials registry.",rs4244285,research
clopidogrel,Efficacy,P value  0.01,"Multiple groups, out of an initial 40 patients(2 of whom did not complete the study), there were 35 Caucasian,2 Maori,2 Fijian Indian and 1 Chinese from the Australian New Zealand Clinical Trials registry.",rs4244285,research
carbamazepine,Metabolism/PK,P value  0.004,African American/Afro-Caribbean,rs28365063,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*1,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*1,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*9,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*9,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*10,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*10,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*17,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*17,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*29,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*29,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*45,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*45,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*46,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*46,research
methylphenidate,Efficacy,P value  0.001,"Multiple groups, European-Brazilian and African-Brazilian",rs1355368,research
methylphenidate,Efficacy,P value  0.001,"Multiple groups, European-Brazilian and African-Brazilian",rs6813183,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.004,European,rs1051792,research
escitalopram,Metabolism/PK,P value  0.005,"Multiple groups, 93% White",CYP2C19*1,research
escitalopram,Metabolism/PK,P value  0.005,"Multiple groups, 93% White",CYP2C19*2,research
escitalopram,Metabolism/PK,P value  0.005,"Multiple groups, 93% White",CYP2C19*3,research
escitalopram,Metabolism/PK,P value  0.005,"Multiple groups, 93% White",CYP2C19*17,research
losartan,Efficacy,P value  0.01,Unknown,rs5186,research
phenprocoumon,Dosage,P value  0.008,"Multiple groups, Netherlands, describe cohort as 85.4% 'European ethnicity'",rs9934438,research
tacrolimus,Metabolism/PK,P value  0.0005,Multiple groups,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0005,Multiple groups,CYP3A5*3,research
irbesartan,Metabolism/PK,P value  0.0001,East Asian,rs1057910,research
irbesartan,Metabolism/PK,P value  0.0001,East Asian,rs1057910,research
methotrexate,Efficacy,P value  0.009,,rs371194629,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*1,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*1,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*3,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*3,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*4,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*4,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*5,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*5,research
metoprolol,Metabolism/PK,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*6,research
metoprolol,Toxicity,P value  0.007,"Multiple groups, Predominantly White (78%), 18% Black, 4% Latino-Hispanic",CYP2D6*6,research
SN-38,Metabolism/PK,P value  0.001,"Multiple groups, Asian (n=126) and Caucasian (n=455)",UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.001,"Multiple groups, Asian (n=126) and Caucasian (n=455)",UGT1A1*28,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.001,European,UGT1A1*28,research
SN-38,Metabolism/PK,P value  0.002,"Multiple groups, Asian (n=126) and Caucasian (n=71)",UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.002,"Multiple groups, Asian (n=126) and Caucasian (n=71)",UGT1A1*28,research
tacrolimus,Metabolism/PK,P value  0.0005,Multiple groups,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0005,Multiple groups,CYP3A5*3,research
irinotecan,Dosage,P value  0.01,East Asian,UGT1A1*1,research
irinotecan,Dosage,P value  0.01,East Asian,UGT1A1*6,research
irinotecan,Dosage,P value  0.01,East Asian,UGT1A1*28,research
captopril,Efficacy,P value  1.0E-4,East Asian,rs1799752,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1xN,research
irbesartan,Metabolism/PK,P value  0.01,East Asian,rs72558187,research
warfarin,Dosage,P value  0.0001,East Asian,rs9923231,research
warfarin,Dosage,P value  0.001,European,rs61742245,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';1216 were *1/*2 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*1,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';1216 were *1/*2 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*2,research
imatinib,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs1045642,research
acenocoumarol,Dosage,P value  0.0001,Unknown,rs9923231,research
irbesartan,Metabolism/PK,P value  0.01,East Asian,rs1057910,research
irbesartan,Metabolism/PK,P value  0.01,East Asian,rs1057910,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,CYP2B6*1,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,CYP2B6*6,research
lamotrigine,Dosage,P value  0.0047,Latino,rs7668258,research
tacrolimus,Metabolism/PK,P value  10E-4,Near Eastern,rs2740574,research
tacrolimus,Metabolism/PK,P value  10E-3,Near Eastern,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.007,Near Eastern,rs776746,research
haloperidol,Metabolism/PK,P value  0.006,European,CYP2D6*1,research
haloperidol,Metabolism/PK,P value  0.006,European,CYP2D6*3,research
haloperidol,Metabolism/PK,P value  0.006,European,CYP2D6*4,research
azathioprine,Metabolism/PK,P value  0.001,Unknown,TPMT low activity,research
azathioprine,Metabolism/PK,P value  0.001,Unknown,TPMT low activity,research
risperidone,Metabolism/PK,P value  0.006,"Multiple groups, Caucasian, African, Unknown",CYP2D6 ultrarapid metabolizer phenotype,research
risperidone,Metabolism/PK,P value  0.007,"Multiple groups, Caucasian, African, Unknown",CYP2D6 ultrarapid metabolizer phenotype,research
maraviroc,Metabolism/PK,P value  0.0001,Unknown,CYP3A5 poor metabolizers,research
tamsulosin,Metabolism/PK,P value  0.005,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
tamsulosin,Metabolism/PK,P value  0.005,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
tamsulosin,Metabolism/PK,P value  0.001,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
tamsulosin,Metabolism/PK,P value  0.001,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.001,European,rs1061622,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs396991,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.001,European,rs1800629,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.004,European,rs1800629,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.003,European,rs1799724,research
antipsychotics,Efficacy,P value  0.008,Near Eastern,rs1801133,research
cyclosporine,Metabolism/PK,P value  2.7E-7,European,rs2740574,research
cyclosporine,Metabolism/PK,P value  6E-4,European,rs2740574,research
cyclosporine,Metabolism/PK,P value  0.004,European,rs2740574,research
tacrolimus,Metabolism/PK,P value  0.005,Near Eastern,rs2740574,research
fentanyl,Metabolism/PK,P value  0.01,Unknown,rs2740574,research
montelukast,Metabolism/PK,P value  0.00659,European,CYP2C8*1,research
montelukast,Metabolism/PK,P value  0.00659,European,CYP2C8*3,research
ibuprofen,Dosage,P value  0.00872,Unknown,CYP2C8*1,research
ibuprofen,Dosage,P value  0.00872,Unknown,CYP2C8*3,research
rosiglitazone,Metabolism/PK,P value  0.002,European,CYP2C8*1,research
rosiglitazone,Metabolism/PK,P value  0.002,European,CYP2C8*3,research
warfarin,Dosage,P value  0.00001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.00001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.00001,East Asian,rs1057910,research
tacrolimus,Dosage,P value  0.001,Near Eastern,rs2740574,research
azathioprine,Efficacy,P value  0.0058,Unknown,rs2413739,research
atorvastatin,Metabolism/PK,P value  0.001,Unknown,SLCO1B1*1,research
atorvastatin,Metabolism/PK,P value  0.001,Unknown,SLCO1B1*5,research
pravastatin,Efficacy,P value  0.003,Unknown,rs4149056,research
pravastatin,Efficacy,P value  9.0E-4,"Multiple groups, mostly White, with some African American,Asian Pacific Islander,Hispanic, and other.",rs20455,research
pravastatin,Metabolism/PK,P value  0.01,European,SLCO1B1*1,research
pravastatin,Metabolism/PK,P value  0.01,European,SLCO1B1*17,research
pitavastatin,Metabolism/PK,P value  0.01,East Asian,SLCO1B1*1,research
pitavastatin,Metabolism/PK,P value  0.01,East Asian,SLCO1B1*15,research
pravastatin,Metabolism/PK,P value  0.01,East Asian,rs4149056,research
pravastatin,Metabolism/PK,P value  0.01,East Asian,rs2306283,research
pravastatin,Metabolism/PK,P value  0.01,East Asian,rs2296651,research
hydralazine,Metabolism/PK,P value  0.001,,NAT2 slow acetylator,research
SN-38,Dosage,P value  0.003,"Multiple groups, Chinese (n=36), Malay (n=8) and Other (n=1)",rs4148323,research
SN-38,Dosage,P value  0.006,"Multiple groups, Chinese (n=36), Malay (n=8) and Other (n=1)",rs4148323,research
irbesartan,Metabolism/PK,P value  0.001,East Asian,rs1057910,research
atenolol,PD,P value  2E-09,African American/Afro-Caribbean,rs17117817,research
docetaxel,Efficacy,P value  0.002,East Asian,rs2227310,research
peginterferon alfa-2b,Efficacy,P value  0.0001,Near Eastern,rs12979860,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs11265572,research
antidepressants,Efficacy,P value  0.003,European,rs10879346,research
tacrolimus,Metabolism/PK,P value  0.0001,European,rs776746,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';81 were *2/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*1,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';81 were *2/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*2,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';81 were *2/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*3,research
cysteamine,Efficacy,P value  0.0001,Unknown,rs113993960,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';24 were *3/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*1,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';24 were *3/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*3,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';759 were *1/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*1,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';759 were *1/*3 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*3,research
nifedipine,Efficacy,P value  0.006,East Asian,rs1048101,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';78 were *2/*2 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*1,research
warfarin,Dosage,P value  0.000000000000010,"Multiple groups, For all genotypes, there were 7907 subjects.  5749 were '*1/*1';78 were *2/*2 (the rest were other genotypes). 12 studies were performed in Asia,13 in the Americas and 14 in Europe.",CYP2C9*2,research
docetaxel,Efficacy,P value  0.005,East Asian,rs12415607,research
zidovudine,Metabolism/PK,P value  0.004,Sub-Saharan African,rs28365062,research
ivacaftor,Efficacy,P value  6.0E-4,Multiple groups,rs75527207,research
docetaxel,Efficacy,P value  0.001,East Asian,rs4353229,research
hydralazine,Metabolism/PK,P value  0.005,Unknown,NAT2 slow acetylator,research
atenolol,PD,P value  1E-08,African American/Afro-Caribbean,rs2364349,research
sirolimus,Metabolism/PK,P value  0.003,Unknown,CYP3A5*1,research
sirolimus,Metabolism/PK,P value  0.003,Unknown,CYP3A5*3,research
cladribine,Efficacy,P value  0.001,Multiple groups,rs1561876,research
cladribine,Efficacy,P value  0.0012,Multiple groups,rs1561876,research
cladribine,Efficacy,P value  0.009,Multiple groups,rs1561876,research
warfarin,Dosage,P value  1.6E-8,Multiple groups,rs8050894,research
cladribine,Efficacy,P value  0.0004,Multiple groups,rs1042919,research
niacin,Efficacy,P value  0.0053,European,rs2454727,research
cyclosporine,Metabolism/PK,P value  0.01,Unknown,rs35599367,research
clozapine,Dosage,P value  0.00404,East Asian,rs2975226,research
clozapine,Efficacy,P value  0.00404,East Asian,rs2975226,research
clopidogrel,Efficacy,P value  0.0001,Unknown,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.0001,Unknown,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.0001,Unknown,CYP2C19*4,research
clopidogrel,Efficacy,P value  0.0001,Unknown,CYP2C19*17,research
nicotine,Metabolism/PK,P value  3.9E-6,Unknown,rs2266780,research
nicotine,Metabolism/PK,P value  0.002,Unknown,rs2266780,research
nicotine,Metabolism/PK,P value  0.005,Unknown,rs2266780,research
nicotine,Metabolism/PK,P value  0.007,Unknown,rs2266780,research
clozapine,Efficacy,P value  0.005,African American/Afro-Caribbean,rs742105,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
citalopram,Efficacy,P value  0.0089,East Asian,rs153549,research
deferasirox,Metabolism/PK,P value  0.01,Multiple groups,rs2585428,research
citalopram,Efficacy,P value  0.0036,East Asian,rs153560,research
citalopram,Efficacy,P value  0.01,East Asian,rs153560,research
deferasirox,Metabolism/PK,P value  0.01,Multiple groups,rs2248359,research
apixaban,Metabolism/PK,P value  0.01,East Asian,rs2231142,research
tacrolimus,Metabolism/PK,P value  0.0038,Unknown,rs776746,research
warfarin,Metabolism/PK,P value  8.8E-13,Unknown,rs1799853,research
warfarin,Dosage,P value  8.8E-13,Unknown,rs1799853,research
ivacaftor,Efficacy,P value  0.0001,Near Eastern,rs121908757,research
ivacaftor,Efficacy,P value  0.0002,Near Eastern,rs121908757,research
ivacaftor,Efficacy,P value  0.0029,Near Eastern,rs121908757,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0004,East Asian,rs1799964,research
warfarin,Dosage,P value  1.6E-5,Unknown,rs2108622,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0021,East Asian,rs1799724,research
peginterferon alfa-2b,Efficacy,P value  0.001,East Asian,rs8099917,research
codeine,Metabolism/PK,P value  0.0011,Unknown,CYP2D6 poor metabolizers,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Asian, Black, Caucasian, Other",rs35599367,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Asian, Black, Caucasian, Other",rs35599367,research
tacrolimus,Dosage,P value  0.004,"Multiple groups, Asian, Black, Caucasian, Other",rs35599367,research
tacrolimus,Dosage,P value  0.004,Multiple groups,rs35599367,research
endoxifen,Metabolism/PK,P value  1E-10,European,CYP2D6 poor metabolizers,research
endoxifen,Metabolism/PK,P value  1E-10,East Asian,CYP2D6 poor metabolizers,research
endoxifen,Metabolism/PK,P value  1E-3,Near Eastern,CYP2D6 poor metabolizers,research
rabeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*1,research
rabeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*2,research
rabeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*3,research
rabeprazole,Metabolism/PK,P value  0.0035,East Asian,CYP2C19*1,research
rabeprazole,Metabolism/PK,P value  0.0035,East Asian,CYP2C19*2,research
rabeprazole,Metabolism/PK,P value  0.0035,East Asian,CYP2C19*3,research
rabeprazole,Metabolism/PK,P value  0.0052,East Asian,CYP2C19*1,research
rabeprazole,Metabolism/PK,P value  0.0052,East Asian,CYP2C19*2,research
rabeprazole,Metabolism/PK,P value  0.0052,East Asian,CYP2C19*3,research
allopurinol,Efficacy,P value  2.0E-8,European,rs2231142,research
rosuvastatin,Metabolism/PK,P value  0.0021,East Asian,rs2231142,research
warfarin,Dosage,P value  0.001,East Asian,rs7294,research
warfarin,Efficacy,P value  0.001,East Asian,rs7294,research
warfarin,Dosage,P value  1.6e-8,American,rs9923231,research
warfarin,Dosage,P value  1.4e-5,American,rs9923231,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
tacrolimus,Dosage,P value  0.002,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.002,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Asian, Black, Caucasian, Other",rs776746,research
mercaptopurine,Dosage,P value  8.6E-9,Multiple groups,rs116855232,research
mercaptopurine,Dosage,P value  0.0024,Multiple groups,rs116855232,research
antipsychotics,Metabolism/PK,P value  0.0088,Central/South Asian,rs2032582,research
antipsychotics,Dosage,P value  0.0088,Central/South Asian,rs2032582,research
nitrendipine,Efficacy,P value  0.01,European,rs5186,research
ethanol,Efficacy,P value  0.006,Unknown,rs1799971,research
tacrolimus,Metabolism/PK,P value  0.006,"Multiple groups, Asian, Black, Caucasian, Other",rs35599367,research
tacrolimus,Metabolism/PK,P value  0.006,"Multiple groups, Asian, Black, Caucasian, Other",rs35599367,research
atazanavir,Metabolism/PK,P value  1.71e-8,"Multiple groups, 194 African Americans, 57 whites, 53 Latinos",rs73208473,research
atazanavir,Metabolism/PK,P value  3.09e-6,European,rs73208473,research
atazanavir,Metabolism/PK,P value  0.0025,African American/Afro-Caribbean,rs73208473,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
warfarin,Efficacy,P value  0.001,East Asian,rs9923231,research
pantoprazole,Metabolism/PK,P value  0.010,European,CYP2C19*1,research
pantoprazole,Metabolism/PK,P value  0.010,European,CYP2C19*2,research
antipsychotics,Metabolism/PK,P value  0.0053,Central/South Asian,rs1045642,research
antipsychotics,Dosage,P value  0.0053,Central/South Asian,rs1045642,research
bupropion,Efficacy,P value  0.01,Unknown,SLC6A4 HTTLPR long form (L allele),research
bupropion,Efficacy,P value  0.01,Unknown,SLC6A4 HTTLPR short form (S allele),research
warfarin,Dosage,P value  0.001,European,rs1057910,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
acenocoumarol,Dosage,P value  0.006,European,rs429358,research
lansoprazole,Metabolism/PK,P value  0.0011,East Asian,CYP2C19*1,research
lansoprazole,Metabolism/PK,P value  0.0011,East Asian,CYP2C19*2,research
lansoprazole,Metabolism/PK,P value  0.0011,East Asian,CYP2C19*3,research
mercaptopurine,Dosage,P value  8.6E-9,Multiple groups,rs1142345,research
mercaptopurine,Dosage,P value  1.8E-8,Multiple groups,rs1142345,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Efficacy,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
warfarin,Efficacy,P value  0.001,European,CYP2C9*3,research
clopidogrel,Efficacy,P value  0.001,European,rs4244285,research
efavirenz,Metabolism/PK,P value  0.001,"Multiple groups, 30/36 patients were of African origin (countries of origin: Burundi, Eritrea, Ethiopia, Sudan, Ivory Coast, Kenya, Liberia, Rwanda, Somalia, Tanzania and Uganda), 4/36 were of Asian origin (countries of origin: India, Philippines, Thailand and Uzbekistan) and 2/36 were of Latin American origin (countries of origin: Chile and Honduras)",rs28399433,research
cytarabine,Efficacy,P value  5.0E-4,Unknown,rs6811453,research
voriconazole,Dosage,P value  0.01,European,CYP2C19*1,research
voriconazole,Dosage,P value  0.01,European,CYP2C19*2,research
voriconazole,Dosage,P value  0.01,European,CYP2C19*17,research
tenofovir,Metabolism/PK,P value  0.007,East Asian,rs3742106,research
cytarabine,Efficacy,P value  9.0E-4,Unknown,rs1826909,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.01,Unknown,rs35599367,research
tacrolimus,Metabolism/PK,P value  0.01,Unknown,rs35599367,research
efavirenz,Metabolism/PK,P value  0.0005,"Multiple groups, 30/36 patients were of African origin (countries of origin: Burundi, Eritrea, Ethiopia, Sudan, Ivory Coast, Kenya, Liberia, Rwanda, Somalia, Tanzania and Uganda), 4/36 were of Asian origin (countries of origin: India, Philippines, Thailand and Uzbekistan) and 2/36 were of Latin American origin (countries of origin: Chile and Honduras)",rs3745274,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,rs776746,research
dimethyl fumarate,Efficacy,P value  0.0017,Unknown,rs1695,research
atorvastatin,Efficacy,P value  0.01,Unknown,rs20455,research
efavirenz,Metabolism/PK,P value  0.0005,"Multiple groups, 30/36 patients were of African origin (countries of origin: Burundi, Eritrea, Ethiopia, Sudan, Ivory Coast, Kenya, Liberia, Rwanda, Somalia, Tanzania and Uganda), 4/36 were of Asian origin (countries of origin: India, Philippines, Thailand and Uzbekistan) and 2/36 were of Latin American origin (countries of origin: Chile and Honduras)",rs35303484,research
silibinin,Metabolism/PK,P value  0.0007,East Asian,rs1045642,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.005,East Asian,rs776746,research
pantoprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*1,research
pantoprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*2,research
pantoprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*17,research
anthracyclines and related substances,Efficacy,P value  0.006,Multiple groups,GSTM1 non-null,research
anthracyclines and related substances,Efficacy,P value  0.006,Multiple groups,GSTM1 null,research
methotrexate,Metabolism/PK,P value  0.0001,Near Eastern,rs1801133,research
methotrexate,Toxicity,P value  0.0001,Near Eastern,rs1801133,research
lansoprazole,Efficacy,P value  0.0038,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.0038,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.0038,Unknown,CYP2C19*3,research
cisplatin,Efficacy,P value  0.006,European,rs2072671,research
warfarin,Dosage,P value  1.6e-8,American,rs9934438,research
warfarin,Dosage,P value  1.4e-5,American,rs9934438,research
sufentanil,Metabolism/PK,P value  0.01,Unknown,CYP3A4*1,research
sufentanil,Metabolism/PK,P value  0.01,Unknown,CYP3A4*1G,research
warfarin,Dosage,P value  0.001,European,rs9934438,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
imatinib,Efficacy,P value  0.00629,European,rs1045642,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.003,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.003,East Asian,CYP3A5*3,research
nicotine,Metabolism/PK,P value  0.005,East Asian,rs28399433,research
fentanyl,Efficacy,P value  0.006,East Asian,rs7439366,research
imatinib,Efficacy,P value  0.00629,European,rs683369,research
imipramine,Metabolism/PK,P value  0.01,European,CYP2C19 poor metabolizers,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, 84.4% Caucasian;9.8% African ancestry;2.9% Asian;2.9% other.",CYP2C9*1,research
warfarin,Dosage,P value  0.001,"Multiple groups, 84.4% Caucasian;9.8% African ancestry;2.9% Asian;2.9% other.",CYP2C9*3,research
tacrolimus,Metabolism/PK,P value  0.0011,Unknown,CYP3A5 poor metabolizers,research
warfarin,Dosage,P value  0.001,"Multiple groups, 84.4% Caucasian;9.8% African ancestry;2.9% Asian;2.9% other.",rs9923231,research
tacrolimus,Dosage,P value  0.0001,Unknown,CYP3A5*1,research
tacrolimus,Dosage,P value  0.0001,Unknown,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  5.5E-6,Multiple groups,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  5.5E-6,Multiple groups,CYP3A5*3,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2D6 poor metabolizers,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2D6 poor metabolizers,research
warfarin,Metabolism/PK,P value  4.5E-17,Unknown,rs1057910,research
warfarin,Dosage,P value  4.5E-17,Unknown,rs1057910,research
lansoprazole,Metabolism/PK,P value  0.0024,Unknown,CYP2C19*1,research
lansoprazole,Metabolism/PK,P value  0.0024,Unknown,CYP2C19*2,research
lansoprazole,Metabolism/PK,P value  0.0024,Unknown,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.001,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Latino,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.01,Latino,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.01,Latino,CYP3A5*3,research
hmg coa reductase inhibitors,Efficacy,P value  0.0024,African American/Afro-Caribbean,rs11591147,research
cisplatin,Efficacy,P value  0.0001,Unknown,rs25648,research
cisplatin,Efficacy,P value  0.003,Unknown,rs25648,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,rs9282564,research
tacrolimus,Metabolism/PK,P value  0.005,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.005,Unknown,CYP3A5*3,research
citalopram,Efficacy,P value  0.01,Multiple groups,rs4713916,research
citalopram,Efficacy,P value  0.01,European,rs4713916,research
tacrolimus,Dosage,P value  0.003,Near Eastern,rs1045642,research
bupropion,Metabolism/PK,P value  0.003,East Asian,CYP2B6*1,research
bupropion,Metabolism/PK,P value  0.003,East Asian,CYP2B6*6,research
mianserin,Metabolism/PK,P value  0.007,East Asian,CYP2D6*1,research
mianserin,Metabolism/PK,P value  0.007,East Asian,CYP2D6*5,research
mianserin,Metabolism/PK,P value  0.007,East Asian,CYP2D6*10,research
aripiprazole,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
aripiprazole,Metabolism/PK,P value  0.01,East Asian,CYP2D6*5,research
aripiprazole,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
aripiprazole,Metabolism/PK,P value  0.01,East Asian,CYP2D6*41,research
bevacizumab,Efficacy,P value  0.007,East Asian,rs800292,research
bevacizumab,Efficacy,P value  0.006,East Asian,rs11200638,research
olanzapine,Efficacy,P value  3.33E-4,European,rs221253,research
bevacizumab,Efficacy,P value  0.007,East Asian,rs10490924,research
tacrolimus,Metabolism/PK,P value  0.002,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.007,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs909530,research
tacrolimus,Dosage,P value  0.0001,Latino,CYP3A5*1,research
tacrolimus,Dosage,P value  0.0001,Latino,CYP3A5*3,research
olanzapine,Efficacy,P value  2.07E-4,European,rs2247408,research
tacrolimus,Metabolism/PK,P value  0.008,East Asian,rs1800822,research
perphenazine,Efficacy,P value  4.83E-4,European,rs11100483,research
quetiapine,Efficacy,P value  1.81E-4,European,rs35793,research
risperidone,Efficacy,P value  4.99E-5,European,rs9713,research
risperidone,Efficacy,P value  1.85E-4,European,rs874295,research
tacrolimus,Metabolism/PK,P value  0.0082,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0082,Unknown,CYP3A5*3,research
mephenytoin,Metabolism/PK,P value  0.0001,European,CYP2C19*1,research
mephenytoin,Metabolism/PK,P value  0.0001,European,CYP2C19*2,research
perphenazine,Efficacy,P value  1.69E-5,European,rs2278773,research
valproic acid,Dosage,P value  0.003,East Asian,UGT1A6*1a,research
valproic acid,Dosage,P value  0.003,East Asian,UGT1A6*2a,research
valproic acid,Dosage,P value  0.003,East Asian,UGT1A6*3a,research
valproic acid,Dosage,P value  0.003,East Asian,UGT1A6*4a,research
valproic acid,Dosage,P value  0.003,East Asian,UGT1A6*8,research
valproic acid,Dosage,P value  0.004,East Asian,UGT1A6*1a,research
valproic acid,Dosage,P value  0.004,East Asian,UGT1A6*2a,research
valproic acid,Dosage,P value  0.004,East Asian,UGT1A6*3a,research
valproic acid,Dosage,P value  0.004,East Asian,UGT1A6*4a,research
valproic acid,Dosage,P value  0.004,East Asian,UGT1A6*8,research
valproic acid,Dosage,P value  0.006,East Asian,UGT1A6*1a,research
valproic acid,Dosage,P value  0.006,East Asian,UGT1A6*2a,research
valproic acid,Dosage,P value  0.006,East Asian,UGT1A6*3a,research
valproic acid,Dosage,P value  0.006,East Asian,UGT1A6*4a,research
valproic acid,Dosage,P value  0.006,East Asian,UGT1A6*8,research
valproic acid,Dosage,P value  0.01,East Asian,UGT1A6*1a,research
valproic acid,Dosage,P value  0.01,East Asian,UGT1A6*2a,research
valproic acid,Dosage,P value  0.01,East Asian,UGT1A6*3a,research
valproic acid,Dosage,P value  0.01,East Asian,UGT1A6*4a,research
valproic acid,Dosage,P value  0.01,East Asian,UGT1A6*8,research
perphenazine,Efficacy,P value  2.09E-4,European,rs2116971,research
perphenazine,Efficacy,P value  3.41E-4,European,rs9952628,research
simvastatin,Efficacy,P value  0.0059,"Multiple groups, 75% white, 20% black, 5% asian",rs2003569,research
ziprasidone,Efficacy,P value  4.41E-4,European,rs17194378,research
ziprasidone,Efficacy,P value  4.79E-4,European,rs9585618,research
cyclosporine,Metabolism/PK,P value  0.00003,"Multiple groups, Caucasian, Mediterranean, Asian, Black, Other",CYP3A4*1,research
cyclosporine,Metabolism/PK,P value  0.00003,"Multiple groups, Caucasian, Mediterranean, Asian, Black, Other",CYP3A4*22,research
fluoxetine,Efficacy,P value  0.00059,European,rs9361235,research
sulfinpyrazone,Metabolism/PK,P value  0.01,Unknown,rs72551330,research
fluoxetine,Efficacy,P value  0.0018,European,rs9361233,research
risperidone,Efficacy,P value  3.04E-4,European,rs1315115,research
ivacaftor,Efficacy,P value  0.0001,Multiple groups,rs75527207,research
ivacaftor,Efficacy,P value  0.0001,Multiple groups,rs75527207,research
ivacaftor,Efficacy,P value  0.0001,Multiple groups,rs75527207,research
ivacaftor,Efficacy,P value  0.0006,Multiple groups,rs75527207,research
risperidone,Efficacy,P value  4.11E-4,European,rs3738883,research
ziprasidone,Efficacy,P value  6.29E-5,European,rs4925300,research
warfarin,Dosage,P value  0.004,East Asian,rs10517,research
latanoprost,Efficacy,P value  0.003,East Asian,rs11568658,research
latanoprost,Efficacy,P value  0.008,East Asian,rs11568658,research
latanoprost,Efficacy,P value  0.009,East Asian,rs11568658,research
warfarin,Dosage,P value  0.003,Near Eastern,rs2108622,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*1,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*3,research
tacrolimus,Dosage,P value  0.0003,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*1,research
tacrolimus,Dosage,P value  0.0003,"Multiple groups, Caucasian, East Asian, South Asian, Black, Other",CYP3A5*3,research
methacholine chloride,Other,P value  9.0E-4,Unknown,rs11702779,research
cotinine,Metabolism/PK,P value  0.003,African American/Afro-Caribbean,rs2942857,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
cotinine,Metabolism/PK,P value  0.002,African American/Afro-Caribbean,rs2942857,research
clopidogrel,Efficacy,P value  0.001,"Multiple groups, Chinese, Malay, Indian mixed population.",rs4244285,research
methacholine chloride,Other,P value  9.0E-4,Unknown,rs11702779,research
tacrolimus,Metabolism/PK,P value  0.000,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.000,East Asian,CYP3A4*18,research
clopidogrel,Efficacy,P value  0.001,"Multiple groups, Chinese, Malay, Indian mixed population.",rs4986893,research
tacrolimus,Dosage,P value  0.001,European,rs3814055,research
citalopram,Efficacy,P value  0.01,European,rs7124442,research
clopidogrel,Efficacy,P value  1.0E-4,"Multiple groups, Chinese, Malay, Indian mixed population.",rs12248560,research
tacrolimus,Metabolism/PK,P value  0.002,European,rs3814055,research
tacrolimus,Metabolism/PK,P value  0.004,European,rs3814055,research
efavirenz,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,rs3745274,research
tacrolimus,Dosage,P value  1E-4,European,CYP3A5*1,research
tacrolimus,Dosage,P value  1E-4,European,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*3,research
anastrozole,Efficacy,P value  0.002,East Asian,rs4646,research
tacrolimus,Metabolism/PK,P value  0.000,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.000,East Asian,CYP3A5*3,research
metformin,Metabolism/PK,P value  0.002,European,rs12943590,research
metformin,Efficacy,P value  0.002,European,rs12943590,research
hydrochlorothiazide,Efficacy,P value  0.01,European,rs2269879,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.009,European,rs3761847,research
lovastatin acid,Metabolism/PK,P value  0.000,East Asian,rs4149056,research
citalopram,Efficacy,P value  0.001,European,rs6265,research
tacrolimus,Metabolism/PK,P value  0.00006,East Asian,rs776746,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*3,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*4,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*5,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*6,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*10,research
tramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6*41,research
methotrexate,Efficacy,P value  0.007,Unknown,rs17731538,research
fentanyl,Efficacy,P value  0.001,East Asian,rs7583431,research
lovastatin,Metabolism/PK,P value  0.005,East Asian,rs4823613,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs2257401,research
nevirapine,Metabolism/PK,P value  0.001,Sub-Saharan African,rs3745274,research
dolutegravir,Metabolism/PK,P value  0.0005,East Asian,rs2231142,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Black or White",CYP2D6 normal metabolizer and ultrarapid metabolizer,research
endoxifen,Metabolism/PK,P value  0.01,Multiple groups,CYP2D6 normal metabolizer and ultrarapid metabolizer,research
serotonin,Other,P value  9.28E-8,European,rs696692,research
serotonin,Other,P value  3.99E-7,European,rs696692,research
serotonin,Other,P value  7.54E-7,European,rs696692,research
warfarin,Dosage,P value  0.004,Unknown,rs1799853,research
citalopram,Efficacy,P value  0.003,European,rs7103411,research
serotonin,Other,P value  7.84E-9,European,rs11947402,research
serotonin,Other,P value  5.6E-8,European,rs11947402,research
serotonin,Other,P value  1.25E-6,European,rs11947402,research
exenatide,Efficacy,P value  0.002,Unknown,rs10305420,research
imipramine,Metabolism/PK,P value  0.0076,European,CYP2C19*1,research
imipramine,Metabolism/PK,P value  0.0076,European,CYP2C19*2,research
ramipril,Efficacy,P value  0.003,African American/Afro-Caribbean,rs4359,research
o-desmethyltramadol,Metabolism/PK,P value  0.0001,Near Eastern,CYP2D6 poor metabolizer,research
irbesartan,Efficacy,P value  0.004,European,rs1367117,research
irbesartan,Metabolism/PK,P value  0.004,European,rs1367117,research
irbesartan,Efficacy,P value  0.004,European,rs1367117,research
adalimumab,Efficacy,P value  0.009,European,rs2071303,research
allopurinol,Efficacy,P value  8.1E-11,Multiple groups,rs2231142,research
allopurinol,Efficacy,P value  4.7E-9,European,rs2231142,research
allopurinol,Efficacy,P value  5.4E-9,"Multiple groups, Non-Hispanic whites, Asians, African Americans and Latinos",rs2231142,research
warfarin,Dosage,P value  0.01,European,rs9923231,research
warfarin,Dosage,P value  0.01,European,rs9923231,research
warfarin,Dosage,P value  0.0009,African American/Afro-Caribbean,rs4889606,research
warfarin,Dosage,P value  0.005,African American/Afro-Caribbean,rs4889606,research
antidepressants,Efficacy,P value  0.0063760,East Asian,rs521093,research
antidepressants,Efficacy,P value  0.001,"Multiple groups, Caucasian and Asian",rs6313,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2 slow acetylator,research
antidepressants,Efficacy,P value  0.0042650,East Asian,rs2299267,research
antidepressants,Efficacy,P value  0.0057920,East Asian,rs2112460,research
allopurinol,Efficacy,P value  4.03E-7,"Multiple groups, Non-Hispanic White, Asian, African American and Latino",rs1934341,research
allopurinol,Efficacy,P value  3.2E-6,Multiple groups,rs1934341,research
allopurinol,Efficacy,P value  0.009,European,rs1934341,research
tacrolimus,Metabolism/PK,P value  0.0002,East Asian,rs4844880,research
escitalopram,Efficacy,P value  0.008,European,SLC6A4 HTTLPR long form (L allele),research
escitalopram,Efficacy,P value  0.008,European,SLC6A4 HTTLPR short form (S allele),research
allopurinol,Efficacy,P value  1.4E-7,European,rs77567654,research
antidepressants,Efficacy,P value  0.0024890,East Asian,rs10997242,research
allopurinol,Efficacy,P value  7.94E-8,European,rs45499402,research
antidepressants,Efficacy,P value  0.0035970,East Asian,rs16873129,research
clopidogrel,Efficacy,P value  1.66e-5,East Asian,rs4244285,research
acenocoumarol,Dosage,P value  0.004,Multiple groups,rs3735814,research
citalopram,Efficacy,P value  0.006,European,rs2270007,research
peginterferon alfa-2b,Efficacy,P value  0.00014,East Asian,rs8099917,research
antidepressants,Efficacy,P value  0.0009939,East Asian,rs49411,research
antidepressants,Efficacy,P value  0.002075,East Asian,rs2532560,research
efavirenz,Metabolism/PK,P value  0.002,East Asian,rs2279345,research
efavirenz,Metabolism/PK,P value  0.005,East Asian,rs2279345,research
efavirenz,Metabolism/PK,P value  0.007,East Asian,rs2279345,research
tipiracil hydrochloride,Efficacy,P value  0.001,East Asian,rs9394992,research
efavirenz,Metabolism/PK,P value  0.007,East Asian,rs2279345,research
antidepressants,Efficacy,P value  0.003134,East Asian,rs766127,research
antidepressants,Efficacy,P value  0.003246,East Asian,rs4737771,research
antidepressants,Efficacy,P value  0.00001,East Asian,rs9315310,research
buprenorphine,Efficacy,P value  0.001,African American/Afro-Caribbean,rs678849,research
antidepressants,Efficacy,P value  0.001748,East Asian,rs672170,research
rosuvastatin,Metabolism/PK,P value  0.003,East Asian,rs4149056,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*1,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*2xN,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*3,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*4,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*5,research
peginterferon alfa-2b,Efficacy,P value  0.009,European,rs12979860,research
voriconazole,Metabolism/PK,P value  0.00001,Near Eastern,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.00001,Near Eastern,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.00001,Near Eastern,CYP2C19*17,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*4,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*5,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*5,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*6,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*6,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*7,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*7,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*14,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*14,research
isoniazid,Metabolism/PK,P value  0.003,East Asian,NAT2*19,research
isoniazid,Dosage,P value  0.003,East Asian,NAT2*19,research
omeprazole,Metabolism/PK,P value  0.01,European,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.01,European,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.01,European,CYP2C19*17,research
corticosteroids,Efficacy,P value  0.009,Unknown,rs3842689,research
peginterferon alfa-2b,Efficacy,P value  2.70E-7,European,rs11322783,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*3,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*2xN,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*3,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*4,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*5,research
benazepril,Efficacy,P value  0.001,Unknown,rs2106089,research
voriconazole,Metabolism/PK,P value  0.002,Unknown,CYP2C19 poor metabolizers and intermediate metabolizers,research
nicotine,Efficacy,P value  0.007,"Multiple groups, 74% Caucasian;16% Hispanic;4% African American;6% other.",rs4950,research
nicotine,Other,P value  0.007,"Multiple groups, 74% Caucasian;16% Hispanic;4% African American;6% other.",rs4950,research
mephenytoin,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
mephenytoin,Metabolism/PK,P value  0.01,Unknown,CYP2C19*26,research
mephenytoin,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
mephenytoin,Metabolism/PK,P value  0.01,Unknown,CYP2C19*26,research
benazepril,Efficacy,P value  0.001,East Asian,rs4762,research
imatinib,Efficacy,P value  0.001,"Multiple groups, Mixed Asian",rs776746,research
irbesartan,Efficacy,P value  0.0096,European,rs1799752,research
deferasirox,Efficacy,P value  0.005,"Multiple groups, Caucasian and 'Other' ethnicities.",rs887829,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*3,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*4,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*5,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*6,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*1,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*3,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*4,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*5,research
trimipramine,Metabolism/PK,P value  0.005,Unknown,CYP2D6*6,research
deferasirox,Efficacy,P value  0.009,"Multiple groups, Caucasian and 'Other' ethnicities.",rs1983023,research
deferasirox,Efficacy,P value  0.010,"Multiple groups, Caucasian and 'Other' ethnicities.",rs10877012,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs10499563,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs10499563,research
methotrexate,Metabolism/PK,P value  0.008,Unknown,rs717620,research
efavirenz,Metabolism/PK,P value  0.00038,"Multiple groups, Self-identified as Black, White or Hispanic.",rs28399433,research
efavirenz,Metabolism/PK,P value  0.001,European,rs28399433,research
efavirenz,Metabolism/PK,P value  0.004,"Multiple groups, Self-identified as Black, White or Hispanic.",rs28399433,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2C19*2,research
efavirenz,Metabolism/PK,P value  0.0063,"Multiple groups, Self-identified as Black, White or Hispanic.",rs28365062,research
antipsychotics,Efficacy,P value  3.8E-7,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs2229949,research
efavirenz,Metabolism/PK,P value  0.004,"Multiple groups, Self-identified as Black, White or Hispanic.",rs28399499,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, 87% White",CYP2D6 poor metabolizers,research
benazepril,Efficacy,P value  0.001,East Asian,rs2229437,research
benazepril,Efficacy,P value  0.001,East Asian,rs2229437,research
benazepril,Efficacy,P value  0.005,East Asian,rs2229437,research
tacrolimus,Metabolism/PK,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Central/South Asian,CYP3A5*3,research
carbamazepine,Metabolism/PK,P value  0.01,East Asian,rs776746,research
valproic acid,Metabolism/PK,P value  0.006,East Asian,rs3816877,research
antipsychotics,Efficacy,P value  3.42E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs2238087,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs5030728,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs3804099,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs3804099,research
antipsychotics,Efficacy,P value  2.34E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs12060765,research
salbutamol,PD,P value  0.004,Unknown,rs3025039,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*1,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*2,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*3,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*4,research
antipsychotics,Efficacy,P value  2.49E-7,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs4505744,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*1,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19*17,research
antipsychotics,Efficacy,P value  3.15E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs10741058,research
rosiglitazone,Efficacy,P value  0.0033,East Asian,rs6467136,research
rosiglitazone,Efficacy,P value  0.0070,East Asian,rs6467136,research
rosiglitazone,Efficacy,P value  0.0091,East Asian,rs6467136,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.001,European,rs9923231,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Caucasian, Asian, Latino",CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Caucasian, Asian, Latino",CYP3A5*3,research
carbamazepine,Metabolism/PK,P value  0.001,East Asian,rs1045642,research
antipsychotics,Efficacy,P value  1.37E-8,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs982003,research
rosiglitazone,Efficacy,P value  0.0063,East Asian,rs6467136,research
simvastatin,Efficacy,P value  0.01,East Asian,rs662799,research
simvastatin acid,Metabolism/PK,P value  0.0001,"Multiple groups, Patients were of Caucasian, Hispanic or African American ethnicity",rs4149056,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
antipsychotics,Efficacy,P value  2.3E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs12245847,research
tacrolimus,Metabolism/PK,P value  6.08E-98,European,rs776746,research
tacrolimus,Metabolism/PK,P value  2.34E-14,African American/Afro-Caribbean,rs776746,research
tacrolimus,Metabolism/PK,P value  1.46E-79,European,rs2257401,research
atorvastatin,Efficacy,P value  0.01,East Asian,rs662799,research
atorvastatin,Efficacy,P value  0.01,East Asian,rs662799,research
tacrolimus,Metabolism/PK,P value  6.08E-98,European,rs2242480,research
tacrolimus,Metabolism/PK,P value  1.91E-08,African American/Afro-Caribbean,rs2242480,research
warfarin,Dosage,P value  0.002,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.002,Multiple groups,CYP2C9*2,research
warfarin,Dosage,P value  0.002,Multiple groups,CYP2C9*3,research
tacrolimus,Metabolism/PK,P value  5.63E-53,European,rs4646437,research
tacrolimus,Metabolism/PK,P value  8.86E-08,African American/Afro-Caribbean,rs4646437,research
tacrolimus,Dosage,P value  0.001,Latino,rs776746,research
antipsychotics,Efficacy,P value  1.76E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs1277733,research
tacrolimus,Metabolism/PK,P value  4.81E-19,European,rs35599367,research
antipsychotics,Efficacy,P value  0.00004,European,rs11030104,research
peginterferon alfa-2a,Efficacy,P value  0.001,European,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.0036,European,rs12979860,research
hdl cholesterol,Toxicity,P value  0.001,European,rs8450,research
antipsychotics,Efficacy,P value  1.55E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs4237348,research
tacrolimus,Metabolism/PK,P value  1.74E-24,European,rs2740574,research
atorvastatin,Other,P value  0.001,East Asian,rs662799,research
tacrolimus,Dosage,P value  1.0E-4,Unknown,rs776746,research
antipsychotics,Efficacy,P value  3.25E-7,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs1859204,research
paroxetine,Efficacy,P value  0.0001,Unknown,SLC6A4 HTTLPR long form (L allele),research
paroxetine,Efficacy,P value  0.0001,Unknown,SLC6A4 HTTLPR short form (S allele),research
nortriptyline,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*1,research
nortriptyline,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*2,research
nortriptyline,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*3,research
antipsychotics,Efficacy,P value  1.36E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs7427395,research
tacrolimus,Metabolism/PK,P value  0.01,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
sertraline,Metabolism/PK,P value  0.0001,Unknown,CYP2B6*1,research
sertraline,Metabolism/PK,P value  0.0001,Unknown,CYP2B6*6,research
sertraline,Metabolism/PK,P value  0.0001,Unknown,CYP2B6*9,research
antipsychotics,Efficacy,P value  2.36E-6,"Multiple groups, 80% South African Coloured, 12% Xhosa, 8% European",rs3768652,research
cyclosporine,Metabolism/PK,P value  0.01,"Multiple groups, White, Black, Asian",rs1045642,research
venlafaxine,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
venlafaxine,Metabolism/PK,P value  0.01,East Asian,CYP2D6*2,research
venlafaxine,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
morphine,Dosage,P value  2.96E-7,European,rs795484,research
morphine,Efficacy,P value  2.96E-7,European,rs795484,research
morphine,Dosage,P value  1.01E-6,European,rs795484,research
morphine,Efficacy,P value  1.01E-6,European,rs795484,research
morphine,Dosage,P value  1.55E-5,"Multiple groups, European Caucasian and African American patients",rs795484,research
morphine,Efficacy,P value  1.55E-5,"Multiple groups, European Caucasian and African American patients",rs795484,research
morphine,Dosage,P value  1E-4,European,rs795484,research
morphine,Efficacy,P value  1E-4,European,rs795484,research
prednisone,Efficacy,P value  0.008,East Asian,rs6196,research
antipsychotics,Efficacy,P value  0.0006,European,rs10501087,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, 74% Caucasian",CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, 74% Caucasian",CYP3A4*22,research
antipsychotics,Efficacy,P value  0.0013,European,rs6265,research
docetaxel,Metabolism/PK,P value  0.009,East Asian,rs4842198,research
morphine,Dosage,P value  7.99E-7,European,rs1277441,research
morphine,Efficacy,P value  7.99E-7,European,rs1277441,research
morphine,Dosage,P value  2.77E-6,European,rs1277441,research
morphine,Efficacy,P value  2.77E-6,European,rs1277441,research
morphine,Dosage,P value  1.41E-5,"Multiple groups, European Caucasian and African American patients",rs1277441,research
morphine,Efficacy,P value  1.41E-5,"Multiple groups, European Caucasian and African American patients",rs1277441,research
morphine,Dosage,P value  1E-4,European,rs1277441,research
morphine,Efficacy,P value  1E-4,European,rs1277441,research
warfarin,Dosage,P value  0.001,Unknown,rs1057910,research
irinotecan,Metabolism/PK,P value  0.009,Unknown,rs10934498,research
irinotecan,Toxicity,P value  0.009,Unknown,rs10934498,research
imatinib,Dosage,P value  0.0002,Unknown,rs2231137,research
imatinib,Dosage,P value  0.001,Unknown,rs2231137,research
acenocoumarol,Dosage,P value  0.005,Unknown,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.005,Unknown,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*3,research
fluvoxamine,Efficacy,P value  0.01,East Asian,rs6311,research
clozapine,Metabolism/PK,P value  0.01,East Asian,rs2231142,research
acenocoumarol,Dosage,P value  0.001,Unknown,rs9923231,research
tacrolimus,Metabolism/PK,P value  1.2E-105,Multiple groups,CYP3A5*1,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0036,European,rs3794271,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs1128503,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs776746,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6 poor metabolizers,research
repaglinide,Metabolism/PK,P value  0.010,East Asian,rs4149056,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs1128503,research
docetaxel,Metabolism/PK,P value  0.009,East Asian,rs3132291,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.003,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.003,East Asian,CYP3A5*3,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*1,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*2,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*3,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.006,Unknown,rs1136703,research
peginterferon alfa-2a,Efficacy,P value  0.0001,Latino,rs12979860,research
caffeine,Metabolism/PK,P value  0.001,Multiple groups,rs762551,research
caffeine,Metabolism/PK,P value  0.003,Multiple groups,rs762551,research
caffeine,Metabolism/PK,P value  0.005,Multiple groups,rs762551,research
caffeine,Metabolism/PK,P value  0.005,Multiple groups,rs762551,research
methotrexate,Metabolism/PK,P value  0.004,European,rs4149056,research
peginterferon alfa-2a,Efficacy,P value  0.009,Near Eastern,HLA-B*38:01:01,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*1,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*2,research
sertraline,Metabolism/PK,P value  0.001,European,CYP2C19*3,research
methotrexate,Metabolism/PK,P value  6.9E-8,Unknown,rs4149056,research
methotrexate,Metabolism/PK,P value  3.2E-7,Unknown,rs4149056,research
methotrexate,Metabolism/PK,P value  3.5E-4,Unknown,rs4149056,research
peginterferon alfa-2b,Efficacy,P value  6.71E-4,Multiple groups,rs1792774,research
methylphenidate,Efficacy,P value  0.01,East Asian,rs5569,research
peginterferon alfa-2b,Efficacy,P value  9.47E-4,Multiple groups,rs17461620,research
methotrexate,Metabolism/PK,P value  5.5E-3,Unknown,rs2306283,research
methotrexate,Metabolism/PK,P value  7.7E-3,Unknown,rs2306283,research
buprenorphine,Efficacy,P value  0.003,Unknown,rs2740574,research
allopurinol,Efficacy,P value  0.00063,"Multiple groups, 53% White, 42% Polynesian (Maori), 5% Asian",rs2231142,research
tamoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
tamoxifen,Metabolism/PK,P value  0.0009,Multiple groups,CYP2D6 intermediate metabolizers,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*1xN,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*2xN,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.001,Multiple groups,CYP2D6*41,research
oxycodone,Dosage,P value  0.001,Unknown,rs1799971,research
peginterferon alfa-2b,Efficacy,P value  0.0046,European,rs12979860,research
peginterferon alfa-2b,Efficacy,P value  0.0002,European,rs12979860,research
metformin,Efficacy,P value  0.0009,Central/South Asian,rs622342,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*6,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.006,Unknown,rs1059491,research
peginterferon alfa-2b,Efficacy,P value  8.62E-5,Multiple groups,rs1931704,research
peginterferon alfa-2b,Efficacy,P value  8.91E-5,Multiple groups,rs7750468,research
repaglinide,Metabolism/PK,P value  0.003,East Asian,rs4149056,research
repaglinide,Metabolism/PK,P value  0.004,East Asian,rs4149056,research
repaglinide,Metabolism/PK,P value  0.004,East Asian,rs4149056,research
peginterferon alfa-2b,Efficacy,P value  1.53E-4,Multiple groups,rs1503391,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*17,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*41,research
peginterferon alfa-2b,Efficacy,P value  2.58E-4,Multiple groups,rs2066911,research
peginterferon alfa-2b,Efficacy,P value  2.87E-4,Multiple groups,rs557905,research
omeprazole,Metabolism/PK,P value  0.01,European,rs11188072,research
omeprazole,Dosage,P value  0.01,European,rs11188072,research
peginterferon alfa-2b,Efficacy,P value  4.30E-4,Multiple groups,rs568910,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.00069,European,CYP2D6*6,research
peginterferon alfa-2b,Efficacy,P value  4.47E-4,Multiple groups,rs3093390,research
omeprazole,Metabolism/PK,P value  0.01,European,rs12248560,research
omeprazole,Dosage,P value  0.01,European,rs12248560,research
glucose,Metabolism/PK,P value  0.003,East Asian,rs4149056,research
glucose,Metabolism/PK,P value  0.003,East Asian,rs4149056,research
glucose,Metabolism/PK,P value  0.005,East Asian,rs4149056,research
methotrexate,Efficacy,P value  0.001,Central/South Asian,rs2853539,research
atorvastatin,Efficacy,P value  0.001,Central/South Asian,rs3808607,research
peginterferon alfa-2b,Efficacy,P value  9.25E-9,Multiple groups,rs8099917,research
warfarin,Dosage,P value  0.0012,European,rs4760658,research
amisulpride,Efficacy,P value  1.0E-6,East Asian,rs10042486,research
amisulpride,Efficacy,P value  9.0E-5,East Asian,rs10042486,research
amisulpride,Efficacy,P value  0.002,East Asian,rs10042486,research
warfarin,Dosage,P value  0.0026,European,rs11168292,research
lansoprazole,Metabolism/PK,P value  0.01,Near Eastern,CYP2C19*1,research
lansoprazole,Metabolism/PK,P value  0.01,Near Eastern,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*3,research
peginterferon alfa-2b,Efficacy,P value  4.3E-7,East Asian,rs8099917,research
peginterferon alfa-2b,Efficacy,P value  3.6E-6,East Asian,rs7248668,research
peginterferon alfa-2b,Efficacy,P value  0.0006,East Asian,rs10853728,research
voriconazole,Metabolism/PK,P value  0.007,Multiple groups,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.007,Multiple groups,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.007,Multiple groups,CYP2C19*17,research
atazanavir,Dosage,P value  0.001,Unknown,rs1045642,research
donepezil,Efficacy,P value  0.005,European,rs1803274,research
donepezil,Efficacy,P value  0.01,European,rs1803274,research
voriconazole,Metabolism/PK,P value  0.01,Multiple groups,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Multiple groups,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.01,Multiple groups,CYP2C19*17,research
atazanavir,Dosage,P value  0.001,Unknown,rs2472677,research
rituximab,Efficacy,P value  0.008,European,rs1800471,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*17,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP2D6*41,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*17,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*41,research
rituximab,Efficacy,P value  0.002,European,rs1800470,research
rituximab,Efficacy,P value  0.008,European,rs1800470,research
morphine,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African-American children.",rs34059508,research
docetaxel,Efficacy,P value  0.0083,"Multiple groups, 43 white, 3 african american, 1 asian",rs1402467,research
peginterferon alfa-2b,Efficacy,P value  1.48E-7,East Asian,rs4803219,research
bevacizumab,Efficacy,P value  0.008,Unknown,rs329007,research
peginterferon alfa-2b,Efficacy,P value  3.1E-8,East Asian,rs12979860,research
morphine,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African-American children.",rs12208357,research
peginterferon alfa-2b,Efficacy,P value  1.1E-7,East Asian,rs11881222,research
morphine,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African-American children.",rs72552763,research
peginterferon alfa-2b,Efficacy,P value  2.0E-6,East Asian,rs12980275,research
peginterferon alfa-2b,Efficacy,P value  5.5E-7,East Asian,rs8105790,research
carbamazepine,Metabolism/PK,P value  1.0E-4,East Asian,rs1051740,research
carbamazepine,Dosage,P value  1.0E-4,East Asian,rs1051740,research
carbamazepine,Metabolism/PK,P value  1.0E-4,East Asian,rs1051740,research
carbamazepine,Dosage,P value  1.0E-4,East Asian,rs1051740,research
methotrexate,Metabolism/PK,P value  0.00064,Multiple groups,SLCO1B1*1A,research
methotrexate,Metabolism/PK,P value  0.00064,Multiple groups,SLCO1B1*1B,research
methotrexate,Metabolism/PK,P value  0.00064,Multiple groups,SLCO1B1*5,research
risperidone,Efficacy,P value  1.1E-8,Multiple groups,rs1875705,research
cisplatin,Efficacy,P value  0.008,East Asian,rs4492666,research
morphine,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African-American children.",rs34130495,research
methotrexate,Metabolism/PK,P value  9.2e-9,Multiple groups,SLCO1B1*1A,research
methotrexate,Metabolism/PK,P value  9.2e-9,Multiple groups,SLCO1B1*1B,research
methotrexate,Metabolism/PK,P value  9.2e-9,Multiple groups,SLCO1B1*15,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*10,research
nortriptyline,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
nortriptyline,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
carbamazepine,Metabolism/PK,P value  1.0E-4,East Asian,rs3812718,research
carbamazepine,Dosage,P value  1.0E-4,East Asian,rs3812718,research
methotrexate,Metabolism/PK,P value  0.009,Multiple groups,SLCO1B1*1A,research
methotrexate,Metabolism/PK,P value  0.009,Multiple groups,SLCO1B1*1B,research
methotrexate,Metabolism/PK,P value  0.009,Multiple groups,SLCO1B1*23,research
carbamazepine,Metabolism/PK,P value  1.0E-4,East Asian,rs3812718,research
carbamazepine,Dosage,P value  1.0E-4,East Asian,rs3812718,research
simvastatin,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP3A4*1,research
simvastatin,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP3A4*22,research
cisplatin,Efficacy,P value  0.006,East Asian,rs232043,research
cisplatin,Efficacy,P value  0.007,East Asian,rs2284449,research
ranibizumab,Efficacy,P value  0.001,East Asian,rs833069,research
ranibizumab,Efficacy,P value  0.002,East Asian,rs833069,research
arsenite,Metabolism/PK,P value  7.0E-4,Latino,rs11191439,research
arsenite,Toxicity,P value  7.0E-4,Latino,rs11191439,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,CYP2B6*6,research
simvastatin,Efficacy,P value  0.002,East Asian,rs717620,research
SN-38,Metabolism/PK,P value  0.0014,East Asian,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.0014,East Asian,UGT1A1*28,research
efavirenz,Metabolism/PK,P value  0.000000234,Sub-Saharan African,CYP2B6*6,research
gemcitabine,Metabolism/PK,P value  0.00001,Unknown,rs2072671,research
peginterferon alfa-2a,Efficacy,P value  0.007,Unknown,rs12979860,research
hydroxyurea,Efficacy,P value  0.0001,European,rs10901080,research
peginterferon alfa-2b,Efficacy,P value  0.001,East Asian,rs8099917,research
bilirubin,Metabolism/PK,P value  0.007,East Asian,UGT1A1*1,research
bilirubin,Metabolism/PK,P value  0.007,East Asian,UGT1A1*28,research
methylphenidate,Efficacy,P value  0.001,Unknown,rs1800544,research
methadone,Metabolism/PK,P value  0.009,Unknown,CYP3A5*1,research
methadone,Metabolism/PK,P value  0.009,Unknown,CYP3A5*3,research
methylphenidate,Efficacy,P value  0.0007,Multiple groups,rs5569,research
methacholine,Efficacy,P value  0.009,"Multiple groups, African American and White",rs1042713,research
efavirenz,Metabolism/PK,P value  0.001,Unknown,rs2279345,research
docetaxel,Efficacy,P value  0.009,Unknown,rs1563828,research
methotrexate,Metabolism/PK,P value  1.5e-7,Multiple groups,SLCO1B1*1A,research
methotrexate,Metabolism/PK,P value  1.5e-7,Multiple groups,SLCO1B1*1B,research
methotrexate,Metabolism/PK,P value  1.5e-7,Multiple groups,SLCO1B1*14,research
antidepressants,Efficacy,P value  3.0E-5,European,rs3800373,research
warfarin,Metabolism/PK,P value  0.001,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*1,research
methotrexate,Metabolism/PK,P value  0.007,Multiple groups,SLCO1B1*1A,research
methotrexate,Metabolism/PK,P value  0.007,Multiple groups,SLCO1B1*1B,research
methotrexate,Metabolism/PK,P value  0.007,Multiple groups,SLCO1B1*35,research
antidepressants,Efficacy,P value  3.1E-4,European,rs4713916,research
methylphenidate,Efficacy,P value  0.0001,Multiple groups,rs28386840,research
antidepressants,Efficacy,P value  4.8E-4,European,rs1360780,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.004,European,rs96844,research
peginterferon alfa-2b,Efficacy,P value  0.0000000311,European,rs8099917,research
efavirenz,Metabolism/PK,P value  0.0012,Sub-Saharan African,rs3842,research
methylphenidate,Efficacy,P value  0.01,Multiple groups,rs1800544,research
docetaxel,Efficacy,P value  1.0E-4,"Multiple groups, 43 white, 3 african american, 1 asian",rs4148943,research
interferon alfa-n1,Efficacy,P value  0.001,Unknown,rs12979860,research
interferon alfa-n1,Efficacy,P value  0.006,Unknown,rs8099917,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.003,European,rs11126740,research
docetaxel,Efficacy,P value  0.0056,"Multiple groups, 43 white, 3 african american, 1 asian",rs2016520,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.008,East Asian,CYP2C19*3,research
docetaxel,Efficacy,P value  0.0089,"Multiple groups, 43 white, 3 african american, 1 asian",rs3734254,research
tacrolimus,Metabolism/PK,P value  0.009,East Asian,rs776746,research
docetaxel,Efficacy,P value  0.0055,"Multiple groups, 43 white, 3 african american, 1 asian",rs7769719,research
docetaxel,Efficacy,P value  0.0011,"Multiple groups, 43 white, 3 african american, 1 asian",rs6922548,research
phenprocoumon,Dosage,P value  0.002,Unknown,rs4086116,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
docetaxel,Efficacy,P value  5.0E-4,"Multiple groups, 43 white, 3 african american, 1 asian",rs12418,research
docetaxel,Efficacy,P value  0.0061,"Multiple groups, 43 white, 3 african american, 1 asian",rs1883322,research
phenprocoumon,Dosage,P value  1.0E-4,Unknown,rs10871454,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*1,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*3,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*4,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*9,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*10,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*17,research
venlafaxine,Dosage,P value  0.002,Unknown,CYP2D6*41,research
valproic acid,Metabolism/PK,P value  0.0021,Unknown,rs4244285,research
valproic acid,Dosage,P value  0.0021,Unknown,rs4244285,research
peginterferon alfa-2b,Efficacy,P value  0.000013,European,rs8103142,research
peginterferon alfa-2b,Efficacy,P value  0.000013,European,rs28416813,research
atorvastatin,Efficacy,P value  0.009,"Multiple groups, 82.4% white",rs7412,research
paclitaxel,Metabolism/PK,P value  0.0006,"Multiple groups, '93.2% Caucasian'",CYP2C8*3,research
atorvastatin,Efficacy,P value  1.0E-4,"Multiple groups, 82.4% white",rs12003906,research
atorvastatin,Efficacy,P value  0.005,"Multiple groups, 82.4% white",rs12003906,research
peginterferon alfa-2b,Efficacy,P value  0.000022,European,rs12979860,research
peginterferon alfa-2b,Efficacy,P value  0.000075,European,rs8113007,research
methylphenidate,Efficacy,P value  0.0002,Unknown,rs6265,research
methylphenidate,Efficacy,P value  0.0003,Unknown,rs6265,research
peginterferon alfa-2b,Efficacy,P value  0.0001,European,rs8099917,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs10052999,research
tacrolimus,Metabolism/PK,P value  0.003,East Asian,rs10052999,research
clobazam,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*1,research
clobazam,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*2,research
clobazam,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*3,research
dextromethorphan,Metabolism/PK,P value  1.0E-4,East Asian,rs5030865,research
adrenergics,Efficacy,P value  0.006,European,rs3752120,research
Drugs used in nicotine dependence,Other,P value  9.7E-7,Unknown,rs16969968,research
propafenone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
propafenone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*2,research
propafenone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
propafenone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
propafenone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*36,research
Drugs used in nicotine dependence,Other,P value  9.7E-7,Unknown,rs680244,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  3.34E-11,Unknown,rs3794271,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  1.74E-5,European,rs3794271,research
Drugs used in nicotine dependence,Other,P value  2.7E-8,Unknown,rs16969968,research
fluorouracil,Efficacy,P value  0.001,East Asian,rs11615,research
fluorouracil,Efficacy,P value  0.002,East Asian,rs11615,research
Drugs used in nicotine dependence,Other,P value  2.7E-8,Unknown,rs680244,research
warfarin,Dosage,P value  0.001,Near Eastern,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Near Eastern,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Near Eastern,CYP2C9*3,research
Drugs Used In Diabetes,Efficacy,P value  0.001,Unknown,rs1801278,research
Drugs Used In Diabetes,Efficacy,P value  0.008,Unknown,rs1801278,research
warfarin,Dosage,P value  0.0001,Near Eastern,rs9934438,research
peginterferon alfa-2b,Efficacy,P value  0.000013,European,rs4803217,research
fluorouracil,Efficacy,P value  0.005,East Asian,rs25487,research
gabapentin,Efficacy,P value  0.001,"Multiple groups, Participants were of the following ethnicities: Punjabi, Pathan, Urdu Speaking, Kashmiri and Others",rs4240803,research
methotrexate,Efficacy,P value  0.0016,European,rs1801394,research
methotrexate,Efficacy,P value  0.004,European,rs1801394,research
acenocoumarol,Dosage,P value  0.008,Multiple groups,CYP2C9*3,research
infliximab,Efficacy,P value  0.0046,European,rs3794271,research
tacrolimus,Dosage,P value  2.0E-7,Multiple groups,rs4646458,research
tacrolimus,Dosage,P value  1.12E-11,Multiple groups,rs4646457,research
glatiramer acetate,Efficacy,P value  0.0056,European,rs1012335,research
tacrolimus,Dosage,P value  1.0E-4,"Multiple groups, Caucasian n=44, African-American n=13, Hispanic n=30, Asian n=6, Other n=2.",rs776746,research
tacrolimus,Dosage,P value  6.3E-6,Multiple groups,rs12333983,research
etanercept,Efficacy,P value  2.8E-4,European,rs3794271,research
low density lipoprotein,Other,P value  0.005,Unknown,rs3888190,research
low density lipoprotein,Other,P value  0.007,European,rs3888190,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*13,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*16,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*60,research
metformin,Efficacy,P value  4e-6,European,rs2162145,research
tacrolimus,Metabolism/PK,P value  9.2E-75,Multiple groups,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  9.2E-75,Multiple groups,CYP3A5*3,research
metformin,Efficacy,P value  3.79e-6,Multiple groups,rs254271,research
sumatriptan,Metabolism/PK,P value  3.1e-4,Unknown,rs12208357,research
peginterferon alfa-2a,Efficacy,P value  0.001,East Asian,rs12979860,research
warfarin,Dosage,P value  0.001,Unknown,rs1057910,research
enalapril,Efficacy,P value  0.002,"Multiple groups, Brazil",rs699947,research
fenoterol,Metabolism/PK,P value  4e-6,Unknown,rs12208357,research
fenoterol,Metabolism/PK,P value  4e-6,Unknown,rs34059508,research
furosemide,Efficacy,P value  0.0001,"Multiple groups, Majority Caucasian",rs17268282,research
methadone,Dosage,P value  0.0063,"Multiple groups, Israeli - European, Middle Eastern and Asian mixed ancestry",rs2279343,research
peginterferon alfa-2a,Efficacy,P value  0.001,East Asian,rs8099917,research
fenoterol,Metabolism/PK,P value  4e-6,Unknown,rs55918055,research
sumatriptan,Metabolism/PK,P value  3.1e-4,Unknown,rs34059508,research
hydrocodone,Metabolism/PK,P value  0.0001,European,CYP2D6 poor metabolizers,research
hydrocodone,Metabolism/PK,P value  0.0001,European,CYP2D6 poor metabolizers,research
hydrocodone,Metabolism/PK,P value  0.0001,European,CYP2D6 poor metabolizers,research
benazepril,Efficacy,P value  0.001,East Asian,rs7079,research
sumatriptan,Metabolism/PK,P value  3.1e-4,Unknown,rs55918055,research
benazepril,Efficacy,P value  0.001,East Asian,rs2640543,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*17,research
desipramine,Metabolism/PK,P value  0.0005,European,CYP2D6 poor metabolizers,research
fenofibrate,Efficacy,P value  1.0E-4,European,rs964184,research
fenofibrate,Efficacy,P value  1.0E-4,European,rs964184,research
desipramine,Metabolism/PK,P value  0.01,European,CYP2D6 poor metabolizers,research
gemcitabine,Efficacy,P value  0.003,East Asian,rs1060896,research
levodopa,Efficacy,P value  0.004,Unknown,rs1611115,research
desipramine,Metabolism/PK,P value  0.01,European,CYP2D6 poor metabolizers,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*2,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,Unknown,rs2234711,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,Unknown,rs1946518,research
methotrexate,Metabolism/PK,P value  0.003,Unknown,rs4149056,research
warfarin,Dosage,P value  1.0E-4,European,rs9923231,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  9.64E-6,African American/Afro-Caribbean,rs12772169,research
warfarin,Dosage,P value  2.0E-5,African American/Afro-Caribbean,rs12772169,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
desipramine,Metabolism/PK,P value  0.005,European,CYP2D6 poor metabolizers,research
warfarin,Dosage,P value  0.01,"Multiple groups, 91 Malays;96 Chinese;46 Indians.",rs1057910,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,Unknown,rs5744174,research
warfarin,Dosage,P value  0.01,"Multiple groups, 91 Malays;96 Chinese;46 Indians.",rs1799853,research
acenocoumarol,Dosage,P value  1.0E-4,Central/South Asian,rs9923231,research
warfarin,Dosage,P value  0.001,"Multiple groups, 91 Malays;96 Chinese;46 Indians.",rs9923231,research
rosiglitazone,Efficacy,P value  0.01,Unknown,CYP2C8*1,research
rosiglitazone,Efficacy,P value  0.01,Unknown,CYP2C8*3,research
rituximab,Efficacy,P value  0.002,Unknown,rs3759467,research
rituximab,Efficacy,P value  0.01,Unknown,rs3759467,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
imatinib,Metabolism/PK,P value  0.0001,Unknown,rs683369,research
clopidogrel,Metabolism/PK,P value  0.001,European,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,European,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,European,CYP2C19*17,research
tocilizumab,Efficacy,P value  0.007,European,rs11052877,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
voriconazole,Metabolism/PK,P value  0.004,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.004,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.004,East Asian,CYP2C19*3,research
voriconazole,Metabolism/PK,P value  0.004,East Asian,CYP2C19*17,research
pravastatin,Efficacy,P value  0.007,European,rs11666735,research
candesartan,Efficacy,P value  2.044E-4,European,rs3758785,research
hydrochlorothiazide,Efficacy,P value  0.0071,European,rs3758785,research
tramadol,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
tramadol,Metabolism/PK,P value  0.01,Unknown,CYP2D6*2,research
tramadol,Metabolism/PK,P value  0.01,Unknown,CYP2D6*10,research
quetiapine,Efficacy,P value  0.007,East Asian,rs4818,research
quetiapine,Efficacy,P value  0.007,East Asian,rs5993883,research
atenolol,Dosage,P value  0.003,European,rs7184292,research
phenazepam,Efficacy,P value  0.00,European,rs12248560,research
phenazepam,Efficacy,P value  0.00,European,rs12248560,research
phenazepam,Efficacy,P value  0.00,European,rs12248560,research
phenazepam,Efficacy,P value  0.00,European,rs12248560,research
phenazepam,Efficacy,P value  0.00,European,rs12248560,research
phenazepam,Efficacy,P value  0.01,European,rs12248560,research
hydrochlorothiazide,Efficacy,P value  0.006,European,rs3784921,research
antidepressants,Efficacy,P value  0.0045,East Asian,rs28364032,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs12777823,research
efavirenz,Metabolism/PK,P value  1.25e-8,European,rs3745274,research
tocilizumab,Efficacy,P value  0.004,European,rs11265618,research
morphine,Dosage,P value  0.01,"Multiple groups, Chinese and Indian self-reported ethnicities.",rs1143634,research
morphine,Efficacy,P value  0.01,"Multiple groups, Chinese and Indian self-reported ethnicities.",rs1143634,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
tocilizumab,Efficacy,P value  0.004,European,rs12083537,research
morphine,Dosage,P value  0.01,"Multiple groups, Chinese and Indian self-reported ethnicities.",rs1143634,research
morphine,Efficacy,P value  0.01,"Multiple groups, Chinese and Indian self-reported ethnicities.",rs1143634,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs3745274,research
imatinib,Efficacy,P value  0.01,Unknown,rs3745274,research
efavirenz,Metabolism/PK,P value  0.01,Sub-Saharan African,rs28399499,research
warfarin,Dosage,P value  0.01,,rs339097,research
methadone,Efficacy,P value  0.003,European,rs10485058,research
methadone,Efficacy,P value  0.0064,European,rs10485058,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs28371685,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs28371686,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs2279343,research
warfarin,Dosage,P value  5.1E-11,East Asian,rs9934438,research
clopidogrel,Efficacy,P value  0.001,East Asian,rs2307240,research
clopidogrel,Efficacy,P value  0.001,East Asian,rs2307240,research
clopidogrel,Efficacy,P value  0.001,East Asian,rs2307240,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, 38 white, 4 black, 2 asian",rs776746,research
ivacaftor,Efficacy,P value  0.001,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",rs113993960,research
ivacaftor,Efficacy,P value  0.001,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",rs113993960,research
ivacaftor,Efficacy,P value  0.004,Unknown,rs113993960,research
tacrolimus,Metabolism/PK,P value  0.00001,European,rs776746,research
warfarin,Dosage,P value  0.0015,European,rs1799853,research
tacrolimus,Metabolism/PK,P value  0.0001,"Multiple groups, Black n=23, White n=119, Middle Eastern n=12, South Asian n=26",rs776746,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.002,East Asian,CYP2C19*3,research
warfarin,Dosage,P value  1.0E-4,European,rs9923231,research
atorvastatin,Efficacy,P value  0.004,"Multiple groups, European and African Brazilian subjects.",rs5888,research
tacrolimus,Metabolism/PK,P value  0.01,"Multiple groups, 57 Caucasian, 2 African",rs776746,research
tacrolimus,Metabolism/PK,P value  0.002,"Multiple groups, Asian (n=8), Black (n=7), Caucasian (n=120)",rs776746,research
tacrolimus,Dosage,P value  0.002,"Multiple groups, Asian (n=8), Black (n=7), Caucasian (n=120)",rs776746,research
tacrolimus,Metabolism/PK,P value  0.005,"Multiple groups, Asian (n=8), Black (n=7), Caucasian (n=120)",rs776746,research
tacrolimus,Dosage,P value  0.005,"Multiple groups, Asian (n=8), Black (n=7), Caucasian (n=120)",rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Malay, Indian",rs776746,research
midazolam,Metabolism/PK,P value  0.001,European,CYP3A4*1,research
midazolam,Metabolism/PK,P value  0.001,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.0001,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs776746,research
tacrolimus,Dosage,P value  0.01,European,rs776746,research
SN-38,Metabolism/PK,P value  0.006,East Asian,UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.006,East Asian,UGT1A1*6,research
SN-38,Metabolism/PK,P value  0.006,East Asian,UGT1A1*28,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,Central/South Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,Central/South Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,Central/South Asian,CYP3A5*3,research
telmisartan,Metabolism/PK,P value  7e-3,European,UGT1A3*1,research
telmisartan,Metabolism/PK,P value  7e-3,European,UGT1A3*3,research
docetaxel,Efficacy,P value  0.0023,"Multiple groups, 43 white, 3 african american, 1 asian",rs4148947,research
nitroglycerin,Metabolism/PK,P value  0.01,East Asian,rs671,research
docetaxel,Efficacy,P value  0.0034,"Multiple groups, 43 white, 3 african american, 1 asian",rs730720,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,rs776746,research
tacrolimus,Dosage,P value  0.001,Multiple groups,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,European,rs776746,research
tacrolimus,Dosage,P value  0.001,European,rs776746,research
citalopram,Efficacy,P value  3.64E-8,"Multiple groups, non-HIspanic Caucasian, African-American, Hispanic Caucasian",rs520210,research
citalopram,Efficacy,P value  1.87E-6,"Multiple groups, non-Hispanic and Hispanic Caucasian",rs520210,research
citalopram,Efficacy,P value  6.98E-5,European,rs520210,research
tacrolimus,Dosage,P value  0.0001,Unknown,CYP3A4*1,research
tacrolimus,Dosage,P value  0.0001,Unknown,CYP3A4*22,research
ataluren,Efficacy,P value  0.0001,Unknown,rs113993959,research
ivacaftor,Efficacy,P value  0.002,"Multiple groups, Australia, Belgium, Germany, New Zealand, USA CF centers",rs113993960,research
tacrolimus,Metabolism/PK,P value  0.006,East Asian,rs776746,research
hmg coa reductase inhibitors,Efficacy,P value  2.1E-4,European,rs2072183,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.0001,European,rs1057868,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
hmg coa reductase inhibitors,Efficacy,P value  9.4E-7,European,rs629301,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
photodynamic therapy,Efficacy,P value  0.01,European,rs5985,research
ivacaftor,Efficacy,P value  0.0001,European,rs75527207,research
ivacaftor,Efficacy,P value  0.0001,European,rs75527207,research
hmg coa reductase inhibitors,Efficacy,P value  3.9E-15,European,rs4420638,research
Hepatitis vaccines,Efficacy,P value  0.0003,"Multiple groups, Black, White, Other",HLA-DRB1*07:01:01:01,research
clopidogrel,Metabolism/PK,P value  0.001,"Multiple groups, mainly White",CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,"Multiple groups, mainly White",CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,"Multiple groups, mainly White",CYP2C19*3,research
clopidogrel,Metabolism/PK,P value  0.001,"Multiple groups, mainly White",CYP2C19*8,research
clopidogrel,Metabolism/PK,P value  0.001,"Multiple groups, mainly White",CYP2C19*17,research
tacrolimus,Dosage,P value  0.005,Unknown,rs776746,research
alemtuzumab,Efficacy,P value  0.001,European,rs1801157,research
adalimumab,Efficacy,P value  2.45E-4,Unknown,rs1800629,research
atazanavir,Metabolism/PK,P value  0.0015,African American/Afro-Caribbean,rs73208473,research
morphine,Efficacy,P value  0.002,Unknown,rs6517442,research
morphine,Efficacy,P value  0.005,Unknown,rs6517442,research
bisoprolol,Efficacy,P value  2.0E-8,European,rs2514036,research
morphine,Efficacy,P value  0.006,Unknown,rs6517442,research
tacrolimus,Metabolism/PK,P value  0.008,Near Eastern,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.008,Near Eastern,CYP3A5*3,research
Measles vaccines,Efficacy,P value  0.001,"Multiple groups, Caucasian, Asian, Native American, Other",HLA-B*07:02:01,research
warfarin,Dosage,P value  0.001,European,rs2108622,research
Measles vaccines,Efficacy,P value  0.008,"Multiple groups, Caucasian, Asian, Native American, Other",HLA-B*13:01:01,research
Measles vaccines,Efficacy,P value  0.005,"Multiple groups, Caucasian, Asian, Native American, Other",HLA-B*08:01:01,research
remifentanil,Efficacy,P value  0.001,Unknown,rs4680,research
remifentanil,Efficacy,P value  0.002,Unknown,rs4680,research
remifentanil,Efficacy,P value  0.006,Unknown,rs4680,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.01,"Multiple groups, Mainly Caucasian, remainder unspecified",rs776746,research
tacrolimus,Dosage,P value  0.0001,European,rs776746,research
morphine,Efficacy,P value  0.001,Unknown,rs4680,research
morphine,Efficacy,P value  0.001,Unknown,rs4680,research
warfarin,Dosage,P value  0.001,"Multiple groups, White, African-American, Hispanic, Other",CYP2C9*1,research
warfarin,Dosage,P value  0.001,"Multiple groups, White, African-American, Hispanic, Other",CYP2C9*2,research
warfarin,Dosage,P value  0.001,"Multiple groups, White, African-American, Hispanic, Other",CYP2C9*3,research
tacrolimus,Dosage,P value  0.001,European,rs776746,research
warfarin,Dosage,P value  0.0001,"Multiple groups, White, African-American, Hispanic, Other",rs9923231,research
insulin recombinant,Efficacy,P value  0.002,European,rs13266634,research
insulin recombinant,Efficacy,P value  0.01,European,rs13266634,research
Influenza vaccines,Efficacy,P value  0.005,European,HLA-DQB1*03:03:02:01,research
tacrolimus,Dosage,P value  0.0001,Multiple groups,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.008,Unknown,rs776746,research
omeprazole,Efficacy,P value  0.001,Unknown,CYP2C19*1,research
omeprazole,Efficacy,P value  0.001,Unknown,CYP2C19*2,research
omeprazole,Efficacy,P value  0.001,Unknown,CYP2C19*3,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
ataluren,Efficacy,P value  0.0001,Unknown,rs75039782,research
efavirenz,Metabolism/PK,P value  0.0001,Unknown,rs3181842,research
efavirenz,Metabolism/PK,P value  0.0001,Unknown,rs707265,research
efavirenz,Metabolism/PK,P value  0.0001,Unknown,rs7246465,research
ataluren,Efficacy,P value  0.0001,Unknown,rs77010898,research
efavirenz,Metabolism/PK,P value  0.001,Central/South Asian,rs3745274,research
tacrolimus,Dosage,P value  0.001,European,rs776746,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2C19 poor metabolizers,research
tacrolimus,Metabolism/PK,P value  0.0001,European,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,European,CYP3A5*3,research
lamotrigine,Metabolism/PK,P value  0.010,East Asian,rs628031,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*3,research
l-tryptophan,Metabolism/PK,P value  8.6E-4,Unknown,rs316019,research
tacrolimus,Metabolism/PK,P value  0.0001,,rs2242480,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, Asian (n=8), Black (n=7), Caucasian (n=120)",rs776746,research
tacrolimus,Metabolism/PK,P value  0.0001,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
tacrolimus,Dosage,P value  0.0001,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
efavirenz,Metabolism/PK,P value  0.001,Multiple groups,rs3745274,research
omeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*1,research
omeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*2,research
omeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
ataluren,Efficacy,P value  0.0001,Unknown,rs113993959,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
fluorouracil,Dosage,P value  0.003,Multiple groups,DPYD poor metabolizer,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*3,research
warfarin,Dosage,P value  0.0047,African American/Afro-Caribbean,rs12777823,research
tacrolimus,Dosage,P value  0.01,Unknown,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,Unknown,CYP3A5*3,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*3,research
clopidogrel,Efficacy,P value  0.002,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.002,East Asian,CYP2C19*3,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, White, African American, Asian, Unknown",CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, White, African American, Asian, Unknown",CYP3A5*3,research
efavirenz,Metabolism/PK,P value  0.001,Multiple groups,rs3745274,research
adalimumab,Efficacy,P value  1.0E-4,Multiple groups,rs10919563,research
lansoprazole,Efficacy,P value  0.004,Multiple groups,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.004,Multiple groups,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.004,Multiple groups,CYP2C19*3,research
desethyl hydroxychloroquine,Metabolism/PK,P value  0.01,East Asian,rs1135840,research
phenprocoumon,Dosage,P value  0.001,European,rs9923231,research
rosuvastatin,Efficacy,P value  5.8e-4,European,rs17111584,research
(S)-methadone,Metabolism/PK,P value  0.0019,"Multiple groups, 'All subjects were Caucasians with the exception of two Africans'",rs3745274,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*3,research
rosuvastatin,Efficacy,P value  5.8e-19,European,rs7412,research
metformin,Efficacy,P value  0.00188,Unknown,rs7541245,research
rosuvastatin,Efficacy,P value  1.7e-15,European,rs1481012,research
rosuvastatin,Efficacy,P value  3.5e-9,European,rs10455872,research
warfarin,Dosage,P value  0.002,African American/Afro-Caribbean,rs17886199,research
nicotine,Metabolism/PK,P value  7.03E-25,European,rs113288603,research
rosuvastatin,Efficacy,P value  2.9e-4,European,rs71352238,research
nicotine,Metabolism/PK,P value  3.66E-76,European,rs12461964,research
nicotine,Metabolism/PK,P value  9.35E-51,European,rs12461964,research
nicotine,Metabolism/PK,P value  2.25E-36,European,rs12461964,research
nicotine,Metabolism/PK,P value  4.79E-22,European,rs12461964,research
tacrolimus,Metabolism/PK,P value  0.01,Multiple groups,rs776746,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9923231,research
rosuvastatin,Efficacy,P value  2.1e-12,European,rs2199939,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*1,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*2,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*4,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*5,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*9,research
amitriptyline,Metabolism/PK,P value  0.002,European,CYP2D6*10,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*1,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*2,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*4,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*5,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*9,research
amitriptyline,Metabolism/PK,P value  0.004,European,CYP2D6*10,research
tacrolimus,Metabolism/PK,P value  0.0002,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
tacrolimus,Dosage,P value  0.0002,"Multiple groups, Caucasian (n=120), African (n=12), Asia (n=3).",rs776746,research
imatinib,Efficacy,P value  0.001,European,rs2631367,research
venlafaxine,Efficacy,P value  0.001,East Asian,rs3810651,research
methadone,,P value  0.003,European,rs2070995,research
imatinib,Efficacy,P value  0.001,European,rs1050152,research
desethyl hydroxychloroquine,Metabolism/PK,P value  0.01,East Asian,rs1065852,research
warfarin,Dosage,P value  0.00001,East Asian,rs9934438,research
warfarin,Dosage,P value  0.00001,East Asian,rs9934438,research
warfarin,Dosage,P value  0.003,East Asian,rs9934438,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs4819554,research
platinum,Efficacy,P value  0.0,"Multiple groups, White, Asian",rs25487,research
platinum,Efficacy,P value  0.001,"Multiple groups, White, Asian",rs25487,research
cyclosporine,Metabolism/PK,P value  0.01,"Multiple groups, White, Black, Asian, Unknown",rs1057868,research
nicotine,Metabolism/PK,P value  5.77E-86,European,rs56113850,research
nicotine,Metabolism/PK,P value  4.56E-45,European,rs56113850,research
nicotine,Metabolism/PK,P value  8.76E-19,European,rs56113850,research
nicotine,Metabolism/PK,P value  2.87E-17,European,rs56113850,research
Platinum compounds,Efficacy,P value  0.01,East Asian,rs1799782,research
carboplatin,Efficacy,P value  0.01,East Asian,rs3740556,research
Selective serotonin reuptake inhibitors,Efficacy,P value  8.08E-5,Unknown,rs6108160,research
Selective serotonin reuptake inhibitors,Efficacy,P value  2.13E-8,Unknown,rs10514475,research
tacrolimus,Metabolism/PK,P value  0.005,East Asian,rs776746,research
phenprocoumon,Dosage,P value  0.0001,"Multiple groups, Mostly white",rs9923231,research
fluorouracil,Efficacy,P value  0.008,Unknown,rs17109924,research
methadone,Metabolism/PK,P value  0.001,Unknown,CYP2B6*1,research
methadone,Metabolism/PK,P value  0.001,Unknown,CYP2B6*6,research
methadone,Metabolism/PK,P value  0.003,Unknown,CYP2B6*1,research
methadone,Metabolism/PK,P value  0.003,Unknown,CYP2B6*6,research
acetaminophen,Metabolism/PK,P value  0.001,"Multiple groups, Black, White",rs1902023,research
acetaminophen,Metabolism/PK,P value  0.003,"Multiple groups, White, Black",rs1902023,research
phenprocoumon,Efficacy,P value  0.0001,Unknown,rs2359612,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.005,European,rs396991,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,European,rs396991,research
tacrolimus,Metabolism/PK,P value  0.0001,European,rs776746,research
acetaminophen,Metabolism/PK,P value  0.001,"Multiple groups, White, Black",rs1902023,research
acetaminophen,Metabolism/PK,P value  0.001,"Multiple groups, White, Black",rs1902023,research
acetaminophen,Metabolism/PK,P value  0.001,"Multiple groups, Black, White",rs1902023,research
acetaminophen,Metabolism/PK,P value  0.001,"Multiple groups, Black, White",rs1902023,research
interferon beta-1a,Efficacy,P value  0.008,Near Eastern,HLA-DRB1*04:01:01,research
tacrolimus,Other,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Other,P value  0.01,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, Vanderbilt USA: 89.2% White, 9.8% Black, 1% Hispanic",rs2884737,research
warfarin,Dosage,P value  0.001,"Multiple groups, Vanderbilt USA: 89.2% White, 9.8% Black, 1% Hispanic",rs9923231,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, Vanderbilt USA: 89.2% White, 9.8% Black, 1% Hispanic",rs9934438,research
phenprocoumon,Dosage,P value  0.001,"Multiple groups, southern Brazilian population, 81% of European ancestry",rs9923231,research
phenprocoumon,Dosage,P value  0.001,"Multiple groups, southern Brazilian population, 81% of European ancestry",rs9934438,research
phenprocoumon,Dosage,P value  0.010,"Multiple groups, southern Brazilian population, 81% of European ancestry",rs7294,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Malay, Chinese, Indian",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Malay, Chinese, Indian",CYP3A5*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, Vanderbilt USA: 89.2% White, 9.8% Black, 1% Hispanic",rs8050894,research
phenprocoumon,Dosage,P value  0.0001,Unknown,rs9923231,research
tacrolimus,Metabolism/PK,P value  0.01,Multiple groups,rs776746,research
sumatriptan,Efficacy,P value  0.0074,European,rs5443,research
sulfonamides,Efficacy,P value  9.0E-4,Unknown,rs1057910,research
sulfonamides,Efficacy,P value  9.0E-4,Unknown,rs1799853,research
rosuvastatin,Efficacy,P value  0.001,European,rs12487736,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs2276707,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs35599367,research
phenprocoumon,Dosage,P value  0.004,"Multiple groups, southern Brazilian population, 81% of European ancestry",CYP2C9*1,research
phenprocoumon,Dosage,P value  0.004,"Multiple groups, southern Brazilian population, 81% of European ancestry",CYP2C9*2,research
phenprocoumon,Dosage,P value  0.004,"Multiple groups, southern Brazilian population, 81% of European ancestry",CYP2C9*3,research
atenolol,Efficacy,P value  0.003,European,rs2301339,research
atenolol,Efficacy,P value  0.004,European,rs2301339,research
atenolol,Efficacy,P value  0.004,European,rs11064426,research
atenolol,Efficacy,P value  0.004,European,rs11064426,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, 38 white, 4 black, 2 asian",rs776746,research
warfarin,Dosage,P value  0.001,"Multiple groups, Vanderbilt USA: 89.2% White, 9.8% Black, 1% Hispanic",rs2359612,research
ivacaftor,Efficacy,P value  0.0001,European,rs75527207,research
ulinastatin,Efficacy,P value  0.001,Unknown,rs3918242,research
capecitabine,Efficacy,P value  0.001,"Multiple groups, Majority Caucasian",rs45445694,research
tacrolimus,Metabolism/PK,P value  0.00001,"Multiple groups, Mostly Caucasian and Asian",rs776746,research
ulinastatin,Efficacy,P value  0.001,Unknown,rs243865,research
tacrolimus,Metabolism/PK,P value  2.2E-8,European,rs776746,research
tacrolimus,Metabolism/PK,P value  5.0E-6,European,rs776746,research
tacrolimus,Metabolism/PK,P value  2.6E-5,European,rs776746,research
tacrolimus,Metabolism/PK,P value  5.0E-5,European,rs776746,research
tacrolimus,Metabolism/PK,P value  1.1E-4,European,rs776746,research
nicotine,Metabolism/PK,P value  1.25E-21,European,rs4803381,research
nicotine,Metabolism/PK,P value  4.53E-5,Unknown,rs4803381,research
fentanyl,Metabolism/PK,P value  0.002,"Multiple groups, Volunteers of European or Latino ethnicity.",CYP3A4*1,research
fentanyl,Metabolism/PK,P value  0.002,"Multiple groups, Volunteers of European or Latino ethnicity.",CYP3A4*22,research
bilirubin,Metabolism/PK,P value  0.004,Unknown,rs11563250,research
acenocoumarol,Metabolism/PK,P value  0.01,Unknown,CYP2C9*1,research
acenocoumarol,Metabolism/PK,P value  0.01,Unknown,CYP2C9*2,research
acenocoumarol,Metabolism/PK,P value  0.01,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,rs3814637,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
fentanyl,Metabolism/PK,P value  0.001,"Multiple groups, Volunteers of European or Latino ethnicity.",rs1128503,research
fentanyl,Metabolism/PK,P value  0.001,"Multiple groups, Volunteers of European or Latino ethnicity.",rs1128503,research
fentanyl,Metabolism/PK,P value  0.001,"Multiple groups, Volunteers of European or Latino ethnicity.",rs1128503,research
warfarin,Dosage,P value  0.01,East Asian,rs699664,research
anastrozole,Efficacy,P value  4.83E-6,Unknown,rs6990851,research
deferasirox,Metabolism/PK,P value  0.002,European,rs1983023,research
lamotrigine,Metabolism/PK,P value  0.010,East Asian,rs2071197,research
atenolol,Efficacy,P value  8.2e-6,African American/Afro-Caribbean,rs10739150,research
lamotrigine,Metabolism/PK,P value  0.010,East Asian,rs3114020,research
lamotrigine,Metabolism/PK,P value  0.009,East Asian,rs2231142,research
oxcarbazepine,Efficacy,P value  0.009,East Asian,rs1045642,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
alprazolam,Efficacy,P value  0.007,Unknown,rs35599367,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.0001,Unknown,CYP2C9*3,research
lansoprazole,Efficacy,P value  0.0019,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.0019,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.0019,Unknown,CYP2C19*3,research
carvedilol,Dosage,P value  0.01,Unknown,rs1801253,research
warfarin,Dosage,P value  0.001,East Asian,rs2108622,research
atenolol,Efficacy,P value  3.2e-6,European,rs12346562,research
tacrolimus,Metabolism/PK,P value  1.0E-4,European,rs776746,research
hydrochlorothiazide,Efficacy,P value  0.0018,European,rs12346562,research
alprazolam,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
lansoprazole,Efficacy,P value  0.0029,Unknown,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.0029,Unknown,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.0029,Unknown,CYP2C19*3,research
atenolol,Efficacy,P value  5.9e-6,European,rs1104514,research
voriconazole,Metabolism/PK,P value  0.002,Unknown,CYP3A4*1,research
voriconazole,Metabolism/PK,P value  0.002,Unknown,CYP3A4*22,research
propofol,Other,P value  0.001,East Asian,rs6746030,research
doxorubicin,Efficacy,P value  0.0001,"Multiple groups, >95% Nordic Caucasian",rs2229109,research
doxorubicin,Efficacy,P value  0.006,"Multiple groups, >95% Nordic Caucasian",rs1045642,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
etanercept,Efficacy,P value  8.0E-4,Multiple groups,rs1800629,research
propofol,Dosage,P value  0.01,East Asian,rs6313,research
bumetanide,Efficacy,P value  0.007,European,rs5443,research
bumetanide,Efficacy,P value  0.008,European,rs5443,research
warfarin,Dosage,P value  0.00001,East Asian,rs9923231,research
warfarin,Dosage,P value  0.00001,East Asian,rs9923231,research
warfarin,Dosage,P value  0.0001,East Asian,rs9923231,research
Vitamin K1,Metabolism/PK,P value  0.007,Unknown,CYP4F2*1,research
Vitamin K1,Metabolism/PK,P value  0.007,Unknown,CYP4F2*3,research
Vitamin K1,Metabolism/PK,P value  0.010,Unknown,CYP4F2*1,research
Vitamin K1,Metabolism/PK,P value  0.010,Unknown,CYP4F2*3,research
cetuximab,Efficacy,P value  0.001,Unknown,rs1801274,research
cetuximab,Efficacy,P value  0.001,Unknown,rs1801274,research
bumetanide,Efficacy,P value  0.006,European,rs1799752,research
cyclosporine,Efficacy,P value  0.0075,European,rs1045642,research
methylphenidate,Efficacy,P value  0.0055,Unknown,rs2070762,research
bumetanide,Efficacy,P value  0.007,European,rs5065,research
nortriptyline,Efficacy,P value  0.0016,European,rs2273623,research
clopidogrel,Efficacy,P value  0.001,Unknown,rs4244285,research
voriconazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*3,research
codeine,Dosage,P value  0.002,Multiple groups,rs7439366,research
methylphenidate,Efficacy,P value  0.009,European,rs4680,research
atazanavir,Toxicity,P value  9.3E-14,"Multiple groups, White, Black, Hispanic",rs887829,research
atazanavir,Toxicity,P value  1.8E-11,European,rs887829,research
atazanavir,Toxicity,P value  3.0E-4,African American/Afro-Caribbean,rs887829,research
atazanavir,Toxicity,P value  2.3E-3,Latino,rs887829,research
acenocoumarol,Dosage,P value  0.004,European,rs9934438,research
acenocoumarol,Efficacy,P value  0.004,European,rs9934438,research
amitriptyline,Metabolism/PK,P value  0.001,Unknown,CYP2C19*1,research
amitriptyline,Metabolism/PK,P value  0.001,Unknown,CYP2C19*2,research
amitriptyline,Metabolism/PK,P value  0.004,Unknown,CYP2C19*1,research
amitriptyline,Metabolism/PK,P value  0.004,Unknown,CYP2C19*2,research
sertraline,Efficacy,P value  0.004,Near Eastern,rs5441,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.00057,Unknown,rs3794271,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19 poor metabolizers,research
codeine,Dosage,P value  0.000,Multiple groups,rs1799971,research
fentanyl,Efficacy,P value  0.001,East Asian,rs2242480,research
acenocoumarol,Dosage,P value  0.006,Unknown,rs9923231,research
adalimumab,Efficacy,P value  8.11E-4,European,rs10210302,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*3,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*3,research
atorvastatin,Efficacy,P value  0.00151,European,rs7412,research
simvastatin,Efficacy,P value  0.00282,European,rs1800588,research
clozapine,Efficacy,P value  0.005,European,rs6318,research
atorvastatin,Efficacy,P value  0.00237,European,rs4149036,research
bevacizumab,Efficacy,P value  0.004,Multiple groups,rs1061170,research
atorvastatin,Efficacy,P value  0.00126,European,rs2032582,research
atorvastatin,Efficacy,P value  0.00842,European,rs2032582,research
fluvastatin,Efficacy,P value  0.00107,European,rs1800588,research
acenocoumarol,Dosage,P value  0.003,European,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.003,European,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.003,European,CYP2C9*3,research
fluvastatin,Efficacy,P value  0.00348,European,rs4986910,research
peginterferon alfa-2b,Efficacy,P value  0.001,European,rs11322783,research
peginterferon alfa-2b,Efficacy,P value  0.001,European,rs11322783,research
atorvastatin,Efficacy,P value  0.00244,European,rs776746,research
sulfonamides,Efficacy,P value  0.005,Unknown,rs12255372,research
lovastatin,Efficacy,P value  0.00269,European,rs688,research
peginterferon alfa-2b,Efficacy,P value  0.001,Unknown,rs8099917,research
varenicline,Efficacy,P value  0.001,Unknown,CYP2A6 normal metabolizer,research
acenocoumarol,Dosage,P value  2e-123,European,rs10871454,research
sitagliptin,Efficacy,P value  0.006,European,rs6923761,research
acenocoumarol,Dosage,P value  2e-8,European,rs2108622,research
pravastatin,Efficacy,P value  0.00809,European,rs328,research
acenocoumarol,Dosage,P value  0.001,Unknown,rs9923231,research
paroxetine,Efficacy,P value  0.001,Unknown,rs11042725,research
lovastatin,Efficacy,P value  0.00587,European,rs5925,research
peginterferon alfa-2a,Efficacy,P value  0.003,European,rs8099917,research
acenocoumarol,Dosage,P value  0.0001,European,rs9934438,research
acenocoumarol,Dosage,P value  0.0001,European,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.0001,European,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.0001,European,CYP2C9*3,research
fluvastatin,Efficacy,P value  0.0061,European,rs4149056,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*1a,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*2,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*3,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*1a,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*2,research
raloxifene,Metabolism/PK,P value  0.001,Unknown,UGT1A8*3,research
raloxifene,Metabolism/PK,P value  0.0025,Unknown,UGT1A8*1a,research
raloxifene,Metabolism/PK,P value  0.0025,Unknown,UGT1A8*2,research
raloxifene,Metabolism/PK,P value  0.0025,Unknown,UGT1A8*3,research
warfarin,Dosage,P value  0.004,European,rs2108622,research
warfarin,Dosage,P value  0.01,Multiple groups,rs2108622,research
antiepileptics,Metabolism/PK,P value  4.76E-10,European,rs16935279,research
pravastatin,Efficacy,P value  0.0082,European,rs4341,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs12777823,research
warfarin,Dosage,P value  0.002,Multiple groups,rs12777823,research
methylphenidate,Efficacy,P value  0.008,East Asian,rs5569,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19 poor metabolizers,research
methotrexate,Efficacy,P value  0.01,"Multiple groups, non-Caucasian.",rs45445694,research
lovastatin,Efficacy,P value  0.00951,European,rs708272,research
sertraline,Efficacy,P value  0.01,Unknown,SLC6A4 HTTLPR long form (L allele),research
sertraline,Efficacy,P value  0.01,Unknown,SLC6A4 HTTLPR short form (S allele),research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
methotrexate,Efficacy,P value  0.01,European,rs4673993,research
gemcitabine,Metabolism/PK,P value  0.001,East Asian,rs60369023,research
gemcitabine,Other,P value  0.001,East Asian,rs60369023,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9923231,research
warfarin,Dosage,P value  0.001,European,rs9923231,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs9923231,research
peginterferon alfa-2b,Efficacy,P value  0.0035,East Asian,rs8099917,research
clozapine,Efficacy,P value  0.002,European,rs6280,research
alendronate,Efficacy,P value  0.002,East Asian,rs10161126,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*1,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*2,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*4,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*5,research
imipramine,Dosage,P value  0.0017,European,CYP2D6*1,research
imipramine,Dosage,P value  0.0017,European,CYP2D6*2,research
imipramine,Dosage,P value  0.0017,European,CYP2D6*4,research
imipramine,Dosage,P value  0.0017,European,CYP2D6*5,research
imipramine,Dosage,P value  0.0029,European,CYP2D6*1,research
imipramine,Dosage,P value  0.0029,European,CYP2D6*2,research
imipramine,Dosage,P value  0.0029,European,CYP2D6*4,research
imipramine,Dosage,P value  0.0029,European,CYP2D6*5,research
clozapine,Efficacy,P value  0.002,European,rs686,research
oxaliplatin,Efficacy,P value  0.001,Unknown,rs1042522,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*1,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*1xN,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*2,research
imipramine,Dosage,P value  0.0001,European,CYP2D6*2xN,research
salmeterol,Efficacy,P value  0.005,Unknown,rs1042713,research
rosiglitazone,Efficacy,P value  0.005,East Asian,rs10192566,research
peginterferon alfa-2b,Efficacy,P value  0.001,Unknown,rs8099917,research
desipramine,Metabolism/PK,P value  0.0001,European,CYP2D6*4,research
desipramine,Metabolism/PK,P value  0.0001,European,CYP2D6*5,research
desipramine,Metabolism/PK,P value  0.0017,European,CYP2D6*4,research
desipramine,Metabolism/PK,P value  0.0017,European,CYP2D6*5,research
desipramine,Metabolism/PK,P value  0.0026,European,CYP2D6*4,research
desipramine,Metabolism/PK,P value  0.0026,European,CYP2D6*5,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*3,research
morphine,Dosage,P value  0.005,Unknown,rs7439366,research
warfarin,Dosage,P value  0.01,European,CYP2C9*1,research
warfarin,Dosage,P value  0.01,European,CYP2C9*2,research
warfarin,Dosage,P value  0.01,European,CYP2C9*3,research
tacrolimus,Efficacy,P value  0.002,East Asian,rs1128503,research
tacrolimus,Efficacy,P value  0.002,East Asian,rs1128503,research
tacrolimus,Efficacy,P value  0.003,East Asian,rs1128503,research
tacrolimus,Efficacy,P value  0.004,East Asian,rs1128503,research
peginterferon alfa-2b,Efficacy,P value  0.000031,European,rs12979860,research
warfarin,Metabolism/PK,P value  4.4E-13,East Asian,rs1057910,research
warfarin,Dosage,P value  4.4E-13,East Asian,rs1057910,research
peginterferon alfa-2b,Efficacy,P value  0.0001,"Multiple groups, Caucasian, African American, Hispanic",rs12979860,research
sildenafil,Efficacy,P value  0.01,European,rs5443,research
cotinine,Metabolism/PK,P value  0.0006,European,rs13253389,research
peginterferon alfa-2b,Efficacy,P value  0.001,European,rs12979860,research
methotrexate,Efficacy,P value  0.01,European,rs1045642,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*1,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*2,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*3,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*5,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*8,research
warfarin,Dosage,P value  0.003,African American/Afro-Caribbean,CYP2C9*11,research
warfarin,Dosage,P value  0.004,African American/Afro-Caribbean,rs9923231,research
o-desmethyltramadol,Metabolism/PK,P value  0.0001,Near Eastern,CYP2D6 ultrarapid metabolizer,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*1,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*4,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*5,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*6,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*10,research
primaquine,Efficacy,P value  0.002,Unknown,CYP2D6*41,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*1,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*4,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*5,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*6,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*10,research
primaquine,Efficacy,P value  0.008,Unknown,CYP2D6*41,research
ethanol,Metabolism/PK,P value  0.0081,East Asian,rs17376019,research
ethanol,Metabolism/PK,P value  0.008,East Asian,rs671,research
citalopram,Efficacy,P value  0.002,East Asian,rs334558,research
acetaldehyde,Metabolism/PK,P value  0.001,East Asian,rs671,research
ethanol,Other,P value  0.001,Unknown,rs1799971,research
fluorouracil,Metabolism/PK,P value  0.002,European,rs67376798,research
fluorouracil,Toxicity,P value  0.002,European,rs67376798,research
fluorouracil,Metabolism/PK,P value  0.001,European,rs3918290,research
fluorouracil,Toxicity,P value  0.001,European,rs3918290,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
imatinib,Efficacy,P value  0.001,Unknown,rs12505410,research
imatinib,Efficacy,P value  0.005,Unknown,rs12505410,research
imatinib,Efficacy,P value  0.006,Unknown,rs12505410,research
ticagrelor,Metabolism/PK,P value  8.64E-12,European,rs56324128,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
cyclophosphamide,Metabolism/PK,P value  0.005,East Asian,rs3957356,research
cyclophosphamide,Efficacy,P value  0.005,East Asian,rs3957356,research
cyclophosphamide,Toxicity,P value  0.005,East Asian,rs3957356,research
tamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Han Chinese, Indian, Malay in Singapore",CYP2C19*1,research
tamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Han Chinese, Indian, Malay in Singapore",CYP2C19*2,research
metoprolol,Efficacy,P value  0.0018,"Multiple groups, white, African; American, and Hispanic men and women with hypertension",rs1801253,research
ticagrelor,Metabolism/PK,P value  2.13E-12,European,rs4149056,research
ticagrelor,Metabolism/PK,P value  7.7E-14,European,rs61361928,research
tacrolimus,Metabolism/PK,P value  0.002,"Multiple groups, Mostly White",rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
ethanol,Dosage,P value  0.001,European,rs10485057,research
ticagrelor,Metabolism/PK,P value  3.63E-13,European,rs113681054,research
salbutamol,Efficacy,P value  1.18E-8,Multiple groups,rs17834628,research
etidronic acid,Efficacy,P value  0.002,Unknown,rs1800012,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, White, Asian",rs776746,research
salbutamol,Efficacy,P value  3.33E-8,Unknown,rs35661809,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*3,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*5,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*3,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*5,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*3,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*5,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*3,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*4,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*5,research
tacrolimus,Dosage,P value  0.003,"Multiple groups, Mostly White",rs776746,research
fentanyl,Dosage,P value  0.003,East Asian,rs2835859,research
fentanyl,Efficacy,P value  0.003,East Asian,rs2835859,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*2,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*3,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*4,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*5,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*9,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*10,research
mephedrone,Metabolism/PK,P value  0.001,Unknown,CYP2D6*41,research
Dipeptidyl peptidase 4 (DPP-4) inhibitors,Efficacy,P value  0.001,East Asian,rs7756992,research
Dipeptidyl peptidase 4 (DPP-4) inhibitors,Efficacy,P value  0.002,East Asian,rs7756992,research
Dipeptidyl peptidase 4 (DPP-4) inhibitors,Efficacy,P value  0.008,East Asian,rs7756992,research
fentanyl,Dosage,P value  1.3E-6,East Asian,rs2952768,research
fentanyl,Efficacy,P value  1.3E-6,East Asian,rs2952768,research
Dipeptidyl peptidase 4 (DPP-4) inhibitors,Efficacy,P value  0.01,East Asian,rs7754840,research
Dipeptidyl peptidase 4 (DPP-4) inhibitors,Efficacy,P value  0.01,East Asian,rs7754840,research
voriconazole,Dosage,P value  0.0001,Unknown,CYP2C19*2,research
voriconazole,Dosage,P value  0.0001,Unknown,CYP2C19*17,research
bevacizumab,Efficacy,P value  0.008,East Asian,rs2010963,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*1xN,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*2,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*2xN,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*9,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*10,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*35,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*35xN,research
doxepin,Metabolism/PK,P value  0.001,European,CYP2D6*41,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*1xN,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*2,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*2xN,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*9,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*10,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*35,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*35xN,research
doxepin,Metabolism/PK,P value  0.002,European,CYP2D6*41,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*1,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*1xN,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*2,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*2xN,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*9,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*10,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*35,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*35xN,research
doxepin,Metabolism/PK,P value  0.003,European,CYP2D6*41,research
clopidogrel,Efficacy,P value  1.87e-3,East Asian,rs2254638,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, White, Asian",rs776746,research
candesartan,Efficacy,P value  3.8E-8,"Multiple groups, See Figure 1A for genetic ancestry data",rs1275988,research
warfarin,Efficacy,P value  0.0001,East Asian,rs9923231,research
warfarin,Efficacy,P value   0.0003,East Asian,rs9923231,research
warfarin,Efficacy,P value  0.0001,East Asian,rs9923231,research
warfarin,Efficacy,P value  0.0001,East Asian,rs9923231,research
ustekinumab,Efficacy,P value  0.008,Unknown,HLA-C*06:02:01:01,research
hydrochlorothiazide,Efficacy,P value  8.8E-7,"Multiple groups, See Figure 1A for genetic ancestry data",rs1378942,research
hydrochlorothiazide,Efficacy,P value  2.96E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs12579720,research
warfarin,Dosage,P value  1.0E-4,European,rs9934438,research
peginterferon alfa-2a,Efficacy,P value  6.153e-8,European,rs11322783,research
peginterferon alfa-2a,Efficacy,P value  8.940e-8,European,rs11322783,research
benazepril,Efficacy,P value  0.001,East Asian,rs1799998,research
benazepril,Efficacy,P value  0.002,East Asian,rs1799998,research
cisplatin,Efficacy,P value  0.001,European,rs3087403,research
hydrochlorothiazide,Efficacy,P value  6.55E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs932764,research
hydrochlorothiazide,Efficacy,P value  4.94E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs10995311,research
phenytoin,Dosage,P value  0.001,East Asian,CYP2C19*2,research
phenytoin,Dosage,P value  0.001,East Asian,CYP2C19*3,research
candesartan,Efficacy,P value  1.1E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs740406,research
phenytoin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
hydrochlorothiazide,Efficacy,P value  1.77E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs757081,research
candesartan,Efficacy,P value  1.81E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs6722745,research
atenolol,Efficacy,P value  3.38E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs4387287,research
metoprolol,Efficacy,P value  2.65E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs1446468,research
efavirenz,Metabolism/PK,P value  0.0001,East Asian,rs3745274,research
duloxetine,Efficacy,P value  5E-5,European,rs6700741,research
duloxetine,Efficacy,P value  5E-5,European,rs4971678,research
hydrochlorothiazide,Efficacy,P value  1.17E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs12521868,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
fluoxetine,Efficacy,P value  0.00002,European,rs4570625,research
duloxetine,Efficacy,P value  5E-5,European,rs2933304,research
candesartan,Efficacy,P value  2.29E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs3184504,research
warfarin,Dosage,P value  0.004,East Asian,rs2108622,research
duloxetine,Efficacy,P value  5E-5,European,rs12630569,research
fluoxetine,Efficacy,P value  0.00009,European,rs130058,research
duloxetine,Efficacy,P value  5E-5,European,rs4334661,research
clopidogrel,Efficacy,P value  0.004,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.004,East Asian,CYP2C19*2,research
duloxetine,Efficacy,P value  5E-5,European,rs13093500,research
duloxetine,Efficacy,P value  5E-5,European,rs7616119,research
tamoxifen,Efficacy,P value  0.004,"Multiple groups, 81.6% Caucasian, 18.4% African-America",rs1042028,research
duloxetine,Efficacy,P value  5E-5,European,rs7625956,research
folic acid,Efficacy,P value  0.009,European,rs45445694,research
duloxetine,Efficacy,P value  5E-5,European,rs9310657,research
folic acid,Efficacy,P value  0.009,European,rs1051266,research
duloxetine,Efficacy,P value  5E-5,European,rs7653345,research
duloxetine,Efficacy,P value  5E-5,European,rs9310658,research
duloxetine,Efficacy,P value  5E-5,European,rs9819548,research
ondansetron,Metabolism/PK,P value  0.001,Multiple groups,rs776746,research
ondansetron,Metabolism/PK,P value  0.003,"Multiple groups, 139 Caucasians, 2 Black Africans",rs776746,research
duloxetine,Efficacy,P value  5E-5,European,rs9873889,research
duloxetine,Efficacy,P value  5E-5,European,rs9824595,research
duloxetine,Efficacy,P value  5E-5,European,rs9879065,research
duloxetine,Efficacy,P value  5E-5,European,rs10007051,research
duloxetine,Efficacy,P value  5E-5,European,rs11933890,research
duloxetine,Efficacy,P value  5E-5,European,rs55881666,research
ticagrelor,Metabolism/PK,P value  0.004,European,CYP3A4*1,research
ticagrelor,Metabolism/PK,P value  0.004,European,CYP3A4*22,research
epoetin alfa,Metabolism/PK,P value  0.01,European,rs1800562,research
epoetin alfa,Dosage,P value  0.01,European,rs1800562,research
duloxetine,Efficacy,P value  5E-5,European,rs56229625,research
fluvastatin,Efficacy,P value  0.005,Multiple groups,rs1799752,research
duloxetine,Efficacy,P value  5E-5,European,rs62319299,research
atenolol,Efficacy,P value  0.01,European,rs1042714,research
duloxetine,Efficacy,P value  5E-5,European,rs61692318,research
duloxetine,Efficacy,P value  5E-5,European,rs10123866,research
epoetin alfa,Metabolism/PK,P value  0.01,European,rs1799945,research
epoetin alfa,Dosage,P value  0.01,European,rs1799945,research
duloxetine,Efficacy,P value  5E-5,European,rs10124893,research
ondansetron,Metabolism/PK,P value  0.003,"Multiple groups, 139 Caucasian, 2 Black African",CYP2D6*1,research
ondansetron,Metabolism/PK,P value  0.003,"Multiple groups, 139 Caucasian, 2 Black African",CYP2D6*1xN,research
duloxetine,Efficacy,P value  5E-5,European,rs10989064,research
duloxetine,Efficacy,P value  5E-5,European,rs6479008,research
nelfinavir,Metabolism/PK,P value  0.001,Multiple groups,rs4244285,research
nelfinavir,Metabolism/PK,P value  0.001,European,rs4244285,research
nelfinavir,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,rs4244285,research
duloxetine,Efficacy,P value  5E-5,European,rs7472,research
imipramine,Metabolism/PK,P value  0.0027,European,CYP2C19 poor metabolizers,research
digoxin,Metabolism/PK,P value  0.006,European,rs1045642,research
duloxetine,Efficacy,P value  5E-5,European,rs12595802,research
duloxetine,Efficacy,P value  5E-5,European,rs12603700,research
duloxetine,Efficacy,P value  5E-5,European,rs56355515,research
duloxetine,Efficacy,P value  5E-5,European,rs58042962,research
ondansetron,Efficacy,P value  0.001,Unknown,CYP2D6*1,research
ondansetron,Efficacy,P value  0.001,Unknown,CYP2D6*1xN,research
cyclosporine,Metabolism/PK,P value  2.7E-7,European,CYP3A5*1,research
cyclosporine,Metabolism/PK,P value  2.7E-7,European,CYP3A5*3,research
cyclosporine,Metabolism/PK,P value  6E-4,European,CYP3A5*1,research
cyclosporine,Metabolism/PK,P value  6E-4,European,CYP3A5*3,research
cyclosporine,Metabolism/PK,P value  0.004,Unknown,CYP3A5*1,research
cyclosporine,Metabolism/PK,P value  0.004,Unknown,CYP3A5*3,research
irbesartan,Efficacy,P value  0.01,European,rs1801701,research
efavirenz,Metabolism/PK,P value  0.01,East Asian,rs3745274,research
irbesartan,Efficacy,P value  0.008,European,rs699,research
methotrexate,Efficacy,P value  0.01,European,rs1051266,research
warfarin,Dosage,P value  0.000,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
deferasirox,Metabolism/PK,P value  0.002,"Multiple groups, Italy",rs3806596,research
warfarin,Dosage,P value  1.0E-4,Near Eastern,rs1799853,research
methotrexate,Efficacy,P value  0.005,Multiple groups,rs17602729,research
peginterferon alfa-2a,Efficacy,P value  0.002,East Asian,rs8099917,research
warfarin,Dosage,P value  1.0E-4,Near Eastern,rs56165452,research
propofol,Metabolism/PK,P value  0.0014,Unknown,rs2279343,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs28399499,research
atenolol,Efficacy,P value  0.006,European,rs1800545,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs1045642,research
etoposide,Metabolism/PK,P value  0.002,"Multiple groups, Black(25) and White (77) Children",rs1045642,research
duloxetine,Efficacy,P value  5E-5,European,rs12094644,research
warfarin,Dosage,P value  1.0E-4,Near Eastern,rs9923231,research
duloxetine,Efficacy,P value  5E-5,European,rs12502866,research
olanzapine,Metabolism/PK,P value  1.5E-5,"Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.",rs472660,research
olanzapine,Dosage,P value  1.5E-5,"Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.",rs472660,research
olanzapine,Efficacy,P value  1.5E-5,"Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.",rs472660,research
olanzapine,Toxicity,P value  1.5E-5,"Multiple groups, subset of CATIE-SZ.  multiple U.S. sites. 161 White, 74  African American.",rs472660,research
duloxetine,Efficacy,P value  5E-5,European,rs4437856,research
duloxetine,Efficacy,P value  5E-5,European,rs4639250,research
duloxetine,Efficacy,P value  5E-5,European,rs12657120,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs3745274,research
paroxetine,Efficacy,P value  0.0055,European,rs4680,research
duloxetine,Efficacy,P value  5E-5,European,rs13204353,research
fluoxetine,Efficacy,P value  0.003,East Asian,SLC6A4 HTTLPR long form (L allele),research
fluoxetine,Efficacy,P value  0.003,East Asian,SLC6A4 HTTLPR short form (S allele),research
duloxetine,Efficacy,P value  5E-5,European,rs9369266,research
duloxetine,Efficacy,P value  5E-5,European,rs3128624,research
fluoxetine,Efficacy,P value  0.01,East Asian,rs57098334,research
duloxetine,Efficacy,P value  5E-5,European,rs3124955,research
duloxetine,Efficacy,P value  5E-5,European,rs10771997,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*3,research
clopidogrel,Efficacy,P value  0.007,European,CYP2C19*17,research
peginterferon alfa-2b,Efficacy,P value  1.0E-4,East Asian,rs8099917,research
duloxetine,Efficacy,P value  5E-5,European,rs10771998,research
duloxetine,Efficacy,P value  5E-5,European,rs7306991,research
duloxetine,Efficacy,P value  5E-5,European,rs7316769,research
desipramine,Metabolism/PK,P value  0.01,European,CYP2D6 poor metabolizers,research
duloxetine,Efficacy,P value  5E-5,European,rs17724452,research
duloxetine,Efficacy,P value  5E-5,European,rs17724464,research
allopurinol,Dosage,P value  0.001,"Multiple groups, 22 African American, 2 Asian, 77 Caucasian, 1 Pacific Islander",rs3731722,research
duloxetine,Efficacy,P value  5E-5,European,rs17724494,research
duloxetine,Efficacy,P value  5E-5,European,rs61908402,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.000039,East Asian,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.000039,East Asian,CYP2D6*10,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.00021,East Asian,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.00021,East Asian,CYP2D6*10,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
duloxetine,Efficacy,P value  5E-5,European,rs61908403,research
deferiprone,Efficacy,P value  0.001,Central/South Asian,rs2070959,research
(S)-methadone,Metabolism/PK,P value  0.0001,"Multiple groups, 96% of participants were Caucasian. Study carried out in Switzerland.",CYP2B6*1,research
(S)-methadone,Metabolism/PK,P value  0.0001,"Multiple groups, 96% of participants were Caucasian. Study carried out in Switzerland.",CYP2B6*6,research
duloxetine,Efficacy,P value  5E-5,European,rs61908406,research
deferiprone,Efficacy,P value  0.01,Central/South Asian,rs2070959,research
duloxetine,Efficacy,P value  5E-5,European,rs61908407,research
duloxetine,Efficacy,P value  5E-5,European,rs61908408,research
duloxetine,Efficacy,P value  5E-5,European,rs61908410,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
duloxetine,Efficacy,P value  5E-5,European,rs61908409,research
duloxetine,Efficacy,P value  5E-5,European,rs61908411,research
duloxetine,Efficacy,P value  5E-5,European,rs78482393,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP3A4*1,research
endoxifen,Metabolism/PK,P value  0.001,Unknown,CYP3A4*22,research
duloxetine,Efficacy,P value  5E-5,European,rs78615940,research
midazolam,Metabolism/PK,P value  0.01,European,CYP3A4*1,research
midazolam,Metabolism/PK,P value  0.01,European,CYP3A4*22,research
midazolam,Metabolism/PK,P value  0.01,European,CYP3A4*1,research
midazolam,Metabolism/PK,P value  0.01,European,CYP3A4*22,research
tacrolimus,Dosage,P value  0.0002,European,CYP3A4*1,research
tacrolimus,Dosage,P value  0.0002,European,CYP3A4*22,research
tacrolimus,Dosage,P value  0.0007,European,CYP3A4*1,research
tacrolimus,Dosage,P value  0.0007,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.001,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.006,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.006,European,CYP3A4*22,research
opioids,Dosage,P value  0.00001,Unknown,rs1799971,research
imatinib,Efficacy,P value  0.001,Unknown,rs2725252,research
imatinib,Efficacy,P value  0.005,Unknown,rs2725252,research
imatinib,Efficacy,P value  0.006,Unknown,rs2725252,research
dobutamine,Efficacy,P value  1.0E-4,Unknown,rs1801253,research
lansoprazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19 poor metabolizers,research
imatinib,Efficacy,P value  0.001,Unknown,rs12505410,research
warfarin,Dosage,P value  1.0E-4,"Multiple groups, mostly white",rs9923231,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*3,research
dobutamine,Efficacy,P value  0.005,Unknown,rs1801253,research
dobutamine,Efficacy,P value  0.009,Unknown,rs1801253,research
ivacaftor,Efficacy,P value  0.01,Unknown,rs75527207,research
cisplatin,Efficacy,P value  2.0E-5,Unknown,rs9679162,research
cisplatin,Efficacy,P value  4.43E-4,Unknown,rs9679162,research
cisplatin,Efficacy,P value  0.003695,Unknown,rs9679162,research
risperidone,Efficacy,P value  0.001,East Asian,rs2661319,research
fentanyl,Dosage,P value  0.0001,East Asian,rs2076222,research
fentanyl,Efficacy,P value  0.0001,East Asian,rs2076222,research
escitalopram,Efficacy,P value  0.001,European,rs41271330,research
escitalopram,Efficacy,P value  0.001,European,rs41271330,research
cetuximab,Efficacy,P value  0.007,Unknown,rs1570360,research
tacrolimus,Metabolism/PK,P value  0.0009,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.0009,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.007,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.007,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.008,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.008,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.01,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.01,European,CYP3A4*22,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,CYP3A5*6,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,CYP3A5*7,research
tacrolimus,Metabolism/PK,P value  0.0006,European,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.0006,European,CYP3A4*22,research
buprenorphine,Efficacy,P value  0.009,"Multiple groups, European American - mainly White but some Latino/White.",rs581111,research
vincristine,Metabolism/PK,P value  4.0E-4,Multiple groups,CYP3A5*1,research
vincristine,Metabolism/PK,P value  4.0E-4,Multiple groups,CYP3A5*3,research
pantoprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19 poor metabolizers,research
warfarin,Dosage,P value  0.000,East Asian,rs2592551,research
warfarin,Dosage,P value  0.000,East Asian,rs2592551,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*6,research
phenprocoumon,Dosage,P value  0.001,European,CYP2C9*2,research
phenprocoumon,Toxicity,P value  0.001,European,CYP2C9*2,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*41,research
tacrolimus,Metabolism/PK,P value  0.005,Near Eastern,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.005,Near Eastern,CYP3A5*3,research
fluvoxamine,Efficacy,P value  5.0E-4,East Asian,rs6295,research
fluvoxamine,Efficacy,P value  1.0E-4,East Asian,rs10042486,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.0001,Unknown,CYP2D6*41,research
mercaptopurine,Dosage,P value  0.001,European,TPMT*1,research
mercaptopurine,Dosage,P value  0.001,European,TPMT*3A,research
nicotine,Dosage,P value  0.008,"Multiple groups, Participants were of Caucasian, Asian, Afro-Caribbean or Other ethnicities. 13 participants did not give an ethnicity.",rs1137070,research
fluvastatin,Metabolism/PK,P value  8.5e-11,European,rs77760615,research
fluvastatin,Metabolism/PK,P value  8.5e-11,European,CYP2C9*1,research
fluvastatin,Metabolism/PK,P value  8.5e-11,European,CYP2C9*3,research
fluvastatin,Metabolism/PK,P value  3.07e-10,European,rs58310495,research
nicotine,Dosage,P value  0.007,"Multiple groups, Participants were of Caucasian, Asian, Afro-Caribbean or Other ethnicities. 13 participants did not give an ethnicity.",rs77905,research
nicotine,Dosage,P value  0.007,"Multiple groups, Participants were of Caucasian, Asian, Afro-Caribbean or Other ethnicities. 13 participants did not give an ethnicity.",rs77905,research
sirolimus,Metabolism/PK,P value  0.01,"Multiple groups, White, Hispanic, Asian/Pacific Islander, Other",rs2032582,research
clopidogrel,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.0001,East Asian,CYP2C19*2,research
cyclophosphamide,Efficacy,P value  0.0043,Central/South Asian,rs4244285,research
4-hydroxycyclophosphamide,Metabolism/PK,P value  0.01,Central/South Asian,rs776746,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*2xN,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*5,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*2xN,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.001,European,CYP2D6*5,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*2xN,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*5,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*2xN,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*5,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*2xN,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.01,European,CYP2D6*5,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.0001,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
mercaptopurine,Dosage,P value  0.0009,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.0009,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
mercaptopurine,Dosage,P value  0.01,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*1,research
mercaptopurine,Dosage,P value  0.01,"Multiple groups, White, Asian (Indian sub-continent), mixed, Black, Oriental, unknown",TPMT*3A,research
carbamazepine,Dosage,P value  0.0051,European,rs3812718,research
phenytoin,Metabolism/PK,P value  0.0066,European,rs1057910,research
phenytoin,Dosage,P value  0.0066,European,rs1057910,research
deferasirox,Metabolism/PK,P value  0.007,Unknown,rs7975232,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African American",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African American",CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.008,"Multiple groups, Caucasian and African American",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.008,"Multiple groups, Caucasian and African American",CYP3A5*3,research
deferasirox,Metabolism/PK,P value  0.003,Unknown,rs2228570,research
deferasirox,Metabolism/PK,P value  0.008,Unknown,rs2228570,research
deferasirox,Metabolism/PK,P value  0.010,Unknown,rs2228570,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*1,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*2,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*3,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*4,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*5,research
nortriptyline,Dosage,P value  0.001,"Multiple groups, mostly White",CYP2D6*10,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*1,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*2,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*3,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*4,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*5,research
nortriptyline,Dosage,P value  0.002,"Multiple groups, mostly White",CYP2D6*10,research
rivastigmine,Efficacy,P value  0.003,East Asian,rs1803274,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*3,research
azathioprine,Toxicity,P value  4.93E-11,East Asian,rs116855232,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C19*3,research
omeprazole,Metabolism/PK,P value  0.0001,European,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.0001,European,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.0001,European,CYP2C19*3,research
paroxetine,Metabolism/PK,P value  0.0001,European,CYP2D6 poor metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.0002,"Multiple groups,  majority (~93%) of the subjects enrolled in this study were white",CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.0002,"Multiple groups,  majority (~93%) of the subjects enrolled in this study were white",CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.0002,"Multiple groups,  majority (~93%) of the subjects enrolled in this study were white",CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.0002,"Multiple groups,  majority (~93%) of the subjects enrolled in this study were white",CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.0002,"Multiple groups,  majority (~93%) of the subjects enrolled in this study were white",CYP2D6*6,research
amlodipine,Efficacy,P value  0.01,African American/Afro-Caribbean,rs2246709,research
calcium channel blockers,Efficacy,P value  1.1E-4,European,rs2239050,research
remifentanil,Efficacy,P value  0.01,East Asian,rs1045642,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African American",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Caucasian and African American",CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.008,"Multiple groups, Caucasian and African American",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.008,"Multiple groups, Caucasian and African American",CYP3A5*3,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
metoprolol,Efficacy,P value  1.0E-4,European,rs5030655,research
amoxicillin,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
amoxicillin,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
amoxicillin,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
warfarin,Dosage,P value  0.001,East Asian,rs4072879,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*1,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*2,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*3,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*1,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*2,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*3,research
mercaptopurine,Toxicity,P value  0.00048,East Asian,NUDT15*5,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
fluorouracil,Metabolism/PK,P value  0.01,"Multiple groups, Malay, Chinese, Indian",rs1801159,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
risperidone,Metabolism/PK,P value  0.007,European,rs2231142,research
Platinum compounds,Efficacy,P value  0.01,Unknown,rs1799782,research
Platinum compounds,Efficacy,P value  0.01,Unknown,rs1799782,research
ataluren,Efficacy,P value  0.002,Unknown,rs75039782,research
ataluren,Efficacy,P value  0.002,Unknown,rs77010898,research
warfarin,Dosage,P value  0.001,Multiple groups,rs9923231,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*3,research
nicotine,Other,P value  0.00,"Multiple groups, Asian and Caucasian subjects",rs1799971,research
valproic acid,Metabolism/PK,P value  0.002,"Multiple groups, Mostly Asian",rs7668258,research
simvastatin acid,Metabolism/PK,P value  0.001,Unknown,rs4149056,research
ataluren,Efficacy,P value  0.002,Unknown,rs113993959,research
isoniazid,Metabolism/PK,P value  0.009,Sub-Saharan African,rs1799930,research
valproic acid,Metabolism/PK,P value  0.004,"Multiple groups, Mostly Asian",rs7668258,research
valproic acid,Metabolism/PK,P value  0.01,"Multiple groups, Mostly Asian",rs7668258,research
valproic acid,Metabolism/PK,P value  0.0006,"Multiple groups, Mostly Asian",rs12233719,research
valproic acid,Metabolism/PK,P value  0.01,"Multiple groups, Mostly Asian",rs12233719,research
paroxetine,Metabolism/PK,P value  0.0028,East Asian,rs762551,research
amlodipine,Efficacy,P value  2.5E-9,European,rs2238032,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
atazanavir,Toxicity,P value  0.005,Latino,UGT1A1*1,research
atazanavir,Toxicity,P value  0.005,Latino,UGT1A1*28,research
atazanavir,Toxicity,P value  0.005,Latino,UGT1A1*36,research
erlotinib,Efficacy,P value  0.001,Unknown,rs121434568,research
carbamazepine,Metabolism/PK,P value  0.002,European,rs3812718,research
warfarin,Dosage,P value  0.001,European,rs9923231,research
estrone sulfate,Metabolism/PK,P value  0.001,"Multiple groups, USA Michigan and Indiana Universities, 88% white, 9% black, 3% other.",SLCO1B1*1,research
estrone sulfate,Metabolism/PK,P value  0.001,"Multiple groups, USA Michigan and Indiana Universities, 88% white, 9% black, 3% other.",SLCO1B1*5,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,rs4917639,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*1,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*2,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*5,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*10,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*14,research
paroxetine,Metabolism/PK,P value  0.002,East Asian,CYP2D6*41,research
rituximab,Efficacy,P value  0.004,Unknown,rs396991,research
gefitinib,Efficacy,P value  0.001,Unknown,rs121434568,research
celecoxib,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
celecoxib,Metabolism/PK,P value  0.001,East Asian,CYP2C9*3,research
celecoxib,Metabolism/PK,P value  0.001,East Asian,CYP2C9*13,research
cyclosporine,Metabolism/PK,P value  0.01,East Asian,CYP3A5*1,research
cyclosporine,Metabolism/PK,P value  0.01,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*5,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*6,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*11,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*5,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*6,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*8,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*9,research
warfarin,Dosage,P value  0.001,Sub-Saharan African,CYP2C9*11,research
clopidogrel,Efficacy,P value  5.1E-40,European,CYP2C19*2,research
Antihypertensives,Efficacy,P value  1.6E-6,Multiple groups,rs12817819,research
Antihypertensives,Efficacy,P value  6.31E-6,Multiple groups,rs12817819,research
Antihypertensives,Efficacy,P value  7.69E-4,Latino,rs12817819,research
Antihypertensives,Efficacy,P value  0.0024,European,rs12817819,research
peginterferon alfa-2a,Efficacy,P value  0.001,"Multiple groups, mostly white",rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.001,"Multiple groups, mostly white",rs11322783,research
allopurinol,Dosage,P value  0.0008,Unknown,rs2231142,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
peginterferon alfa-2a,Efficacy,P value  0.0001,East Asian,rs11322783,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.002,Unknown,CYP2D6*8,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs1019385,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs1019385,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs1019385,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs1019385,research
peginterferon alfa-2a,Efficacy,P value  0.007,East Asian,rs8099917,research
warfarin,Dosage,P value  0.001,East Asian,rs7294,research
warfarin,Dosage,P value  0.001,East Asian,rs7294,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs1105879,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs1105879,research
peginterferon alfa-2a,Efficacy,P value  0.007,East Asian,rs11881222,research
atazanavir,Toxicity,P value  0.0001,"Multiple groups, 80% Caucasian",UGT1A1*1,research
atazanavir,Toxicity,P value  0.0001,"Multiple groups, 80% Caucasian",UGT1A1*28,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs2070959,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs2070959,research
metformin,Metabolism/PK,P value  0.01,East Asian,rs2289669,research
Platinum compounds,Efficacy,P value  0.01,East Asian,rs7958904,research
peginterferon alfa-2a,Efficacy,P value  0.008,Multiple groups,rs12979860,research
fentanyl,Dosage,P value  0.01,Unknown,rs1045642,research
fentanyl,Efficacy,P value  0.01,Unknown,rs1045642,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs6759892,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs6759892,research
warfarin,Metabolism/PK,P value  1.0E-4,East Asian,rs9923231,research
warfarin,Dosage,P value  1.0E-4,East Asian,rs9923231,research
cetuximab,Efficacy,P value  0.006,Unknown,rs13104811,research
clonidine,Efficacy,P value  1.0E-4,Unknown,rs5443,research
clonidine,Efficacy,P value  0.002,Unknown,rs5443,research
clonidine,Efficacy,P value  0.009,Unknown,rs5443,research
methylphenidate,Efficacy,P value  0.006,Multiple groups,rs5326,research
warfarin,Dosage,P value  0.010,East Asian,rs2108622,research
warfarin,Dosage,P value  1.0E-4,European,rs7294,research
warfarin,Dosage,P value  1.0E-4,European,rs9934438,research
peginterferon alfa-2a,Efficacy,P value  0.009,East Asian,rs3828913,research
estrone sulfate,Metabolism/PK,P value  0.004,"Multiple groups, USA Michigan and Indiana Universities, 88% white, 9% black, 3% other.",rs10841753,research
peginterferon alfa-2a,Efficacy,P value  0.001,East Asian,rs8099917,research
warfarin,Dosage,P value  1.0E-4,European,rs9923231,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
iloperidone,Efficacy,P value  0.002,"Multiple groups, The three ethnic/racial groups with the largest number of genotyped patients were blacks (n = 211, 50.6%), whites (n = 143, 34.3%) and Asians (n = 39, 9.4%). Additional ethnic/racial groups that included American Indians, Native Alaskans, Native Hawaiians, Pacific Islanders or others, contained only 24 (5.7%) genotyped patients",rs1800169,research
iloperidone,Efficacy,P value  0.004,"Multiple groups, The three ethnic/racial groups with the largest number of genotyped patients were blacks (n = 211, 50.6%), whites (n = 143, 34.3%) and Asians (n = 39, 9.4%). Additional ethnic/racial groups that included American Indians, Native Alaskans, Native Hawaiians, Pacific Islanders or others, contained only 24 (5.7%) genotyped patients",rs1800169,research
iloperidone,Efficacy,P value  0.005,"Multiple groups, The three ethnic/racial groups with the largest number of genotyped patients were blacks (n = 211, 50.6%), whites (n = 143, 34.3%) and Asians (n = 39, 9.4%). Additional ethnic/racial groups that included American Indians, Native Alaskans, Native Hawaiians, Pacific Islanders or others, contained only 24 (5.7%) genotyped patients",rs1800169,research
warfarin,Dosage,P value  0.0001,European,rs4889606,research
warfarin,Dosage,P value  0.0001,Near Eastern,rs4889606,research
warfarin,Dosage,P value  0.003,East Asian,rs887829,research
warfarin,Dosage,P value  0.006,East Asian,rs2108622,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
atazanavir,Metabolism/PK,P value  0.01,"Multiple groups, White, African-American",rs1128503,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
endoxifen,Metabolism/PK,P value  0.003,Unknown,CYP2D6 poor metabolizers,research
tenofovir,Metabolism/PK,P value  1.7E-5,"Multiple groups, Majority African American (n=55)",rs2231142,research
atazanavir,Metabolism/PK,P value  0.01,"Multiple groups, White, African-American",rs1045642,research
metformin,Efficacy,P value  0.005,European,rs622342,research
ranibizumab,Efficacy,P value  0.01,Unknown,rs2070296,research
lopinavir,Metabolism/PK,P value  0.01,European,rs4149056,research
cyclophosphamide,Metabolism/PK,P value  0.001,East Asian,rs7254579,research
nevirapine,Metabolism/PK,P value  0.00005,East Asian,rs3745274,research
nevirapine,Metabolism/PK,P value  0.0004,East Asian,rs3745274,research
bupropion,Metabolism/PK,P value  0.004,Unknown,CYP2B6*1,research
bupropion,Metabolism/PK,P value  0.004,Unknown,CYP2B6*6,research
methotrexate,Efficacy,P value  0.008,Multiple groups,rs246240,research
atazanavir,Metabolism/PK,P value  0.01,"Multiple groups, White, African-American",rs2032582,research
peginterferon alfa-2a,Efficacy,P value  1.37E-28,"Multiple groups, European-Americans: 871; African-Americans: 191; Hispanics: 75.",rs8103142,research
peginterferon alfa-2a,Efficacy,P value  1.37E-28,"Multiple groups, European-Americans: 871; African-Americans: 191; Hispanics: 75.",rs28416813,research
haloperidol,Metabolism/PK,P value  0.003,East Asian,CYP2D6*1,research
haloperidol,Metabolism/PK,P value  0.003,East Asian,CYP2D6*2,research
efavirenz,Metabolism/PK,P value  0.0009,East Asian,rs3745274,research
ethanol,Metabolism/PK,P value  3.0E-4,European,rs1154461,research
ethanol,Toxicity,P value  3.0E-4,European,rs1154461,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*1,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*2,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*3,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*4,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*5,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*6,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*9,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*10,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*17,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*29,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*35,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*41,research
cisplatin,Efficacy,P value  0.00,Central/South Asian,rs3918290,research
irinotecan,Efficacy,P value  0.008,Unknown,UGT1A1*60,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
cyclophosphamide,Metabolism/PK,P value  0.001,East Asian,rs4802101,research
tipiracil hydrochloride,Efficacy,P value  0.008,East Asian,rs760370,research
warfarin,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2C9*1,research
warfarin,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2C9*8,research
peginterferon alfa-2a,Efficacy,P value  4.647e-7,European,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  6.459e-7,European,rs12979860,research
hmg coa reductase inhibitors,Efficacy,P value  0.006,Unknown,rs1532624,research
hmg coa reductase inhibitors,Efficacy,P value  0.006,Unknown,rs1532624,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*2xN,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*17,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*29,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*35,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*41,research
acenocoumarol,Dosage,P value  0.001,European,rs55894764,research
cyclosporine,Metabolism/PK,P value  0.01,Unknown,rs1057868,research
cyclophosphamide,Metabolism/PK,P value  0.001,East Asian,rs4244285,research
benazepril,Efficacy,P value  0.01,East Asian,rs1805087,research
tacrolimus,Dosage,P value  0.01,Multiple groups,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,Multiple groups,CYP3A5*3,research
pitrakinra,Efficacy,P value  0.007,European,rs8832,research
pitrakinra,Efficacy,P value  0.009,European,rs8832,research
simvastatin acid,Metabolism/PK,P value  0.001,East Asian,rs4149056,research
atazanavir,Metabolism/PK,P value  0.007,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs1128503,research
donepezil,Metabolism/PK,P value  0.01,"Multiple groups, n=1 Arabian patient, the rest were Caucasian.",CYP2D6*4,research
donepezil,Metabolism/PK,P value  0.01,"Multiple groups, n=1 Arabian patient, the rest were Caucasian.",CYP2D6*5,research
acenocoumarol,Dosage,P value  1.0E-4,European,rs9934438,research
acenocoumarol,Dosage,P value  1.0E-4,European,rs9934438,research
cisplatin,Efficacy,P value  6.0E-5,Unknown,rs1734791,research
aripiprazole,Efficacy,P value  0.01,East Asian,rs1800497,research
cisplatin,Efficacy,P value  6.0E-5,Unknown,rs1734787,research
nicotine,Efficacy,P value  4.41E-6,Unknown,CYP2A6 high activity,research
pitrakinra,Efficacy,P value  0.005,European,rs1029489,research
cisplatin,Efficacy,P value  6.0E-5,Unknown,rs17435,research
methadone,,P value  0.005,European,rs6275,research
cisplatin,Efficacy,P value  1.5E-5,Unknown,rs5906072,research
fentanyl,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
fentanyl,Metabolism/PK,P value  0.01,Unknown,CYP2D6*29,research
benazepril,Efficacy,P value  0.004,East Asian,rs1801133,research
cisplatin,Efficacy,P value  3.7E-5,Unknown,rs5934731,research
dextromethorphan,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.01,East Asian,CYP2D6*2,research
dextromethorphan,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
dextromethorphan,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10x2,research
cisplatin,Efficacy,P value  3.0E-6,Unknown,rs715171,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs4932551,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*1xN,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*2,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*2xN,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*3,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*4,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*6,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*9,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*35,research
endoxifen,Metabolism/PK,P value  0.01,"Multiple groups, mostly White",CYP2D6*41,research
warfarin,Dosage,P value  0.00001,Multiple groups,rs11676382,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs7170769,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*3,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs6458232,research
atazanavir,Metabolism/PK,P value  0.007,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs1045642,research
cisplatin,Efficacy,P value  1.5E-5,Unknown,rs12613732,research
fluorouracil,Metabolism/PK,P value  0.0001,Unknown,rs3918290,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs6752303,research
valproic acid,Metabolism/PK,P value  0.0089,East Asian,rs28898617,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*1,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*1xN,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*2,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*2xN,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*3,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*4,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*5,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*6,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*9,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*10,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*29,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*35,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, mostly White",CYP2D6*41,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs10209881,research
cisplatin,Efficacy,P value  1.5E-5,Unknown,rs12999804,research
atazanavir,Metabolism/PK,P value  0.007,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs2032582,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs1105879,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs1105879,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs2070959,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs2070959,research
valproic acid,Metabolism/PK,P value  1.0E-4,East Asian,rs6759892,research
valproic acid,Dosage,P value  1.0E-4,East Asian,rs6759892,research
debrisoquine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*1,research
debrisoquine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*2,research
debrisoquine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*17,research
hdl cholesterol,Other,P value  0.00043,Unknown,rs4646,research
triglycerides,Other,P value  0.00028,Unknown,rs4775936,research
cyclophosphamide,Efficacy,P value  0.004,Unknown,CYP2B6*1,research
cyclophosphamide,Efficacy,P value  0.004,Unknown,CYP2B6*6,research
corticosteroids,Efficacy,P value  1.0E-4,European,rs2240017,research
methylphenidate,Efficacy,P value  7.9E-05,"Multiple groups, 173 Caucasian pediatric patients from Spain and 189 adult patients from Brazil",rs17685420,research
triglycerides,Other,P value  0.00019,Unknown,rs700518,research
clopidogrel thiol metabolite H4,Metabolism/PK,P value  0.004,European,rs4244285,research
triglycerides,Other,P value  0.00045,Unknown,rs3759811,research
pazopanib,Efficacy,P value  0.01,Unknown,rs34231037,research
cilostazol,Metabolism/PK,P value  0.006,East Asian,CYP2C19*1,research
cilostazol,Metabolism/PK,P value  0.006,East Asian,CYP2C19*2,research
cilostazol,Metabolism/PK,P value  0.006,East Asian,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Other,P value  0.001,East Asian,rs776746,research
triglycerides,Other,P value  0.0000069,Unknown,rs10046,research
tacrolimus,Metabolism/PK,P value  0.009,East Asian,CYP3A4*1,research
tacrolimus,Other,P value  0.009,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.009,East Asian,CYP3A4*1G,research
tacrolimus,Other,P value  0.009,East Asian,CYP3A4*1G,research
codeine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*1,research
codeine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*5,research
codeine,Metabolism/PK,P value  0.005,Sub-Saharan African,CYP2D6*17,research
triglycerides,Other,P value  0.0000074,Unknown,rs2289105,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
atorvastatin,Metabolism/PK,P value  0.01,East Asian,rs4149056,research
ethanol,Metabolism/PK,P value  0.003,European,rs1662060,research
ethanol,Toxicity,P value  0.003,European,rs1662060,research
warfarin,Dosage,P value  0.0001,East Asian,rs9923231,research
hdl cholesterol,Other,P value  0.00046,Unknown,rs10046,research
sorafenib,Metabolism/PK,P value  0.0001,Multiple groups,UGT1A1*1,research
sorafenib,Metabolism/PK,P value  0.0001,Multiple groups,UGT1A1*28,research
ethanol,Metabolism/PK,P value  0.003,European,rs1229985,research
ethanol,Toxicity,P value  0.003,European,rs1229985,research
hdl cholesterol,Other,P value  0.000043,Unknown,rs1062033,research
hdl cholesterol,Other,P value  0.00037,Unknown,rs1008805,research
fluoxetine,Efficacy,P value  0.001,East Asian,SLC6A4 HTTLPR long form (L allele),research
fluoxetine,Efficacy,P value  0.001,East Asian,SLC6A4 HTTLPR short form (S allele),research
triglycerides,Other,P value  0.000037,Unknown,rs749292,research
dextromethorphan,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2D6*1,research
dextromethorphan,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2D6*17,research
fluoxetine,Efficacy,P value  0.009,East Asian,rs6295,research
tacrolimus,Metabolism/PK,P value  1.0E-4,"Multiple groups, Brazilian",rs776746,research
tacrolimus,Dosage,P value  1.0E-4,"Multiple groups, Brazilian",rs776746,research
tacrolimus,Metabolism/PK,P value  1.0E-4,"Multiple groups, Brazilian",rs41303343,research
tacrolimus,Dosage,P value  1.0E-4,"Multiple groups, Brazilian",rs41303343,research
tacrolimus,Metabolism/PK,P value  1.0E-4,"Multiple groups, Brazilian",rs10264272,research
tacrolimus,Dosage,P value  1.0E-4,"Multiple groups, Brazilian",rs10264272,research
tolbutamide,Metabolism/PK,P value  0.01,,rs771237265,research
tacrolimus,Dosage,P value  0.001,Multiple groups,rs2740574,research
tacrolimus,Dosage,P value  0.001,Multiple groups,rs2740574,research
tacrolimus,Dosage,P value  0.006,Multiple groups,rs2740574,research
azathioprine,Dosage,P value  8.50E-06,Unknown,rs116855232,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,rs2740574,research
omeprazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*17,research
flunisolide,Efficacy,P value  0.0077,European,rs2305089,research
tacrolimus,Metabolism/PK,P value  6.0E-4,"Multiple groups, Predominantly Caucasian cohort",rs1057868,research
tacrolimus,Dosage,P value  6.0E-4,"Multiple groups, Predominantly Caucasian cohort",rs1057868,research
mercaptopurine,Dosage,P value  0.005,Central/South Asian,TPMT*1,research
mercaptopurine,Dosage,P value  0.005,Central/South Asian,TPMT*2,research
mercaptopurine,Dosage,P value  0.005,Central/South Asian,TPMT*3A,research
mercaptopurine,Dosage,P value  0.005,Central/South Asian,TPMT*3C,research
n-desmethyltramadol,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizers and intermediate metabolizers,research
clobazam,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
clobazam,Metabolism/PK,P value  0.01,Unknown,CYP2C19*2,research
clobazam,Metabolism/PK,P value  0.01,Unknown,CYP2C19*3,research
adalimumab,Efficacy,P value  1.14E-4,Unknown,rs510432,research
tacrolimus,Metabolism/PK,P value  1.0E-4,Multiple groups,rs776746,research
tacrolimus,Dosage,P value  1.0E-4,Multiple groups,rs776746,research
adalimumab,Efficacy,P value  5.19E-4,Unknown,rs1130864,research
captopril,Efficacy,P value  0.01,Unknown,rs1799752,research
spironolactone,Efficacy,P value  0.002,African American/Afro-Caribbean,rs3890011,research
carbamazepine,Metabolism/PK,P value  0.006,East Asian,rs776746,research
carbamazepine,Metabolism/PK,P value  0.006,East Asian,rs15524,research
peginterferon alfa-2a,Efficacy,P value  0.0058,East Asian,rs8099917,research
opioids,Dosage,P value  0.001,"Multiple groups, Studies include Asian, Caucasian, Hispanic, Polynesian participants and participants of unreported ethnicity.",rs1799971,research
opioids,Efficacy,P value  0.001,"Multiple groups, Studies include Asian, Caucasian, Hispanic, Polynesian participants and participants of unreported ethnicity.",rs1799971,research
omeprazole,Metabolism/PK,P value  0.01,Unknown,rs1045642,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
clobazam,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clobazam,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
clobazam,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
clobazam,Efficacy,P value  0.002,East Asian,CYP2C19*1,research
clobazam,Efficacy,P value  0.002,East Asian,CYP2C19*2,research
clobazam,Efficacy,P value  0.002,East Asian,CYP2C19*3,research
enalapril,Efficacy,P value  0.01,East Asian,rs1799752,research
nicotine,Metabolism/PK,P value  0.005,East Asian,CYP2A6*1A,research
nicotine,Metabolism/PK,P value  0.005,East Asian,CYP2A6*9A,research
morphine,Dosage,P value  0.001,Unknown,rs1042173,research
nicotine,Metabolism/PK,P value  0.005,East Asian,CYP2A6*1A,research
nicotine,Metabolism/PK,P value  0.005,East Asian,CYP2A6*4A,research
nicotine,Metabolism/PK,P value  0.005,East Asian,CYP2A6*9A,research
warfarin,Dosage,P value  0.0001,European,rs9923231,research
acenocoumarol,Dosage,P value  0.0001,European,rs9923231,research
peginterferon alfa-2a,Efficacy,P value  0.001,Near Eastern,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.001,Near Eastern,rs12979860,research
acenocoumarol,Dosage,P value  0.01,European,rs2108622,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*5B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6A,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6J,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7G,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*13A,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*5B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6A,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6J,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7G,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*13A,research
hmg coa reductase inhibitors,Efficacy,P value  8.52E-13,Unknown,rs247616,research
captopril,Efficacy,P value  0.01,Unknown,rs1799752,research
atenolol,Efficacy,P value  7.2E-8,African American/Afro-Caribbean,rs11313667,research
sirolimus,Metabolism/PK,P value  0.01,Multiple groups,rs2740574,research
sirolimus,Dosage,P value  0.01,Multiple groups,rs2740574,research
ritonavir,Metabolism/PK,P value  0.009,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs1128503,research
atenolol,Efficacy,P value  1.55E-07,African American/Afro-Caribbean,rs1367094,research
ritonavir,Metabolism/PK,P value  0.009,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs2032582,research
peginterferon alfa-2a,Efficacy,P value  0.004,East Asian,rs8099917,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 poor metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 poor metabolizers,research
atenolol,Efficacy,P value  1.10E-07,African American/Afro-Caribbean,rs201279313,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*5B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*5C,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6A,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6J,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*6O,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7B,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*7G,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*12A,research
isoniazid,Metabolism/PK,P value  0.01,Latino,NAT2*13A,research
ritonavir,Metabolism/PK,P value  0.009,"Multiple groups, USA, Colorado : African-American,  Hispanic, Asian, Caucasian",rs1045642,research
warfarin,Dosage,P value  8.65E-31,East Asian,rs9923231,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*17,research
captopril,Efficacy,P value  0.01,Unknown,rs1799752,research
atenolol,Efficacy,P value  8.69E-08,"Multiple groups, White and Hispanic participants",rs261316,research
atenolol,Efficacy,P value  8.64E-06,European,rs261316,research
atenolol,Efficacy,P value  0.001,"Multiple groups, Mixed population of white and Hispanic (Puerto Rico) subjects",rs261316,research
metformin,Efficacy,P value  0.004,East Asian,rs1143623,research
lopinavir,Metabolism/PK,P value  0.001,European,rs4149056,research
lopinavir,Metabolism/PK,P value  0.002,European,rs4149056,research
phenytoin,Metabolism/PK,P value  0.001,Unknown,rs1799853,research
fluorouracil,Efficacy,P value  0.001,Unknown,rs45445694,research
fluorouracil,Efficacy,P value  0.004,Unknown,rs45445694,research
tacrolimus,Dosage,P value  0.001,African American/Afro-Caribbean,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,African American/Afro-Caribbean,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,African American/Afro-Caribbean,CYP3A5*6,research
tacrolimus,Dosage,P value  0.001,African American/Afro-Caribbean,CYP3A5*7,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
warfarin,Metabolism/PK,P value  0.001,East Asian,rs9923231,research
imatinib,Efficacy,P value  0.000,East Asian,rs2231142,research
methotrexate,Efficacy,P value  0.001,East Asian,rs4149056,research
warfarin,Dosage,P value  0.002,Near Eastern,CYP2C9*1,research
warfarin,Dosage,P value  0.002,Near Eastern,CYP2C9*2,research
warfarin,Dosage,P value  0.002,Near Eastern,CYP2C9*3,research
tamoxifen,Metabolism/PK,P value  0.004,"Multiple groups, >95% were Caucasian patients.",CYP2C19*1,research
tamoxifen,Efficacy,P value  0.004,"Multiple groups, >95% were Caucasian patients.",CYP2C19*1,research
tamoxifen,Metabolism/PK,P value  0.004,"Multiple groups, >95% were Caucasian patients.",CYP2C19*2,research
tamoxifen,Efficacy,P value  0.004,"Multiple groups, >95% were Caucasian patients.",CYP2C19*2,research
risperidone,Metabolism/PK,P value  0.01,"Multiple groups, 81% Caucasian",rs1523130,research
risperidone,Metabolism/PK,P value  8.0E-3,"Multiple groups, 81% caucasian",rs35599367,research
warfarin,Dosage,P value  0.001,East Asian,rs7294,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Metabolism/PK,P value  0.004,"Multiple groups, White (n=21), Black (n=3), Asian (n=3), Indian (n=3)",CYP2C9*1,research
warfarin,Metabolism/PK,P value  0.004,"Multiple groups, White (n=21), Black (n=3), Asian (n=3), Indian (n=3)",CYP2C9*2,research
warfarin,Metabolism/PK,P value  0.004,"Multiple groups, White (n=21), Black (n=3), Asian (n=3), Indian (n=3)",CYP2C9*3,research
warfarin,Metabolism/PK,P value  0.004,"Multiple groups, White (n=21), Black (n=3), Asian (n=3), Indian (n=3)",CYP2C9*8,research
adalimumab,Efficacy,P value  0.0044,European,rs763780,research
platinum,Efficacy,P value  0.001,East Asian,rs6878291,research
montelukast,Metabolism/PK,P value  1.83e-10,European,rs7604115,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
voriconazole,Metabolism/PK,P value  0.001,East Asian,CYP2C19*17,research
montelukast,Metabolism/PK,P value  2.99e-10,European,UGT1A3*1,research
montelukast,Metabolism/PK,P value  2.99e-10,European,UGT1A3*2,research
phenytoin,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic; Asian; BlackWhite, Hispanic",CYP2C9*1,research
phenytoin,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic; Asian; BlackWhite, Hispanic",CYP2C9*2,research
montelukast,Metabolism/PK,P value  2.19e-4,European,rs704212,research
fluorouracil,Efficacy,P value  0.001,Unknown,rs11280056,research
fluorouracil,Efficacy,P value  0.004,Unknown,rs11280056,research
busulfan,Metabolism/PK,P value  0.001,East Asian,rs3957356,research
warfarin,Dosage,P value  0.001,Unknown,rs1799853,research
methotrexate,Efficacy,P value  0.001,European,rs12995526,research
methotrexate,Efficacy,P value  0.001,European,rs7563206,research
atenolol,Efficacy,P value  0.0088,"Multiple groups, mostly Whites and Blacks.",rs1024323,research
phenytoin,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic; Asian; Black; White, Hispanic",CYP2C9*1,research
phenytoin,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic; Asian; Black; White, Hispanic",CYP2C9*2,research
phenytoin,Metabolism/PK,P value  0.01,"Multiple groups, White, non-Hispanic; Asian; Black; White, Hispanic",CYP2C9*3,research
caffeine,Metabolism/PK,P value  9.5e-22,European,rs2472297,research
sertraline,Efficacy,P value  0.0006,Near Eastern,rs1799752,research
sertraline,Efficacy,P value  0.006,Near Eastern,rs1799752,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*1,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*10,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.006,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*1,research
n-desmethyltamoxifen,Metabolism/PK,P value  0.006,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*10,research
tamsulosin,Metabolism/PK,P value  0.001,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
tamsulosin,Metabolism/PK,P value  0.001,East Asian,CYP2D6 intermediate metabolizer and normal metabolizer,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*1,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*4,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*5,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*6,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*10,research
primaquine,Metabolism/PK,P value  0.007,Unknown,CYP2D6*41,research
cilostazol,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
cilostazol,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
cilostazol,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
cilostazol,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
cilostazol,Metabolism/PK,P value  0.002,East Asian,CYP3A5*1,research
cilostazol,Metabolism/PK,P value  0.002,East Asian,CYP3A5*3,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*4,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*5,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*6,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*10,research
primaquine,Metabolism/PK,P value  0.01,Unknown,CYP2D6*41,research
lamotrigine,Metabolism/PK,P value  0.006,European,rs2231142,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*10,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*1,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*5,research
endoxifen,Metabolism/PK,P value  0.001,"Multiple groups, Chinese, Indian and Malay from Singapore",CYP2D6*10,research
cyclophosphamide,Efficacy,P value  0.001,Central/South Asian,rs4244285,research
metoprolol,Efficacy,P value  0.001,African American/Afro-Caribbean,rs1024323,research
metoprolol,Efficacy,P value  0.009,African American/Afro-Caribbean,rs1024323,research
metoprolol,Efficacy,P value  0.01,African American/Afro-Caribbean,rs1024323,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.000086,European,rs1800629,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.00012,Multiple groups,rs1800629,research
Bisphosphonates,Efficacy,P value  0.01,European,rs11264359,research
warfarin,Dosage,P value  0.001,East Asian,rs4645974,research
oxycodone,Efficacy,P value  0.004,"Multiple groups, '12 African-American/Black, 18 Caucasian/White, 3 Multiracial, 1 Native-American or Alaskan, 2 chose not to report.; Ethnically, 22% of the sample identified as Hispanic or Latino.'",rs6848893,research
oxycodone,Efficacy,P value  0.004,"Multiple groups, '12 African-American/Black, 18 Caucasian/White, 3 Multiracial, 1 Native-American or Alaskan, 2 chose not to report.; Ethnically, 22% of the sample identified as Hispanic or Latino.'",rs581111,research
Bisphosphonates,Efficacy,P value  0.01,European,rs2297480,research
venlafaxine,Efficacy,P value  0.0013,Unknown,rs4680,research
cotinine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*1A,research
cotinine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*2,research
cotinine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*4A,research
cotinine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*9,research
cotinine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*12,research
ketamine,Metabolism/PK,P value  0.001,European,CYP2B6*1,research
ketamine,Metabolism/PK,P value  0.001,European,CYP2B6*6,research
ketamine,Metabolism/PK,P value  0.001,European,CYP2B6*1,research
ketamine,Metabolism/PK,P value  0.001,European,CYP2B6*6,research
acenocoumarol,Dosage,P value  0.001,Near Eastern,rs9923231,research
debrisoquine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
debrisoquine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
warfarin,Dosage,P value  0.004,Near Eastern,rs9923231,research
esomeprazole,Efficacy,P value  0.002,Multiple groups,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.002,Multiple groups,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.002,Multiple groups,CYP2C19*3,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*2,research
esomeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*3,research
atorvastatin,Efficacy,P value  0.0008,American,rs429358,research
warfarin,Dosage,P value  0.0,Unknown,rs9923231,research
esomeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*1,research
esomeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*2,research
esomeprazole,Metabolism/PK,P value  0.0005,East Asian,CYP2C19*3,research
warfarin,Dosage,P value  0.0,Unknown,rs9923231,research
warfarin,Dosage,P value  0.0,European,rs9923231,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,Multiple groups,rs1799724,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.01,"Multiple groups, Not stated: studies in Denmark, Czech, China and Greece.",rs1799724,research
halothane,Other,P value  0.001,Unknown,rs118192161,research
hmg coa reductase inhibitors,Efficacy,P value  0.01,"Multiple groups, 'White and black or African American' subjects",rs429358,research
ticagrelor,Efficacy,P value  0.005,East Asian,rs12566888,research
warfarin,Dosage,P value  1.0E-4,Multiple groups,rs1799853,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*3,research
ethanol,Other,P value  0.007,"Multiple groups, Asian, African American, White or 'Other' ethnicities",rs28363170,research
ethanol,Other,P value  0.010,European,rs28363170,research
sipoglitazar,Metabolism/PK,P value  0.0001,European,UGT2B15*1,research
sipoglitazar,Metabolism/PK,P value  0.0001,European,UGT2B15*2,research
ethanol,Toxicity,P value  0.001,"Multiple groups, Asian, African American, White or 'Other' ethnicities",rs28363170,research
ethanol,Toxicity,P value  0.001,"Multiple groups, Asian, African American, White or 'Other' ethnicities",rs1799971,research
Platinum compounds,Efficacy,P value  0.01,East Asian,rs9535826,research
Platinum compounds,Efficacy,P value  0.01,East Asian,rs9535828,research
letermovir,Metabolism/PK,P value  0.000595,"Multiple groups, Asian, Black, Other and White ethnicities",rs4149056,research
warfarin,Dosage,P value  0.002,Unknown,rs61742245,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0041,Unknown,rs1143623,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0049,Unknown,rs1143623,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1G,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1G,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0016,Unknown,rs1143627,research
repaglinide,Metabolism/PK,P value  0.0009,East Asian,rs2276706,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0044,Unknown,rs11465996,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.004,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.007,East Asian,rs776746,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0019,Unknown,rs11938228,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0032,Unknown,rs4696480,research
peginterferon alfa-2a,Efficacy,P value  0.000,Multiple groups,rs12979860,research
phenytoin,Metabolism/PK,P value  0.001,Sub-Saharan African,rs28371686,research
phenytoin,Other,P value  0.001,Sub-Saharan African,rs28371686,research
peginterferon alfa-2a,Efficacy,P value  0.005,Multiple groups,rs8099917,research
fenofibrate,Efficacy,P value  0.001,Unknown,rs7412,research
methadone,Dosage,P value  0.001,East Asian,rs3762555,research
ustekinumab,Efficacy,P value  0.0012,Unknown,rs5744174,research
phenytoin,Metabolism/PK,P value  0.001,Sub-Saharan African,rs7900194,research
phenytoin,Other,P value  0.001,Sub-Saharan African,rs7900194,research
phenytoin,Metabolism/PK,P value  0.001,Sub-Saharan African,rs28371685,research
phenytoin,Other,P value  0.001,Sub-Saharan African,rs28371685,research
phenytoin,Metabolism/PK,P value  0.001,Sub-Saharan African,rs9332131,research
phenytoin,Other,P value  0.001,Sub-Saharan African,rs9332131,research
azathioprine,Dosage,P value  0.00001,Multiple groups,rs116855232,research
acenocoumarol,Dosage,P value  0.0001,Near Eastern,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.0001,Near Eastern,CYP2C9*3,research
gemcitabine,Efficacy,P value  0.001,East Asian,rs1044457,research
gemcitabine,Efficacy,P value  0.002,East Asian,rs1044457,research
acenocoumarol,Dosage,P value  0.009,Near Eastern,rs1043550,research
adalimumab,Efficacy,P value  0.008,European,rs9304742,research
SN-38,Metabolism/PK,P value  0.001,East Asian,rs3832043,research
acetaminophen,Metabolism/PK,P value  0.0001,Unknown,UGT2B15*1,research
acetaminophen,Metabolism/PK,P value  0.0001,Unknown,UGT2B15*2,research
doxorubicin,Metabolism/PK,P value  0.009,"Multiple groups, Chinese; Malay; Indian",rs9024,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
oxycodone,Efficacy,P value  0.004,"Multiple groups, '12 African-American/Black, 18 Caucasian/White, 3 Multiracial, 1 Native-American or Alaskan, 2 chose not to report.; Ethnically, 22% of the sample identified as Hispanic or Latino.'",rs4680,research
SN-38,Metabolism/PK,P value  0.002,East Asian,rs4148323,research
SN-38,Metabolism/PK,P value  0.002,East Asian,rs4148323,research
methadone,Dosage,P value  0.001,East Asian,rs3762556,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
gemcitabine,Efficacy,P value  0.001,East Asian,rs12507552,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs1927907,research
cotinine,Metabolism/PK,P value  0.002,East Asian,rs1074287,research
cotinine,Metabolism/PK,P value  0.01,East Asian,rs6912029,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1G,research
cotinine,Metabolism/PK,P value  0.009,East Asian,rs12209447,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*1,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*2,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*17,research
uric acid,Metabolism/PK,P value  2.3E-5,European,rs1002976,research
uric acid,Metabolism/PK,P value  3.5E-4,European,rs1002976,research
cotinine,Metabolism/PK,P value  0.001,East Asian,rs510769,research
gemcitabine,Efficacy,P value  0.001,East Asian,rs35687416,research
cotinine,Metabolism/PK,P value  0.007,East Asian,rs3798676,research
gemcitabine,Efficacy,P value  0.002,East Asian,rs944050,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*1,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*2,research
debrisoquine,Metabolism/PK,P value  0.001,Sub-Saharan African,CYP2D6*17,research
uric acid,Metabolism/PK,P value  4.8E-5,European,rs950569,research
uric acid,Metabolism/PK,P value  2.6E-3,European,rs950569,research
tacrolimus,Dosage,P value  0.000,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.000,East Asian,CYP3A5*3,research
warfarin,Dosage,P value  1.0E-4,Multiple groups,rs9923231,research
cotinine,Metabolism/PK,P value  0.006,East Asian,rs7748401,research
cotinine,Metabolism/PK,P value  0.001,East Asian,rs495491,research
clopidogrel,Efficacy,P value  0.001,East Asian,rs6809699,research
cotinine,Metabolism/PK,P value  0.001,East Asian,rs589046,research
clopidogrel,Efficacy,P value  0.002,East Asian,rs6785930,research
cotinine,Metabolism/PK,P value  0.006,East Asian,rs563649,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1G,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A4*1G,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1G,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,CYP3A4*1G,research
varenicline,Efficacy,P value   0.007,Multiple groups,rs1044396,research
methotrexate,Metabolism/PK,P value  3.13E-19,Multiple groups,rs11045879,research
methotrexate,Efficacy,P value  3.13E-19,Multiple groups,rs11045879,research
methotrexate,Toxicity,P value  3.13E-19,Multiple groups,rs11045879,research
methotrexate,Metabolism/PK,P value  8.31E-10,Multiple groups,rs11045879,research
methotrexate,Efficacy,P value  8.31E-10,Multiple groups,rs11045879,research
methotrexate,Toxicity,P value  8.31E-10,Multiple groups,rs11045879,research
fluorouracil,Efficacy,P value  0.01,East Asian,rs10040363,research
fluorouracil,Efficacy,P value  0.01,East Asian,rs2075685,research
fluorouracil,Efficacy,P value  0.01,East Asian,rs2075685,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
clopidogrel,Efficacy,P value  0.01,East Asian,rs2305948,research
venlafaxine,Metabolism/PK,P value  0.005,Unknown,CYP2D6 poor metabolizer phenotype,research
methadone,Dosage,P value  0.0004,Unknown,rs204047,research
methadone,Metabolism/PK,P value  0.0002,Unknown,rs797397,research
methadone,Metabolism/PK,P value  0.00002,Unknown,rs204047,research
midazolam,Metabolism/PK,P value  0.001,Unknown,rs35599367,research
fluoxetine,Efficacy,P value  0.0066,Central/South Asian,SLC6A4 HTTLPR long form (L allele),research
fluoxetine,Efficacy,P value  0.0066,Central/South Asian,SLC6A4 HTTLPR short form (S allele),research
hydralazine,Metabolism/PK,P value  0.001,Sub-Saharan African,NAT2 slow acetylator,research
ethanol,Toxicity,P value  9.2E-12,European,rs11940694,research
methotrexate,Metabolism/PK,P value  5.59E-12,Multiple groups,rs11045821,research
methotrexate,Efficacy,P value  5.59E-12,Multiple groups,rs11045821,research
methotrexate,Toxicity,P value  5.59E-12,Multiple groups,rs11045821,research
methotrexate,Metabolism/PK,P value  3.33E-8,Multiple groups,rs11045821,research
methotrexate,Efficacy,P value  3.33E-8,Multiple groups,rs11045821,research
methotrexate,Toxicity,P value  3.33E-8,Multiple groups,rs11045821,research
methotrexate,Metabolism/PK,P value  9.74E-19,Multiple groups,rs4149081,research
methotrexate,Efficacy,P value  9.74E-19,Multiple groups,rs4149081,research
methotrexate,Toxicity,P value  9.74E-19,Multiple groups,rs4149081,research
methotrexate,Metabolism/PK,P value  1.58E-10,Multiple groups,rs4149081,research
methotrexate,Efficacy,P value  1.58E-10,Multiple groups,rs4149081,research
methotrexate,Toxicity,P value  1.58E-10,Multiple groups,rs4149081,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs2242480,research
tacrolimus,Metabolism/PK,P value  3.0E-4,Unknown,rs776746,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs4646437,research
tacrolimus,Metabolism/PK,P value  0.010,East Asian,rs2242480,research
telaprevir,Metabolism/PK,P value  0.003,Unknown,rs2585428,research
tacrolimus,Metabolism/PK,P value  0.008,East Asian,rs4553808,research
tacrolimus,Metabolism/PK,P value  0.004,East Asian,rs181781,research
methotrexate,Metabolism/PK,P value  0.01,European,rs9282564,research
atomoxetine,Efficacy,P value  0.0048,East Asian,rs3785143,research
methotrexate,Metabolism/PK,P value  0.01,European,rs3740066,research
imatinib,Metabolism/PK,P value  0.001,Central/South Asian,rs776746,research
warfarin,Efficacy,P value  0.001,East Asian,rs9923231,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizer,research
venlafaxine,Metabolism/PK,P value  0.002,Unknown,CYP2D6 poor metabolizer,research
tacrolimus,Metabolism/PK,P value  3.0E-4,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  3.0E-4,Unknown,CYP3A5*6,research
capecitabine,Efficacy,P value  0.01,Unknown,rs45445694,research
venlafaxine,Metabolism/PK,P value  0.007,Unknown,CYP2D6 heterozygous normal metabolizer,research
venlafaxine,Metabolism/PK,P value  0.008,Unknown,CYP2D6 heterozygous normal metabolizer,research
tacrolimus,Metabolism/PK,P value  3.0E-4,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  3.0E-4,Unknown,CYP3A5*7,research
warfarin,Dosage,P value  0.0001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,East Asian,CYP2C9*3,research
clopidogrel,Efficacy,P value  0.0001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.0001,East Asian,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.0001,East Asian,CYP2C19*3,research
clopidogrel,Efficacy,P value  0.0029,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.0029,East Asian,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.0029,East Asian,CYP2C19*3,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizer,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizer,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizer,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizer,research
venlafaxine,Metabolism/PK,P value  0.002,Unknown,CYP2D6 poor metabolizer,research
fluorouracil,Efficacy,P value  0.004,Unknown,rs1801131,research
mercaptopurine,Efficacy,P value  6.8E-5,"Multiple groups, White, Black, Hispanic, Asian, Other",rs1142345,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 normal metabolizer,research
venlafaxine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 normal metabolizer,research
peginterferon alfa-2a,Efficacy,P value  0.0,East Asian,rs12980275,research
morphine,Dosage,P value  0.010,Near Eastern,rs1799971,research
peginterferon alfa-2a,Efficacy,P value  0.0,East Asian,rs8099917,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19 heterozygous normal metabolizer,research
voriconazole,Metabolism/PK,P value  0.005,East Asian,rs3814057,research
methotrexate,Metabolism/PK,P value  0.01,European,rs3732361,research
escitalopram,Metabolism/PK,P value  0.001,Unknown,CYP2C19 normal metabolizer,research
voriconazole,Metabolism/PK,P value  0.01,Central/South Asian,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Central/South Asian,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.01,Central/South Asian,CYP2C19*3,research
methotrexate,Metabolism/PK,P value  0.006,European,rs6785049,research
phenytoin,Toxicity,P value  0.002,Central/South Asian,CYP2C9*1,research
phenytoin,Toxicity,P value  0.002,Central/South Asian,CYP2C9*3,research
lovastatin acid,Metabolism/PK,P value  0.005,European,SLCO1B1*1A,research
lovastatin acid,Metabolism/PK,P value  0.005,European,SLCO1B1*5,research
lovastatin acid,Metabolism/PK,P value  0.005,European,SLCO1B1*15,research
methadone,Metabolism/PK,P value  5.0E-4,East Asian,rs3745274,research
methadone,Dosage,P value  5.0E-4,East Asian,rs3745274,research
warfarin,Dosage,P value  1.0E-4,"Multiple groups, USA: 73% White, 18.9% African American, 8.1% Asian",rs9934438,research
nevirapine,Metabolism/PK,P value  0.001,Multiple groups,rs3745274,research
nevirapine,Toxicity,P value  0.001,Multiple groups,rs3745274,research
nevirapine,Metabolism/PK,P value  0.008,Multiple groups,rs3745274,research
nevirapine,Toxicity,P value  0.008,Multiple groups,rs3745274,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs3745274,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs3745274,research
warfarin,Dosage,P value  3.3E-5,"Multiple groups, Singapore: 131 Chinese, 81 Malays and 36 Asian Indians",rs2108622,research
warfarin,Dosage,P value  7.2E-6,"Multiple groups, Singapore: 131 Chinese, 81 Malays and 36 Asian Indians",rs7196161,research
warfarin,Dosage,P value  1.61E-4,"Multiple groups, Singapore: 131 Chinese, 81 Malays and 36 Asian Indians",rs1057910,research
phenytoin,Metabolism/PK,P value  0.009,Central/South Asian,CYP2C9*1,research
phenytoin,Metabolism/PK,P value  0.009,Central/South Asian,CYP2C9*2,research
phenytoin,Metabolism/PK,P value  0.009,Central/South Asian,CYP2C9*3,research
methotrexate,Efficacy,P value  0.005,European,rs2372536,research
flurbiprofen,Metabolism/PK,P value  0.0002,Unknown,CYP2C9*1,research
flurbiprofen,Metabolism/PK,P value  0.0002,Unknown,CYP2C9*3,research
ambrisentan,Metabolism/PK,P value  0.01,"Multiple groups, 17 Caucasians, 2 Hispanics, 1 Asian",CYP2C19*1,research
ambrisentan,Metabolism/PK,P value  0.01,"Multiple groups, 17 Caucasians, 2 Hispanics, 1 Asian",CYP2C19*2,research
ambrisentan,Metabolism/PK,P value  0.01,"Multiple groups, 17 Caucasians, 2 Hispanics, 1 Asian",CYP2C19*3,research
ambrisentan,Metabolism/PK,P value  0.01,"Multiple groups, 17 Caucasians, 2 Hispanics, 1 Asian",CYP2C19*4,research
ambrisentan,Metabolism/PK,P value  0.01,"Multiple groups, 17 Caucasians, 2 Hispanics, 1 Asian",CYP2C19*17,research
tacrolimus,Metabolism/PK,P value  0.002,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.005,East Asian,rs776746,research
flurbiprofen,Metabolism/PK,P value  0.0001,Unknown,CYP2C9*1,research
flurbiprofen,Metabolism/PK,P value  0.0001,Unknown,CYP2C9*3,research
tacrolimus,Dosage,P value  0.001,East Asian,rs776746,research
cyclophosphamide,Metabolism/PK,P value  0.0028,Multiple groups,CYP2B6*1,research
cyclophosphamide,Metabolism/PK,P value  0.0028,Multiple groups,CYP2B6*6,research
sertraline,Efficacy,P value  0.001,Unknown,SLC6A4 HTTLPR long form (L allele),research
sertraline,Efficacy,P value  0.001,Unknown,SLC6A4 HTTLPR short form (S allele),research
atorvastatin,Efficacy,P value  1.0E-4,European,rs9471077,research
atorvastatin,Efficacy,P value  2.0E-4,European,rs9471077,research
atorvastatin,Efficacy,P value  0.0026,European,rs9471077,research
SN-38,Metabolism/PK,P value  0.010,"Multiple groups, Caucasian and African-American",rs6498588,research
deferasirox,Metabolism/PK,P value  0.001,"Multiple groups, 95% Caucasian (Italy)",rs2606345,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,CYP2B6*1,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,CYP2B6*6,research
SN-38,Metabolism/PK,P value  0.005,"Multiple groups, Caucasian and African-American",rs12720066,research
Antihypertensives,Efficacy,P value  1.00E-6,Multiple groups,rs13144136,research
Antihypertensives,Efficacy,P value  7.42E-6,European,rs13144136,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.002,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.004,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.004,East Asian,rs776746,research
atorvastatin,Efficacy,P value  1.0E-4,European,rs9462535,research
atorvastatin,Efficacy,P value  0.001,European,rs9462535,research
atorvastatin,Efficacy,P value  0.0056,European,rs9462535,research
warfarin,Dosage,P value  0.0001,East Asian,rs9923231,research
imatinib,Efficacy,P value  0.005,Central/South Asian,rs1045642,research
warfarin,Dosage,P value  0.001,Unknown,rs9923231,research
pioglitazone,Metabolism/PK,P value  0.01,European,CYP2C8*1,research
pioglitazone,Metabolism/PK,P value  0.01,European,CYP2C8*3,research
capecitabine,Efficacy,P value  0.010,European,rs371194629,research
methadone,Dosage,P value  0.0015,"Multiple groups, Israeli, 62 Jewish subjects and 10 subjects that are either Caucasians or Arabs. For simplicity, the Jewish subjects are divided into two main groups: Ashkenazi and non-Ashkenazi. The non-Ashkenazi group includes Moroccan, Yemenite, Iraqi, Turkish, Iranian, Libyan, Syrian, Greek subjects and subjects with mixed origin or unknown origin. Five subjects are Jewish of mixed or unknown origin.",rs2239622,research
atenolol,Efficacy,P value  8.58E-7,European,rs294610,research
atenolol,Efficacy,P value  3.41E-6,European,rs294610,research
atenolol,Efficacy,P value  0.01,European,rs294610,research
itopride,Metabolism/PK,P value  0.001,East Asian,rs2266780,research
atenolol,Efficacy,P value  0.0013,European,rs45545233,research
atenolol,Efficacy,P value  0.007,European,rs45545233,research
fluvoxamine,Efficacy,P value  0.010,East Asian,SLC6A4 HTTLPR short form (S allele),research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*3,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*2,research
mycophenolic acid,Metabolism/PK,P value  0.01,East Asian,rs3832043,research
warfarin,Dosage,P value  0.001,Unknown,rs9923231,research
warfarin,Dosage,P value  4.0E-4,Near Eastern,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
mycophenolic acid,Metabolism/PK,P value  0.01,East Asian,rs2306283,research
warfarin,Dosage,P value  0.003,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.003,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  1.0E-4,Near Eastern,rs9923231,research
warfarin,Dosage,P value  4.0E-4,Near Eastern,rs1799853,research
tacrolimus,Metabolism/PK,P value  0.004,European,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.004,European,CYP3A5*3,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
citalopram,Efficacy,P value  0.01,European,rs1800532,research
peginterferon alfa-2b,Efficacy,P value  1.0E-4,East Asian,rs8099917,research
clopidogrel,Efficacy,P value  6.83e-5,East Asian,rs12456693,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.009,Unknown,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.009,Unknown,CYP2D6*4,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.009,Unknown,CYP2D6*5,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Brazil: '51% Caucasian,  16% African, 32% Intermediate, 1% other'",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, Brazil: '51% Caucasian,  16% African, 32% Intermediate, 1% other'",CYP3A5*3,research
acenocoumarol,Dosage,P value  0.001,European,rs9923231,research
dipyrone,Metabolism/PK,P value  0.001,European,NAT2*5,research
dipyrone,Metabolism/PK,P value  0.001,European,NAT2*6,research
dipyrone,Metabolism/PK,P value  0.001,European,NAT2*7,research
dipyrone,Metabolism/PK,P value  0.001,European,NAT2*14,research
adalimumab,Efficacy,P value  1.88E-9,European,rs9828223,research
acenocoumarol,Dosage,P value  0.0015,Near Eastern,rs9923231,research
dipyrone,Metabolism/PK,P value  0.001,European,CYP2C19*1,research
dipyrone,Metabolism/PK,P value  0.001,European,CYP2C19*2,research
acenocoumarol,Dosage,P value  0.001,European,rs9923231,research
opioids,Dosage,P value  0.003,"Multiple groups, Caucasian and African American",rs4680,research
fluoxetine,Efficacy,P value  0.004,East Asian,SLC6A4 HTTLPR long form (L allele),research
fluoxetine,Efficacy,P value  0.004,East Asian,SLC6A4 HTTLPR short form (S allele),research
ondansetron,Efficacy,P value  0.008,Unknown,CYP2D6*1xN,research
ondansetron,Efficacy,P value  0.008,Unknown,CYP2D6*2,research
ondansetron,Efficacy,P value  0.007,Unknown,CYP2D6*1xN,research
ondansetron,Efficacy,P value  0.007,Unknown,CYP2D6*2,research
ondansetron,Efficacy,P value  0.008,Unknown,CYP2D6*2xN,research
azathioprine,Dosage,P value  0.0087,Unknown,rs1142345,research
tegafur,Metabolism/PK,P value  3.33E-5,East Asian,CYP2A6*1A,research
tegafur,Metabolism/PK,P value  3.33E-5,East Asian,CYP2A6*7,research
tegafur,Metabolism/PK,P value  3.33E-5,East Asian,CYP2A6*1A,research
tegafur,Metabolism/PK,P value  3.33E-5,East Asian,CYP2A6*4A,research
tegafur,Metabolism/PK,P value  3.33E-5,East Asian,CYP2A6*7,research
warfarin,Dosage,P value  1.0E-4,Multiple groups,rs1057910,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*1A,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*2,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*4E,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*9,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*12,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*17,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*20,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*23,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*35,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*1A,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*2,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*4E,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*9,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*12,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*17,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*20,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*23,research
letrozole,Metabolism/PK,P value  1.0E-4,Multiple groups,CYP2A6*35,research
azathioprine,Efficacy,P value  0.0031,Unknown,GSTM1 non-null,research
azathioprine,Efficacy,P value  0.0031,Unknown,GSTM1 null,research
ondansetron,Efficacy,P value  0.007,Unknown,CYP2D6*2xN,research
bevacizumab,Efficacy,P value  1.0E-4,Unknown,rs3025000,research
bevacizumab,Efficacy,P value  0.01,Unknown,rs3025000,research
bevacizumab,Efficacy,P value  0.01,Unknown,rs3025000,research
efavirenz,Efficacy,P value  0.005,Multiple groups,rs3745274,research
nilotinib,Dosage,P value  0.002,East Asian,UGT1A1*1,research
nilotinib,Dosage,P value  0.002,East Asian,UGT1A1*6,research
nilotinib,Dosage,P value  0.002,East Asian,UGT1A1*27,research
nilotinib,Dosage,P value  0.002,East Asian,UGT1A1*28,research
cotinine,Metabolism/PK,P value  0.004,European,CYP2B6*1,research
cotinine,Metabolism/PK,P value  0.004,European,CYP2B6*6,research
warfarin,Dosage,P value  0.001,Latino,rs9923231,research
warfarin,Dosage,P value  0.001,Latino,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Latino,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Latino,CYP2C9*3,research
warfarin,Dosage,P value  0.001,Latino,CYP2C9*5,research
methadone,Metabolism/PK,P value  0.001,European,CYP2B6*1,research
methadone,Metabolism/PK,P value  0.001,European,CYP2B6*6,research
caffeine,Metabolism/PK,P value  0.01,European,rs762551,research
caffeine,Other,P value  0.01,European,rs762551,research
busulfan,Metabolism/PK,P value  0.004,Unknown,rs3957357,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0006,Unknown,CYP2C9*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0006,Unknown,CYP2C9*2,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0006,Unknown,CYP2C9*3,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0032,Unknown,CYP2C9*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0032,Unknown,CYP2C9*2,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0032,Unknown,CYP2C9*3,research
methadone,Metabolism/PK,P value  0.01,European,rs1057868,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*2,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*4,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
risperidone,Metabolism/PK,P value  0.001,East Asian,CYP2D6*41,research
carbamazepine,Efficacy,P value  0.001,East Asian,rs2290732,research
opioids,Dosage,P value  0.0004,East Asian,rs1799971,research
opioids,Efficacy,P value  0.0004,East Asian,rs1799971,research
bevacizumab,Efficacy,P value  1.0E-4,Unknown,rs3025000,research
bevacizumab,Efficacy,P value  0.001,Unknown,rs3025000,research
bevacizumab,Efficacy,P value  0.006,Unknown,rs3025000,research
hydrochlorothiazide,Efficacy,P value  1.7E-3,European,rs11065987,research
hydrochlorothiazide,Efficacy,P value  2.9E-3,European,rs11065987,research
hydralazine,Metabolism/PK,P value  0.001,Unknown,NAT2 slow acetylator,research
hydralazine,Metabolism/PK,P value  0.01,Unknown,NAT2 slow acetylator,research
amitriptyline,Efficacy,P value  0.01,Unknown,CYP2D6 poor metabolizer phenotype,research
paclitaxel,Efficacy,P value  0.001,European,GSTM1 non-null,research
paclitaxel,Efficacy,P value  0.001,European,GSTM1 null,research
azathioprine,Metabolism/PK,P value  0.008,Unknown,rs7270101,research
azathioprine,Toxicity,P value  0.008,Unknown,rs7270101,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*2,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*14,research
paroxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*41,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
ethanol,Efficacy,P value  0.008,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
ethanol,Efficacy,P value  0.008,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs553202,research
warfarin,Dosage,P value  0.00001,Multiple groups,rs2108622,research
warfarin,Dosage,P value  0.00001,European,rs2108622,research
warfarin,Dosage,P value  0.0009,East Asian,rs2108622,research
ethanol,Efficacy,P value  0.001,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs524731,research
ethanol,Efficacy,P value  0.002,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs524731,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs524731,research
ethanol,Efficacy,P value  0.01,"Multiple groups, Participants were of mixed heritage but were at least one sixteenth Native American. 60% of the sample had over 50% Native American heritage.",rs524731,research
opioids,Efficacy,P value  0.01,European,rs1799971,research
warfarin,Dosage,P value  0.001,East Asian,rs9934438,research
erlotinib,Efficacy,P value  0.001,Unknown,rs121434568,research
erlotinib,Efficacy,P value  0.005,Unknown,rs121434568,research
enalapril,Efficacy,P value  0.0001,East Asian,rs1799752,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs1057910,research
naltrexone,Efficacy,P value  0.01,European,rs1611115,research
daptomycin,Metabolism/PK,P value  0.01,European,rs1045642,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*1,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*3,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*4,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*5,research
trimipramine,Metabolism/PK,P value  0.001,Unknown,CYP2D6*6,research
warfarin,Dosage,P value  0.002,African American/Afro-Caribbean,rs9923231,research
adalimumab,Efficacy,P value  0.002,Unknown,rs1800629,research
omeprazole,Efficacy,P value  0.0001,East Asian,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0001,East Asian,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0001,East Asian,CYP2C19*3,research
raltegravir,Metabolism/PK,P value  4.18e-4,Unknown,UGT1A9*3a,research
fenofibrate,Efficacy,P value  4.0E-4,European,rs3135506,research
fenofibrate,Efficacy,P value  0.002,European,rs3135506,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
trimipramine,Metabolism/PK,P value  0.01,Unknown,CYP2C19*2,research
imatinib,Efficacy,P value  0.005,European,rs1045642,research
ethanol,,P value  0.001,Unknown,rs3778150,research
ethanol,,P value  0.010,Unknown,rs3778150,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs1468412,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs1468412,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs1468412,research
acenocoumarol,Dosage,P value  0.008,Central/South Asian,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.008,Central/South Asian,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.008,Central/South Asian,CYP2C9*3,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs165854,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs165854,research
antipsychotics,Efficacy,P value  0.0001,Central/South Asian,rs165854,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*3,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.0001,Unknown,CYP2C19*3,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A4*1G,research
corticosteroids,Efficacy,P value  0.003,Unknown,rs138337,research
risperidone,Metabolism/PK,P value  0.009,Unknown,CYP2D6 poor metabolizer,research
antipsychotics,Efficacy,P value  0.009,Central/South Asian,rs6465084,research
3-hydroxycotinine,Metabolism/PK,P value  0.003,Unknown,rs4105144,research
azathioprine,Efficacy,P value  0.001,East Asian,rs1127354,research
sunitinib,Efficacy,P value  0.005,"Multiple groups, Chinese, Indian, Malay",rs2032582,research
sunitinib,Efficacy,P value  0.01,"Multiple groups, Chinese, Indian, Malay",rs2032582,research
donepezil,Efficacy,P value  6.74E-6,European,rs17798800,research
donepezil,Efficacy,P value  8.23E-5,European,rs17798800,research
donepezil,Efficacy,P value  1.24E-4,European,rs17798800,research
donepezil,Efficacy,P value  1.38E-3,European,rs17798800,research
donepezil,Efficacy,P value  8.78E-3,European,rs17798800,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs2279345,research
corticosteroids,Efficacy,P value  0.01,Unknown,rs138335,research
dobutamine,Efficacy,P value  0.007,East Asian,rs62205366,research
donepezil,Efficacy,P value  2.9E-5,European,rs6720975,research
donepezil,Efficacy,P value  3.87E-4,European,rs6720975,research
donepezil,Efficacy,P value  4.49E-4,European,rs6720975,research
donepezil,Efficacy,P value  5.14E-4,European,rs6720975,research
antipsychotics,Efficacy,P value  0.006,Central/South Asian,rs1529461,research
hydroxyamitriptyline,Metabolism/PK,P value  0.002,East Asian,CYP2D6*1,research
hydroxyamitriptyline,Metabolism/PK,P value  0.002,East Asian,CYP2D6*10,research
bupropion,Efficacy,P value  2.6E-8,European,rs1908557,research
montelukast,Efficacy,P value  1.97E-9,Multiple groups,rs6475448,research
atorvastatin,Metabolism/PK,P value  0.01,Latino,rs1799722,research
amitriptyline,Metabolism/PK,P value  0.0003,East Asian,CYP2C19*1,research
amitriptyline,Metabolism/PK,P value  0.0003,East Asian,CYP2C19*2,research
amitriptyline,Metabolism/PK,P value  0.0003,East Asian,CYP2C19*3,research
acetylcysteine,Efficacy,P value  0.001,East Asian,EPHX1 poor metabolizer,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,rs776746,research
tacrolimus,Dosage,P value  0.001,Unknown,rs776746,research
rifampin,Metabolism/PK,P value  0.006,"Multiple groups, Italy, Caucasian (n=11), African (n=7), Asian (n=3), Latin American (n=3)",rs1544410,research
antidepressants,Efficacy,P value  0.007,Multiple groups,rs1954787,research
warfarin,Dosage,P value  0.01,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.01,Multiple groups,CYP2C9*2,research
tacrolimus,Metabolism/PK,P value  0.001,Multiple groups,rs776746,research
tacrolimus,Dosage,P value  0.001,Multiple groups,rs776746,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0075,European,rs2069705,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.009,European,rs2069705,research
Arsenic compounds,Metabolism/PK,P value  0.005,Latino,rs4920037,research
Arsenic compounds,Toxicity,P value  0.005,Latino,rs4920037,research
Arsenic compounds,Metabolism/PK,P value  0.006,Latino,rs234709,research
Arsenic compounds,Toxicity,P value  0.006,Latino,rs234709,research
ethanol,Dosage,P value  0.002,Unknown,rs3778150,research
acenocoumarol,Dosage,P value  1.0E-4,European,rs9923231,research
cisplatin,Efficacy,P value  0.003,East Asian,rs9597,research
sildenafil,Efficacy,P value  7.0E-4,"Multiple groups, Brazil",rs2070744,research
nevirapine,Metabolism/PK,P value  0.01,Central/South Asian,rs3745274,research
nevirapine,Toxicity,P value  0.01,Central/South Asian,rs3745274,research
atorvastatin,Efficacy,P value  0.0078,Latino,rs717620,research
tacrolimus,Dosage,P value  0.0001,Latino,rs776746,research
Enzyme inhibitors,Other,P value  0.01,Unknown,rs700518,research
azathioprine,Dosage,P value  0.01,Central/South Asian,rs116855232,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs776746,research
tacrolimus,Dosage,P value  0.01,East Asian,rs776746,research
antipsychotics,Efficacy,P value  8.71E-3,Central/South Asian,rs17716295,research
tacrolimus,Dosage,P value  0.01,European,rs776746,research
warfarin,Dosage,P value  0.004,East Asian,rs2108622,research
antipsychotics,Efficacy,P value  7.68E-4,Central/South Asian,rs1544938,research
antipsychotics,Efficacy,P value  6.81E-3,Central/South Asian,rs13250975,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
warfarin,Dosage,P value  0.001,East Asian,rs1057910,research
antipsychotics,Efficacy,P value  1.13E-3,Central/South Asian,rs4586,research
levodopa,Efficacy,P value  0.0001,Unknown,rs3836790,research
levodopa,Efficacy,P value  0.0004,Unknown,rs3836790,research
antipsychotics,Efficacy,P value  1.44E-3,Central/South Asian,rs2513265,research
fluorouracil,Metabolism/PK,P value  0.002,Unknown,DPYD deficiency,research
antipsychotics,Efficacy,P value  7.62E-4,Central/South Asian,rs4795893,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*2,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*3,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*4,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*4xN,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*5,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*9,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*10,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*17,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*29,research
atomoxetine,Metabolism/PK,P value  0.0001,"Multiple groups, White, African-American, Native Hawaiian",CYP2D6*41,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*2,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*3,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*4,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*4xN,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*5,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*9,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*10,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*17,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*29,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*41,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*2,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*3,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*4,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*4xN,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*5,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*9,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*10,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*17,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*29,research
atomoxetine,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6*41,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
methadone,Metabolism/PK,P value  0.002,East Asian,rs6275,research
methadone,Dosage,P value  0.002,East Asian,rs6275,research
nicotine,Other,P value  0.01,"Multiple groups, Caucasian (n=52), African American (n=12) or American Indian or Alaskan native (n=1). One participant did not identify a racial background. Seven participants self identified their ethnicity as Hispanic",rs16969968,research
peginterferon alfa-2a,Efficacy,P value  0.001,European,rs12979860,research
methadone,Metabolism/PK,P value  0.01,East Asian,rs1799978,research
methadone,Dosage,P value  0.01,East Asian,rs1799978,research
peginterferon alfa-2a,Efficacy,P value  0.0037,East Asian,rs8099917,research
lithium,Efficacy,P value  3.42E-4,Unknown,rs16973410,research
peginterferon alfa-2a,Efficacy,P value  0.0028,East Asian,rs8099917,research
rosiglitazone,Efficacy,P value  0.002,East Asian,rs1801282,research
lithium,Efficacy,P value  5.51E-4,Unknown,rs16909440,research
lithium,Efficacy,P value  8.7E-4,Unknown,rs2499984,research
peginterferon alfa-2a,Efficacy,P value  0.0054,"Multiple groups, North American (treated in Boston).  The 25 were a subset of the study cohort of 61(38 White,5 Hispanic,5 Asian,12 African American).",rs12979860,research
metformin,Efficacy,P value  0.0064,Central/South Asian,rs316019,research
pioglitazone,Efficacy,P value  0.001,East Asian,rs2241766,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,rs9923231,research
interferon beta-1a,Efficacy,P value  0.009,European,rs1799752,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,rs11676382,research
tacrolimus,Metabolism/PK,P value  0.01,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.01,Unknown,CYP3A5*3,research
etanercept,Efficacy,P value  0.006,Unknown,rs9304742,research
lithium,Efficacy,P value  4.7E-4,Unknown,rs11869731,research
memantine,Metabolism/PK,P value  0.006,"Multiple groups, 98% Caucasian and 2% Asian",rs1523130,research
ivacaftor,Efficacy,P value  0.01,European,rs7512462,research
warfarin,Dosage,P value  1.0E-4,European,rs9923231,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*3,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.000,Central/South Asian,CYP2C9*3,research
morphine,Metabolism/PK,P value  0.01,Multiple groups,rs4793665,research
milnacipran,Efficacy,P value  0.001,East Asian,rs6295,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*1,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*2,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*3,research
methotrexate,Efficacy,P value  0.008,Unknown,rs35592,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*1,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*2,research
omeprazole,Efficacy,P value  0.009,Unknown,CYP2C19*3,research
clozapine,Efficacy,P value  0.01,Unknown,rs4680,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs2279343,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
efavirenz,Metabolism/PK,P value  0.001,East Asian,rs3745274,research
clozapine,Efficacy,P value  0.002,European,rs10465180,research
Platinum compounds,Efficacy,P value  0.002,Multiple groups,rs1799782,research
thalidomide,Dosage,P value  0.01,Unknown,CYP2C19*1,research
thalidomide,Dosage,P value  0.01,Unknown,CYP2C19*2,research
warfarin,Dosage,P value  4.4e-13,"Multiple groups, Brazilian",rs9332238,research
Platinum compounds,Efficacy,P value  0.001,Multiple groups,rs25487,research
warfarin,Dosage,P value  0.006,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.006,East Asian,CYP2C9*3,research
interferon beta-1a,Efficacy,P value  1.67E-4,Unknown,rs2291858,research
interferon beta-1a,Efficacy,P value  5.53E-4,European,rs2291858,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
interferon beta-1a,Efficacy,P value  1.34E-3,Unknown,rs4278350,research
interferon beta-1a,Efficacy,P value  3.37E-3,European,rs4278350,research
interferon beta-1a,Efficacy,P value  1.66E-4,Unknown,rs1448673,research
interferon beta-1a,Efficacy,P value  9.21E-4,European,rs1448673,research
voriconazole,Metabolism/PK,P value  0.0001,Multiple groups,CYP2C19 poor metabolizers and intermediate metabolizers,research
voriconazole,Metabolism/PK,P value  0.0001,Multiple groups,CYP2C19 poor metabolizers and intermediate metabolizers,research
voriconazole,Metabolism/PK,P value  0.005,Multiple groups,CYP2C19 poor metabolizers and intermediate metabolizers,research
interferon beta-1a,Efficacy,P value  8.15E-5,Unknown,rs10494227,research
interferon beta-1a,Efficacy,P value  1.96E-4,European,rs10494227,research
voriconazole,Metabolism/PK,P value  0.0002,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.0002,Unknown,CYP2C19*17,research
voriconazole,Metabolism/PK,P value  0.002,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.002,Unknown,CYP2C19*17,research
voriconazole,Metabolism/PK,P value  0.0042,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.0042,Unknown,CYP2C19*17,research
voriconazole,Metabolism/PK,P value  0.007,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.007,Unknown,CYP2C19*17,research
interferon beta-1a,Efficacy,P value  1.37E-4,Unknown,rs3133084,research
interferon beta-1a,Efficacy,P value  7.15E-4,European,rs3133084,research
benazepril,Efficacy,P value  0.001,East Asian,rs7079,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*3,research
warfarin,Dosage,P value  0.001,Unknown,rs9923231,research
interferon beta-1a,Efficacy,P value  6.51E-5,Unknown,rs10760397,research
interferon beta-1a,Efficacy,P value  5.08E-4,European,rs10760397,research
interferon beta-1a,Efficacy,P value  9.7E-3,"Multiple groups, Majority Caucasian",rs10760397,research
nicotine,Dosage,P value  0.003,European,CYP2A6 low activity,research
nicotine,Dosage,P value  0.003,European,CYP2A6 low activity,research
interferon beta-1a,Efficacy,P value  6.74E-6,Unknown,rs760316,research
interferon beta-1a,Efficacy,P value  3.49E-4,European,rs760316,research
interferon beta-1a,Efficacy,P value  1.23E-3,"Multiple groups, Majority Caucasian",rs760316,research
peginterferon alfa-2a,Efficacy,P value  0.01,Multiple groups,rs12979860,research
fluvastatin,Efficacy,P value  0.001,Unknown,rs7412,research
peginterferon alfa-2a,Efficacy,P value  0.007,European,rs12979860,research
warfarin,Dosage,P value  0.00,Central/South Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.00,Central/South Asian,CYP2C9*2,research
warfarin,Dosage,P value  0.00,Central/South Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,Central/South Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Central/South Asian,CYP2C9*2,research
warfarin,Dosage,P value  0.001,Central/South Asian,CYP2C9*3,research
voriconazole,Metabolism/PK,P value  2.44E-6,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  2.44E-6,Unknown,CYP2C19*17,research
voriconazole,Metabolism/PK,P value  0.00018,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.00018,Unknown,CYP2C19*17,research
pravastatin,Efficacy,P value  0.01,"Multiple groups, CAP: White; PRINCE: African American and Caucasian",rs11716445,research
warfarin,Dosage,P value  0.001,European,rs2359612,research
lansoprazole,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
lansoprazole,Efficacy,P value  0.003,East Asian,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.003,East Asian,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.003,East Asian,CYP2C19*3,research
warfarin,Dosage,P value  1.6E-8,Multiple groups,rs2359612,research
atazanavir,Metabolism/PK,P value  0.001,Unknown,rs776746,research
atazanavir,Metabolism/PK,P value  0.007,Unknown,rs776746,research
lansoprazole,Efficacy,P value  0.01,East Asian,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.01,East Asian,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.01,East Asian,CYP2C19*3,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19*3,research
efavirenz,Metabolism/PK,P value  0.001,Sub-Saharan African,rs3745274,research
tramadol,Metabolism/PK,P value  0.001,European,CYP2D6 poor metabolizer phenotype,research
warfarin,Dosage,P value  0.0001,Central/South Asian,rs2884737,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
trastuzumab,Toxicity,P value  0.0058,European,rs1136201,research
warfarin,Dosage,P value  0.001,European,rs9923231,research
acenocoumarol,Dosage,P value  0.002,European,rs2108622,research
rocuronium,Metabolism/PK,P value  0.002,Unknown,rs3834939,research
metformin,Efficacy,P value  0.006,European,rs2289669,research
warfarin,Dosage,P value  0.0001,Central/South Asian,rs9934438,research
warfarin,Dosage,P value  0.006,Central/South Asian,rs9934438,research
warfarin,Dosage,P value  0.0001,Central/South Asian,rs7196161,research
warfarin,Dosage,P value  0.00,Central/South Asian,rs9923231,research
warfarin,Dosage,P value  0.0001,Central/South Asian,rs9923231,research
warfarin,Dosage,P value  0.0001,Central/South Asian,rs2108622,research
fenofibrate,Efficacy,P value  0.007,Unknown,rs3135506,research
warfarin,Dosage,P value  1.0E-4,East Asian,rs9923231,research
voriconazole,Dosage,P value  4.3E-11,Unknown,CYP2C19*1,research
voriconazole,Dosage,P value  4.3E-11,Unknown,CYP2C19*17,research
voriconazole,Dosage,P value  0.00074,Unknown,CYP2C19*1,research
voriconazole,Dosage,P value  0.00074,Unknown,CYP2C19*17,research
warfarin,Dosage,P value  0.0009,Central/South Asian,rs2359612,research
warfarin,Dosage,P value  0.010,Central/South Asian,rs2359612,research
warfarin,Dosage,P value  0.00,Central/South Asian,rs7294,research
voriconazole,Metabolism/PK,P value  9.2E-5,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  9.2E-5,Unknown,CYP2C19*2,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*2,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs28399499,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs2279343,research
voriconazole,Metabolism/PK,P value  0.00031,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.00031,Unknown,CYP2C19*17,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,Unknown,CYP2C19*17,research
warfarin,Dosage,P value  0.0066,Central/South Asian,rs8050894,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs3745274,research
warfarin,Dosage,P value  1.08e-33,"Multiple groups, Brazilian",rs749671,research
Beta blocking agents,Efficacy,P value  2.18E-7,European,rs28404156,research
Beta blocking agents,Efficacy,P value  9.33E-5,European,rs28404156,research
Beta blocking agents,Efficacy,P value  1.8E-4,European,rs28404156,research
fluvastatin,Metabolism/PK,P value  0.001,Unknown,rs1057910,research
efavirenz,Metabolism/PK,P value  2e-10,Unknown,rs3745274,research
efavirenz,Metabolism/PK,P value  0.0018,Unknown,rs3745274,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, The majority of donors were Asian, the majority of recipients were Caucasian.",rs776746,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, The majority of donors were Asian, the majority of recipients were Caucasian.",rs776746,research
zafirlukast,Metabolism/PK,P value  0.0001,East Asian,CYP2C9*1,research
zafirlukast,Metabolism/PK,P value  0.0001,East Asian,CYP2C9*3,research
zafirlukast,Metabolism/PK,P value  0.0001,East Asian,CYP2C9*13,research
risperidone,Efficacy,P value  0.004,East Asian,rs2857657,research
tacrolimus,Metabolism/PK,P value  0.001,"Multiple groups, The majority of donors were Asian, the majority of recipients were Caucasian.",rs776746,research
tacrolimus,Dosage,P value  0.001,"Multiple groups, The majority of donors were Asian, the majority of recipients were Caucasian.",rs776746,research
zafirlukast,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
zafirlukast,Metabolism/PK,P value  0.001,East Asian,CYP2C9*3,research
zafirlukast,Metabolism/PK,P value  0.001,East Asian,CYP2C9*13,research
daclatasvir,Metabolism/PK,P value  0.01,Unknown,rs11568820,research
mercaptopurine,Metabolism/PK,P value  3.0E-4,Multiple groups,rs1127354,research
mercaptopurine,Metabolism/PK,P value  0.0057,Multiple groups,rs1127354,research
corticosteroids,Efficacy,P value  0.0021,Unknown,rs1042713,research
risperidone,Efficacy,P value  1.66E-4,East Asian,rs4795893,research
risperidone,Efficacy,P value  0.001,East Asian,rs4795893,research
risperidone,Efficacy,P value  0.002,East Asian,rs4795893,research
risperidone,Efficacy,P value  0.001,East Asian,rs4586,research
risperidone,Efficacy,P value  0.007,East Asian,rs4586,research
hydroxybupropion,Metabolism/PK,P value  0.003,European,CYP2B6*1,research
hydroxybupropion,Metabolism/PK,P value  0.003,European,CYP2B6*6,research
warfarin,Dosage,P value  7.7e-3,Unknown,rs2108622,research
warfarin,Dosage,P value  2.05e-30,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  2.05e-30,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  2.05e-30,Unknown,CYP2C9*3,research
lithium,Efficacy,P value  0.0025,European,rs6438552,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Unknown,CYP2C9*3,research
peginterferon alfa-2a,Efficacy,P value  0.01,European,rs8099917,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
peginterferon alfa-2a,Efficacy,P value  0.01,European,rs11322783,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*1,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*4,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*5,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*6,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*18,research
bupropion,Metabolism/PK,P value  0.001,African American/Afro-Caribbean,CYP2B6*22,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*1,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*4,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*5,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*6,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*18,research
bupropion,Metabolism/PK,P value  0.01,African American/Afro-Caribbean,CYP2B6*22,research
corticosteroids,Dosage,P value  0.002,European,rs28364072,research
aripiprazole,Metabolism/PK,P value  0.01,European,CYP2D6 intermediate metabolizer phenotype,research
aripiprazole,Metabolism/PK,P value  0.01,European,CYP2D6 intermediate metabolizer phenotype,research
fenofibrate,Efficacy,P value  0.004,European,rs4238001,research
fenofibrate,Efficacy,P value  0.01,European,rs4238001,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
warfarin,Dosage,P value  0.0041,African American/Afro-Caribbean,rs61162043,research
calcium channel blockers,Efficacy,P value  0.0001,East Asian,rs588076,research
risperidone,Metabolism/PK,P value  0.01,European,CYP2D6 intermediate metabolizer phenotype,research
peginterferon alfa-2b,Efficacy,P value  0.005,Unknown,rs1049174,research
candesartan,Efficacy,P value  0.005,European,rs5186,research
Platinum compounds,Efficacy,P value  0.008,East Asian,rs25487,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*2,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
risperidone,Efficacy,P value  0.006,East Asian,rs4483927,research
risperidone,Efficacy,P value  0.007,East Asian,rs4483927,research
risperidone,Efficacy,P value  0.007,East Asian,rs4483927,research
methadone,Efficacy,P value  0.0024,European,rs2760118,research
efavirenz,Metabolism/PK,P value  0.001,"Multiple groups, 90% Caucasian, Italy",rs3745274,research
carbamazepine,Efficacy,P value  0.007,East Asian,rs2273697,research
carbamazepine,Efficacy,P value  0.001,East Asian,rs3812718,research
tacrolimus,Dosage,P value  0.01,African American/Afro-Caribbean,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,African American/Afro-Caribbean,CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,African American/Afro-Caribbean,CYP3A5*6,research
calcium channel blockers,Efficacy,P value  0.0001,East Asian,rs10898815,research
sibutramine,Efficacy,P value  0.004,Unknown,rs5443,research
sibutramine,Efficacy,P value  0.01,Unknown,rs5443,research
calcium channel blockers,Efficacy,P value  0.0001,East Asian,rs2429427,research
omeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*1,research
omeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*2,research
omeprazole,Metabolism/PK,P value  0.01,East Asian,CYP2C19*3,research
carbamazepine,Efficacy,P value  0.002,East Asian,rs3812718,research
warfarin,Dosage,P value  7.26e-64,"Multiple groups, mostly Caucasians",rs9923231,research
warfarin,Dosage,P value  0.001,Unknown,rs1057910,research
warfarin,Dosage,P value  0.004,East Asian,rs9923231,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs1799853,research
warfarin,Dosage,P value  2.0E-4,European,rs1057910,research
warfarin,Dosage,P value  9.7E-5,European,rs4917639,research
warfarin,Dosage,P value  3.84E-7,East Asian,rs10509680,research
warfarin,Dosage,P value  0.004,Multiple groups,rs9934438,research
efavirenz,Metabolism/PK,P value  0.0045,Multiple groups,CYP2B6*1,research
efavirenz,Metabolism/PK,P value  0.0045,Multiple groups,CYP2B6*18,research
cotinine,Metabolism/PK,P value  0.004,East Asian,rs10457090,research
mirtazapine,Efficacy,P value  0.007,European,rs1487278,research
warfarin,Dosage,P value  0.01,Near Eastern,rs7412,research
warfarin,Dosage,P value  0.0015,European,rs2884737,research
warfarin,Dosage,P value  1.0E-4,European,rs2359612,research
efavirenz,Metabolism/PK,P value  0.001,Central/South Asian,rs3745274,research
methotrexate,Efficacy,P value  0.008,Central/South Asian,rs1544105,research
lithium,Efficacy,P value  5.45E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs62200793,research
lithium,Efficacy,P value  2.04E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs79403677,research
warfarin,Dosage,P value  0.001,European,rs9923231,research
cortisone acetate,Dosage,P value  0.001,Unknown,CYP3A7*1A,research
cortisone acetate,Dosage,P value  0.001,Unknown,CYP3A7*1C,research
methylphenidate,Metabolism/PK,P value  0.0001,European,rs71647871,research
efavirenz,Metabolism/PK,P value  0.01,Sub-Saharan African,rs3745274,research
warfarin,Dosage,P value  0.0015,European,rs1057910,research
peginterferon alfa-2a,Efficacy,P value  0.0001,Latino,rs8099917,research
peginterferon alfa-2a,Efficacy,P value  0.004,Near Eastern,rs8099917,research
peginterferon alfa-2a,Dosage,P value  9.0E-6,European,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  9.0E-6,European,rs12979860,research
daunorubicin,Metabolism/PK,P value  0.001,Unknown,G6PD A- 202A_376G,research
coumarin,Metabolism/PK,P value  0.001,East Asian,CYP2A6*1A,research
coumarin,Other,P value  0.001,East Asian,CYP2A6*1A,research
coumarin,Metabolism/PK,P value  0.001,East Asian,CYP2A6*4A,research
coumarin,Other,P value  0.001,East Asian,CYP2A6*4A,research
imatinib,Efficacy,P value  0.001,Unknown,rs2725252,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*6A,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*7B,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Efficacy,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Efficacy,P value  0.001,East Asian,CYP2C9*3,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*7B,research
acenocoumarol,Dosage,P value  1.0E-4,European,CYP2C9*3,research
ibuprofen,Metabolism/PK,P value  0.005,Unknown,CYP2C9*3,research
hydrochlorothiazide,Efficacy,P value  7.22E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs10224002,research
acenocoumarol,Dosage,P value  4.0E-4,European,CYP2C9*3,research
acenocoumarol,Dosage,P value  0.0017,European,CYP2C9*3,research
atorvastatin,Efficacy,P value  1.0E-4,European,rs20455,research
atorvastatin,Efficacy,P value  1.0E-4,European,rs20455,research
atorvastatin,Efficacy,P value  0.0045,European,rs20455,research
pitrakinra,Efficacy,P value  0.007,European,rs3024530,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*2,research
losartan,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C9*5,research
losartan,Metabolism/PK,P value  0.01,Sub-Saharan African,CYP2C9*6,research
warfarin,Dosage,P value  0.01,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.01,East Asian,CYP2C9*2,research
warfarin,Dosage,P value  0.01,East Asian,CYP2C9*3,research
glatiramer acetate,Efficacy,P value  0.0056,European,HLA-DRB1*15:01:01:01,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*3,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,NAT2*6A,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*6A,research
nicotine,Efficacy,P value  0.007,"Multiple groups, 74% Caucasian;16% Hispanic;4% African American;6% other.",rs13280604,research
nicotine,Other,P value  0.007,"Multiple groups, 74% Caucasian;16% Hispanic;4% African American;6% other.",rs13280604,research
candesartan,Efficacy,P value  0.005,Unknown,rs1799998,research
gemcitabine,Efficacy,P value  0.001,East Asian,rs11854484,research
antidepressants,Efficacy,P value  0.006,Multiple groups,rs6265,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*17,research
Beta Blocking Agents,Efficacy,P value  0.002,East Asian,rs36217263,research
sumatriptan,Metabolism/PK,P value  3.1e-4,Unknown,rs34130495,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,rs9332131,research
fenoterol,Metabolism/PK,P value  4e-6,Unknown,rs34130495,research
methadone,Dosage,P value  0.001,East Asian,rs769404,research
warfarin,Dosage,P value  0.005,European,rs2108622,research
caffeine,Metabolism/PK,P value  1.0E-4,European,NAT2*4,research
phenprocoumon,Dosage,P value  0.001,European,CYP2C9*3,research
phenprocoumon,Toxicity,P value  0.001,European,CYP2C9*3,research
phenprocoumon,Metabolism/PK,P value  0.005,European,CYP2C9*3,research
warfarin,Metabolism/PK,P value  0.001,European,rs7294,research
warfarin,Dosage,P value  0.001,European,rs7294,research
atorvastatin,Efficacy,P value  0.0,East Asian,CYP3A4*1,research
warfarin,Metabolism/PK,P value  0.001,European,rs9934438,research
warfarin,Dosage,P value  0.001,European,rs9934438,research
duloxetine,Efficacy,P value  5E-5,European,rs17786394,research
duloxetine,Efficacy,P value  5E-5,European,rs17786412,research
diazepam,Metabolism/PK,P value  0.001,East Asian,CYP2C19*1,research
diazepam,Other,P value  0.001,East Asian,CYP2C19*1,research
diazepam,Metabolism/PK,P value  0.001,East Asian,CYP2C19*2,research
diazepam,Other,P value  0.001,East Asian,CYP2C19*2,research
diazepam,Metabolism/PK,P value  0.001,East Asian,CYP2C19*3,research
diazepam,Other,P value  0.001,East Asian,CYP2C19*3,research
fluorouracil,Efficacy,P value  0.01,Unknown,rs25487,research
peginterferon alfa-2b,Efficacy,P value  9.25E-9,Multiple groups,rs8099917,research
fluoxetine,Efficacy,P value  1.0E-4,East Asian,rs57098334,research
ibuprofen,Metabolism/PK,P value  0.001,European,CYP2C9*3,research
ibuprofen,Metabolism/PK,P value  0.001,European,CYP2C9*3,research
ibuprofen,Metabolism/PK,P value  0.001,European,CYP2C9*3,research
catecholamines,Metabolism/PK,P value  0.001,Unknown,rs8187725,research
catecholamines,Other,P value  0.001,Unknown,rs8187725,research
phenytoin,Metabolism/PK,P value  0.001,Unknown,rs4244285,research
phenytoin,Other,P value  0.001,Unknown,rs4244285,research
peginterferon alfa-2a,Efficacy,P value  0.0024,East Asian,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.0083,East Asian,rs12979860,research
thioguanosine diphosphate,Metabolism/PK,P value  0.001,East Asian,TPMT poor metabolizer,research
valproic acid,Metabolism/PK,P value  0.0055,East Asian,CYP2A6*1A,research
valproic acid,Metabolism/PK,P value  0.0055,East Asian,CYP2A6*4A,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*1,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*3,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*1,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*2,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*1,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*2,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*3,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs5009910,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*9A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*9A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*4A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*4A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*1A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*4A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*4A,research
caffeine,Metabolism/PK,P value  0.01,Unknown,CYP2A6*9A,research
caffeine,Other,P value  0.01,Unknown,CYP2A6*9A,research
warfarin,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Metabolism/PK,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
lithium,Efficacy,P value  4.63E-3,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs324899,research
lithium,Efficacy,P value  2.65E-4,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs3919583,research
lithium,Efficacy,P value  3.92E-4,"Multiple groups, 2366 patients were of European descent. The remaining 220 patients were of Asian descent",rs1521470,research
risperidone,Efficacy,P value  2.05E-4,European,rs1869295,research
perphenazine,Efficacy,P value  7.72E-6,European,rs11774231,research
perphenazine,Efficacy,P value  2.25E-5,European,rs17570753,research
ziprasidone,Efficacy,P value  1.3E-4,European,rs1546519,research
olanzapine,Efficacy,P value  2.43E-4,European,rs3819811,research
olanzapine,Efficacy,P value  1.66E-4,European,rs17070785,research
rosuvastatin,Metabolism/PK,P value  0.006,Sub-Saharan African,rs17216177,research
warfarin,Dosage,P value  0.005,"Multiple groups, 89.2% White, 9.8% Black, 1% Hispanic",CYP2C9*1,research
duloxetine,Efficacy,P value  5E-5,European,rs3889402,research
atomoxetine,Metabolism/PK,P value  0.001,East Asian,CYP2C19 poor metabolizers,research
modafinil,Efficacy,P value  0.01,Latino,rs4680,research
nortriptyline,Efficacy,P value  0.0082,European,rs17060812,research
fluvastatin,Metabolism/PK,P value  0.00213,European,CYP2C9*1,research
fluvastatin,Metabolism/PK,P value  0.00213,European,CYP2C9*2,research
warfarin,Dosage,P value  0.002,East Asian,rs17650,research
repaglinide,Efficacy,P value  0.001,East Asian,rs2237895,research
mirtazapine,Metabolism/PK,P value  0.01,Unknown,CYP2B6*6,research
isoniazid,Metabolism/PK,P value  0.001,East Asian,rs4646244,research
isoniazid,Toxicity,P value  0.001,East Asian,rs4646244,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*5B,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*4,research
sulfapyridine,Metabolism/PK,P value  0.001,East Asian,NAT2*7B,research
capecitabine,Efficacy,P value  3.0E-4,East Asian,rs1048943,research
warfarin,Dosage,P value  0.01,Near Eastern,rs429358,research
warfarin,Dosage,P value  4.0E-4,Near Eastern,rs7900194,research
antipsychotics,Metabolism/PK,P value  0.0093,Central/South Asian,rs2032582,research
antipsychotics,Dosage,P value  0.0093,Central/South Asian,rs2032582,research
warfarin,Dosage,P value  0.001,East Asian,rs7294,research
peginterferon alfa-2b,Efficacy,P value  0.001,East Asian,rs12979860,research
warfarin,Dosage,P value  0.01,Near Eastern,rs9923231,research
nicotine,Metabolism/PK,P value  4.7E-5,European,rs1051730,research
tacrolimus,Dosage,P value  1.27E-10,Multiple groups,rs15524,research
acenocoumarol,Dosage,P value  0.0011,Near Eastern,CYP2C9*1,research
isoniazid,Metabolism/PK,P value  1.6E-4,East Asian,NAT2*4,research
isoniazid,Metabolism/PK,P value  4.2E-4,East Asian,NAT2*4,research
ibuprofen,Metabolism/PK,P value  0.001,European,CYP2C8*3,research
ibuprofen,Metabolism/PK,P value  0.001,European,CYP2C8*3,research
ibuprofen,Metabolism/PK,P value  0.002,European,CYP2C8*3,research
atenolol,Efficacy,P value  5.32E-5,"Multiple groups, See Figure 1A for genetic ancestry data",rs8068318,research
acenocoumarol,Dosage,P value  0.0023,Near Eastern,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.001,Central/South Asian,CYP2C9*2,research
warfarin,Dosage,P value  1.0E-4,European,CYP2C9*3,research
peginterferon alfa-2a,Efficacy,P value  1.0E-4,European,rs12979860,research
phenprocoumon,Metabolism/PK,P value  0.001,European,CYP2C9*3,research
phenprocoumon,Dosage,P value  0.001,European,CYP2C9*3,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*3,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*3,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*3,research
lovastatin,Efficacy,P value  0.00339,European,rs2291073,research
phenprocoumon,Metabolism/PK,P value  0.005,European,CYP2C9*2,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
tacrolimus,Metabolism/PK,P value  0.01,East Asian,rs776746,research
warfarin,Dosage,P value  1.0E-4,European,rs8050894,research
peginterferon alfa-2b,Efficacy,P value  0.00003,European,rs11881222,research
simvastatin,Efficacy,P value  0.0015,Unknown,CYP3A4*1,research
simvastatin,Efficacy,P value  0.0015,Unknown,CYP3A4*4,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*13,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.001,East Asian,CYP2C9*13,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*13,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*13,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
losartan,Metabolism/PK,P value  0.01,East Asian,CYP2C9*13,research
peginterferon alfa-2b,Efficacy,P value  1.48E-17,European,rs8099917,research
phenprocoumon,Metabolism/PK,P value  0.001,European,CYP2C9*2,research
phenprocoumon,Dosage,P value  0.001,European,CYP2C9*2,research
nateglinide,Metabolism/PK,P value  0.003,East Asian,CYP2C9*1,research
nateglinide,Metabolism/PK,P value  0.003,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  4.0E-4,Near Eastern,rs56165452,research
phenprocoumon,Dosage,P value  4.0E-4,European,CYP2C9*2,research
phenprocoumon,Dosage,P value  0.0017,European,CYP2C9*2,research
risperidone,Metabolism/PK,P value  0.004,East Asian,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.004,East Asian,CYP2D6*10,research
risperidone,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
risperidone,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
atenolol,Efficacy,P value  0.001,European,rs2301339,research
atenolol,Efficacy,P value  0.003,European,rs2301339,research
lansoprazole,Efficacy,P value  0.006,East Asian,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.006,East Asian,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.006,East Asian,CYP2C19*3,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,CYP2D6*4,research
morphine,Efficacy,P value  4.89E-5,European,rs1045642,research
fluorouracil,Efficacy,P value  6.32E-8,Unknown,rs2293347,research
atenolol,Efficacy,P value  0.007,European,rs5370,research
fenofibrate,Efficacy,P value  2.0E-4,European,rs2230808,research
fenofibrate,Efficacy,P value  0.004,European,rs2230808,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,CYP2D6*10,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,CYP2D6*1,research
carvedilol,Metabolism/PK,P value  0.001,East Asian,CYP2D6*5,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*2,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*2,research
carvedilol,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs776746,research
tacrolimus,Dosage,P value  0.01,European,rs776746,research
tacrolimus,Metabolism/PK,P value  0.003,European,rs776746,research
mephenytoin,Metabolism/PK,P value  1.0E-4,European,CYP2C19*1,research
mephenytoin,Metabolism/PK,P value  1.0E-4,European,CYP2C19*2,research
mephenytoin,Metabolism/PK,P value  1.0E-4,European,CYP2C19*3,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*1,research
lornoxicam,Metabolism/PK,P value  0.01,East Asian,CYP2C9*3,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,rs776746,research
lansoprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*1,research
lansoprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*2,research
lansoprazole,Efficacy,P value  0.001,Multiple groups,CYP2C19*3,research
warfarin,Dosage,P value  0.001,European,rs1057910,research
warfarin,Efficacy,P value  0.001,European,rs1057910,research
esomeprazole,Efficacy,P value  0.007,European,CYP2C19*1,research
esomeprazole,Efficacy,P value  0.007,European,CYP2C19*2,research
tramadol,Metabolism/PK,P value  0.001,European,CYP2D6*1,research
tramadol,Metabolism/PK,P value  0.001,European,CYP2D6*3,research
tramadol,Metabolism/PK,P value  0.001,European,CYP2D6*4,research
tolterodine,Metabolism/PK,P value  0.001,Unknown,CYP2D6 poor metabolizers,research
imipramine,Metabolism/PK,P value  0.01,East Asian,CYP2C19 poor metabolizers,research
omeprazole,Efficacy,P value  0.0005,Multiple groups,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0005,Multiple groups,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0005,Multiple groups,CYP2C19*3,research
lovastatin,Metabolism/PK,P value  0.01,East Asian,CYP2D6*1,research
lovastatin,Metabolism/PK,P value  0.01,East Asian,CYP2D6*5,research
lovastatin,Metabolism/PK,P value  0.01,East Asian,CYP2D6*10,research
methadone,Dosage,P value  0.001,East Asian,rs3749034,research
lamotrigine,Metabolism/PK,P value  0.000,East Asian,rs2011425,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.001,"Multiple groups, 84.4% Caucasian;9.8% African ancestry;2.9% Asian;2.9% other.",CYP2C9*1,research
warfarin,Dosage,P value  0.001,"Multiple groups, 84.4% Caucasian;9.8% African ancestry;2.9% Asian;2.9% other.",CYP2C9*2,research
metformin,Metabolism/PK,P value  0.005,East Asian,rs316019,research
metformin,Metabolism/PK,P value  0.007,East Asian,rs316019,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*2,research
warfarin,Dosage,P value  0.0001,European,CYP2C9*3,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*1,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*2,research
omeprazole,Efficacy,P value  0.0001,Multiple groups,CYP2C19*3,research
bupropion,Metabolism/PK,P value  0.007,European,CYP2B6*1,research
bupropion,Metabolism/PK,P value  0.007,European,CYP2B6*22,research
nifedipine,Metabolism/PK,P value  0.000095,"Multiple groups, African American (n=4), Caucasian (n=7), Hispanic (n=2)",rs776746,research
nifedipine,Metabolism/PK,P value  0.002,"Multiple groups, African American (n=4), Caucasian (n=7), Hispanic (n=2)",rs776746,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.01,European,CYP2C19*2,research
tacrolimus,Metabolism/PK,P value  0.01,European,rs776746,research
tacrolimus,Dosage,P value  0.01,European,rs776746,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*1,research
warfarin,Dosage,P value  0.001,East Asian,CYP2C9*3,research
warfarin,Dosage,P value  0.009,East Asian,rs4645943,research
fluoxetine,Efficacy,P value  0.007,East Asian,SLC6A4 HTTLPR long form (L allele),research
fluoxetine,Efficacy,P value  0.007,East Asian,SLC6A4 HTTLPR short form (S allele),research
escitalopram,Metabolism/PK,P value  0.002,Unknown,CYP2C19 poor metabolizers,research
escitalopram,Metabolism/PK,P value  0.0026,Unknown,CYP2C19 poor metabolizers,research
escitalopram,Metabolism/PK,P value  0.0046,Unknown,CYP2C19 poor metabolizers,research
escitalopram,Metabolism/PK,P value  0.0046,Unknown,CYP2C19 poor metabolizers,research
cisplatin,Efficacy,P value  0.007,East Asian,rs720106,research
interferon beta-1a,Efficacy,P value  5.83E-5,Unknown,rs10819043,research
interferon beta-1a,Efficacy,P value  2.54E-4,European,rs10819043,research
hydralazine,Metabolism/PK,P value  0.001,Unknown,NAT2 slow acetylator,research
efavirenz,Metabolism/PK,P value  0.0001,Sub-Saharan African,rs3745274,research
pridopidine,Metabolism/PK,P value  0.001,European,CYP2D6 poor metabolizers,research
pridopidine,Metabolism/PK,P value  0.001,European,CYP2D6 poor metabolizers,research
pridopidine,Metabolism/PK,P value  0.001,European,CYP2D6 poor metabolizers,research
pridopidine,Metabolism/PK,P value  0.001,European,CYP2D6 poor metabolizers,research
antidepressants,Efficacy,P value  0.01,"Multiple groups, 95% Caucasian",rs8136867,research
warfarin,Dosage,P value  0.008,European,CYP2C9*1,research
warfarin,Dosage,P value  0.008,European,CYP2C9*2,research
clopidogrel,Efficacy,P value  0.0003,"Multiple groups, mostly Caucasian.  Individual studies were conducted in Europe or North America.",CYP2C19*1,research
clopidogrel,Efficacy,P value  0.0003,"Multiple groups, mostly Caucasian.  Individual studies were conducted in Europe or North America.",CYP2C19*17,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Toxicity,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Toxicity,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
clopidogrel,Toxicity,P value  0.001,East Asian,CYP2C19*3,research
pioglitazone,Metabolism/PK,P value  0.002,Unknown,CYP2C8*1,research
pioglitazone,Metabolism/PK,P value  0.002,Unknown,CYP2C8*3,research
flupenthixol,Efficacy,P value  1.75E-5,"Multiple groups, 82 South African Colored (SAC), 13 Xhosa and eight Caucasian individuals",rs3774959,research
flupenthixol,Efficacy,P value  8.38E-5,"Multiple groups, 82 South African Colored (SAC), 13 Xhosa and eight Caucasian individuals",rs3774959,research
azathioprine,Metabolism/PK,P value  0.001,Unknown,TPMT low activity,research
warfarin,Dosage,P value  3.93E-5,African American/Afro-Caribbean,rs7856096,research
repaglinide,Metabolism/PK,P value  0.0009,East Asian,rs3814058,research
sunitinib,Metabolism/PK,P value  0.01,"Multiple groups, Mostly white",CYP3A4*1,research
sunitinib,Metabolism/PK,P value  0.01,"Multiple groups, Mostly white",CYP3A4*22,research
sunitinib,Metabolism/PK,P value  0.01,"Multiple groups, Mostly white",rs776746,research
lamotrigine,Efficacy,P value  0.001,East Asian,rs2011425,research
telmisartan,Efficacy,P value  0.009,East Asian,rs5443,research
carboplatin,Efficacy,P value  0.002,Unknown,rs11623866,research
carboplatin,Efficacy,P value  0.006,Unknown,rs11623866,research
acenocoumarol,Dosage,P value  0.001,European,rs7200749,research
acenocoumarol,Dosage,P value  0.004,European,rs61742245,research
acenocoumarol,Dosage,P value  0.002,European,rs17878544,research
methadone,Metabolism/PK,P value  1.0E-4,East Asian,rs1045642,research
methadone,Dosage,P value  1.0E-4,East Asian,rs1045642,research
itopride,Metabolism/PK,P value  0.001,East Asian,rs2266782,research
losartan,Efficacy,P value  0.0001,East Asian,rs1529909,research
cotinine,Metabolism/PK,P value  0.006,East Asian,rs3778152,research
antiepileptics,Efficacy,P value  0.001,Central/South Asian,rs1045642,research
antiepileptics,Efficacy,P value  0.001,Central/South Asian,rs1045642,research
aspirin,Efficacy,P value  0.001,Unknown,CYP2C19*1,research
aspirin,Efficacy,P value  0.001,Unknown,CYP2C19*2,research
peginterferon alfa-2b,Efficacy,P value  5.34E-4,Multiple groups,rs7512595,research
peginterferon alfa-2b,Efficacy,P value  3.98E-5,Multiple groups,rs6806020,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*1,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*2,research
clopidogrel,Efficacy,P value  0.001,East Asian,CYP2C19*3,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*3,research
clopidogrel,Metabolism/PK,P value  0.009,European,rs71647871,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0001,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0004,Multiple groups,CYP2D6 intermediate metabolizers,research
endoxifen,Metabolism/PK,P value  0.0016,Multiple groups,CYP2D6 intermediate metabolizers,research
acenocoumarol,Dosage,P value  0.001,European,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.001,European,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.005,African American/Afro-Caribbean,rs2359612,research
warfarin,Dosage,P value  0.01,European,rs2359612,research
epirubicin,Efficacy,P value  0.005,East Asian,rs1800566,research
interferon alfa-2a,Efficacy,P value  0.0001,European,rs8099917,research
peginterferon alfa-2a,Efficacy,P value  0.006,Unknown,rs12979860,research
peginterferon alfa-2a,Efficacy,P value  0.01,Unknown,rs12979860,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*1,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*5,research
4-hydroxytamoxifen,Metabolism/PK,P value  0.0001,East Asian,CYP2D6*10,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*3,research
warfarin,Metabolism/PK,P value  0.01,European,CYP2C19*1,research
warfarin,Metabolism/PK,P value  0.01,European,CYP2C19*2,research
warfarin,Metabolism/PK,P value  0.01,European,CYP2C19*17,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*2,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*2,research
SN-38,Metabolism/PK,P value  0.01,"Multiple groups, White, Black, Hispanic",UGT1A1*1,research
SN-38,Metabolism/PK,P value  0.01,"Multiple groups, White, Black, Hispanic",UGT1A1*28,research
sunitinib,Efficacy,P value  0.005,"Multiple groups, Chinese, Indian, Malay",rs1045642,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.001,Multiple groups,CYP2C9*3,research
warfarin,Dosage,P value  0.001,European,CYP2C9*1,research
warfarin,Dosage,P value  0.001,European,CYP2C9*3,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,CYP2C9*1,research
warfarin,Dosage,P value  0.001,African American/Afro-Caribbean,CYP2C9*3,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*2,research
acenocoumarol,Dosage,P value  0.001,Unknown,CYP2C9*3,research
acenocoumarol,Dosage,P value  0.001,Unknown,rs2108622,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*1,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*2,research
warfarin,Dosage,P value  0.0001,Unknown,CYP2C9*3,research
peginterferon alfa-2a,Efficacy,P value  0.0001,Latino,rs12980275,research
voriconazole,Metabolism/PK,P value  0.0029,"Multiple groups, White, Latino, African American, Asian",CYP2C19*1,research
voriconazole,Metabolism/PK,P value  0.0029,"Multiple groups, White, Latino, African American, Asian",CYP2C19*2,research
peginterferon alfa-2a,Efficacy,P value  0.009,East Asian,rs8103142,research
warfarin,Dosage,P value  0.008,European,rs7294,research
belinostat,Metabolism/PK,P value  0.003,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*1,research
belinostat,Metabolism/PK,P value  0.003,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*60,research
belinostat,Metabolism/PK,P value  0.0037,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*1,research
belinostat,Metabolism/PK,P value  0.0037,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*60,research
belinostat,Metabolism/PK,P value  0.0017,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*1,research
belinostat,Metabolism/PK,P value  0.0017,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*60,research
belinostat,Metabolism/PK,P value  0.0077,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*1,research
belinostat,Metabolism/PK,P value  0.0077,"Multiple groups, White, African American, Hispanic, Asian",UGT1A1*60,research
doxepin,Metabolism/PK,P value  0.009,European,CYP2C19*1,research
doxepin,Metabolism/PK,P value  0.009,European,CYP2C19*2,research
doxepin,Metabolism/PK,P value  0.009,European,CYP2C19*1,research
doxepin,Metabolism/PK,P value  0.009,European,CYP2C19*2,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*1,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*2,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*3,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*4,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*5,research
nortriptyline,Metabolism/PK,P value  0.005,"Multiple groups, mostly White",CYP2D6*10,research
boceprevir,Efficacy,P value  4.7e-4,European,rs11322783,research
warfarin,Dosage,P value  0.01,European,CYP2C9*1,research
warfarin,Dosage,P value  0.01,European,CYP2C9*2,research
warfarin,Dosage,P value  0.01,European,CYP2C9*3,research
warfarin,Dosage,P value  0.01,European,CYP2C9*5,research
warfarin,Dosage,P value  0.01,European,CYP2C9*6,research
warfarin,Dosage,P value  0.01,European,CYP2C9*11,research
irbesartan,Metabolism/PK,P value  0.001,East Asian,rs72558187,research
irbesartan,Metabolism/PK,P value  0.01,East Asian,rs72558187,research
warfarin,Dosage,P value  0.01,Multiple groups,CYP2C9*1,research
warfarin,Dosage,P value  0.01,Multiple groups,CYP2C9*2,research
warfarin,Dosage,P value  0.01,Multiple groups,CYP2C9*3,research
warfarin,Dosage,P value  0.01,European,CYP2C9*1,research
warfarin,Dosage,P value  0.01,European,CYP2C9*2,research
warfarin,Dosage,P value  0.01,European,CYP2C9*3,research
duloxetine,Efficacy,P value  5E-5,European,rs7035619,research
warfarin,Dosage,P value  0.0001,East Asian,rs2359612,research
capecitabine,Dosage,P value  0.005,Unknown,rs67376798,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.003,Multiple groups,rs1799724,research
hmg coa reductase inhibitors,Efficacy,P value  0.001,European,rs4149056,research
imatinib,Dosage,P value  0.001,Unknown,rs762551,research
imatinib,Dosage,P value  0.002,Unknown,rs762551,research
hdl cholesterol,Other,P value  0.00046,Unknown,rs2289105,research
perindopril,Efficacy,P value  0.001,European,rs5182,research
carboplatin,Efficacy,P value  1.51E-3,Unknown,rs2229046,research
antidepressants,Efficacy,P value  0.002327,East Asian,rs2831440,research
Platinum compounds,Efficacy,P value  0.009,Multiple groups,rs861539,research
adalimumab,Efficacy,P value  1.55E-3,Unknown,rs9373839,research
fluorouracil,Metabolism/PK,P value  0.01,"Multiple groups, Malay, Chinese, Indian",rs17376848,research
hydroxyurea,Efficacy,P value  0.01,Near Eastern,rs1427407,research
sorafenib,Metabolism/PK,P value  0.007,Unknown,rs2231142,research
efavirenz,Metabolism/PK,P value  0.01,Unknown,rs3745274,research
imatinib,Metabolism/PK,P value  0.001,Central/South Asian,rs1045642,research
etanercept,Efficacy,P value  0.009,Unknown,rs96844,research
cyclosporine,Metabolism/PK,P value  0.005,East Asian,rs4646437,research
venlafaxine,Efficacy,P value  0.009,"Multiple groups, 88.9% European, 9.4% African American, 1.4% Asian, 0.3% admixed",rs2242446,research
valproic acid,Dosage,P value  0.01,Unknown,CYP2C9*1,research
valproic acid,Dosage,P value  0.01,Unknown,CYP2C9*2,research
valproic acid,Dosage,P value  0.01,Unknown,CYP2C9*3,research
nicotine,Metabolism/PK,P value  1.47E-39,African American/Afro-Caribbean,rs12459249,research
antiepileptics,Efficacy,P value  0.000046,Central/South Asian,rs2606345,research
glucose,Other,P value  0.001,European,rs1000940,research
allopurinol,Dosage,P value  0.007,"Multiple groups, 22 African American, 2 Asian, 77 Caucasian, 1 Pacific Islander",rs34650714,research
efavirenz,Metabolism/PK,P value  0.01,Multiple groups,CYP2B6*1,research
efavirenz,Metabolism/PK,P value  0.01,Multiple groups,CYP2B6*6,research
efavirenz,Metabolism/PK,P value  0.001,Unknown,rs28399499,research
olanzapine,Metabolism/PK,P value  0.009,European,rs35694136,research
carfilzomib,Efficacy,P value  0.007,Unknown,rs2305948,research
acenocoumarol,Dosage,P value  0.004,Near Eastern,CYP2C9*1,research
acenocoumarol,Dosage,P value  0.004,Near Eastern,CYP2C9*2,research
tacrolimus,Metabolism/PK,P value  3.46E-38,European,rs4646450,research
tacrolimus,Metabolism/PK,P value  4.91E-07,African American/Afro-Caribbean,rs4646450,research
rosuvastatin,Metabolism/PK,P value  0.003,Sub-Saharan African,rs2287622,research
metformin,Efficacy,P value  4e-8,Multiple groups,rs57081354,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A4*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A4*18,research
duloxetine,Efficacy,P value  5E-5,European,rs2419128,research
morphine,Dosage,P value  0.0091,"Multiple groups, Participants were of Hispanic, African American, Caucasian and other ethnicities",CYP2D6 ultrarapid metabolizer phenotype,research
morphine,Efficacy,P value  0.0091,"Multiple groups, Participants were of Hispanic, African American, Caucasian and other ethnicities",CYP2D6 ultrarapid metabolizer phenotype,research
warfarin,Metabolism/PK,P value  0.001,European,rs9923231,research
warfarin,Metabolism/PK,P value  0.001,European,rs9923231,research
duloxetine,Efficacy,P value  5E-5,European,rs4858478,research
conjugated estrogens,Metabolism/PK,P value  0.008,Unknown,rs4149056,research
conjugated estrogens,Metabolism/PK,P value  0.010,Unknown,rs4149056,research
duloxetine,Efficacy,P value  5E-5,European,rs17786400,research
duloxetine,Efficacy,P value  5E-5,European,rs61908404,research
duloxetine,Efficacy,P value  5E-5,European,rs61908405,research
duloxetine,Efficacy,P value  5E-5,European,rs10771999,research
warfarin,Dosage,P value  0.004,Near Eastern,rs9923231,research
cyclophosphamide,Efficacy,P value  0.001,Central/South Asian,rs6151031,research
warfarin,Dosage,P value  0.0025,European,rs11168293,research
rosuvastatin,Metabolism/PK,P value  0.007,Sub-Saharan African,rs56903885,research
warfarin,Dosage,P value  4.1E-36,European,CYP2C9 normal metabolizers,research
warfarin,Dosage,P value  4.63E-72,European,VKORC1 low activity,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs11045873,research
rosuvastatin,Metabolism/PK,P value  0.002,Sub-Saharan African,rs11045874,research
ustekinumab,Efficacy,P value  0.0051,Unknown,rs8177374,research
fentanyl,Dosage,P value  0.00001,Unknown,CYP3A4*1,research
fentanyl,Dosage,P value  0.00001,Unknown,CYP3A4*1G,research
aspirin,Efficacy,P value  0.00001,"Multiple groups, European, African American and East Asian ancestries",rs2768759,research
aspirin,Efficacy,P value  0.0001,"Multiple groups, European, African American and East Asian ancestries",rs2768759,research
aspirin,Efficacy,P value  0.0002,"Multiple groups, European, African American and East Asian ancestries",rs2768759,research
grazoprevir,PD,P value  0.0001,"Multiple groups, This is a retrospective pharmacogenetic analysis of a pooled dataset of selected HCV GT1- or GT4-infected participants enrolled in ten Phase II/III clinical trials of EBR/GZR: C-WORTHY (MSD Protocol, 5172-035; ClinicalTrials. gov identifier NCT01717326), C-SCAPE (5172-047; NCT01932762), C-SALVAGE (5172-048; NCT02105454), C-SURFER (5172-052; NCT02092350), Japan Phase II/III study (5172-058; NCT02203149), C-SALT (5172-059; NCT02115321), C-EDGE Treatment-Naive (5172-060; NCT02105467), C-EDGE CO-INFECTION (5172-061; NCT02105662), C-EDGE CO-STAR (5172-062; NCT02105688), C-EDGE Treatment-Experienced (5172-068; NCT02105701)",rs4149056,research
grazoprevir,PD,P value  0.0002,"Multiple groups, This is a retrospective pharmacogenetic analysis of a pooled dataset of selected HCV GT1- or GT4-infected participants enrolled in ten Phase II/III clinical trials of EBR/GZR: C-WORTHY (MSD Protocol, 5172-035; ClinicalTrials. gov identifier NCT01717326), C-SCAPE (5172-047; NCT01932762), C-SALVAGE (5172-048; NCT02105454), C-SURFER (5172-052; NCT02092350), Japan Phase II/III study (5172-058; NCT02203149), C-SALT (5172-059; NCT02115321), C-EDGE Treatment-Naive (5172-060; NCT02105467), C-EDGE CO-INFECTION (5172-061; NCT02105662), C-EDGE CO-STAR (5172-062; NCT02105688), C-EDGE Treatment-Experienced (5172-068; NCT02105701)",rs4149056,research
rosuvastatin,Metabolism/PK,P value  0.01,Sub-Saharan African,rs3212207,research
tolbutamide,Metabolism/PK,P value  0.01,,rs762081829,research
amiloride,Efficacy,P value  0.008,African American/Afro-Caribbean,rs1126742,research
capecitabine,Dosage,P value  0.0001,Unknown,rs3918290,research
clopidogrel,Efficacy,P value  3.46e-3,East Asian,rs2487032,research
anastrozole,Metabolism/PK,P value  2.3e-8,Unknown,rs11648166,research
morphine,Dosage,P value  0.009,"Multiple groups, Netherlands: 62 Caucasian, 1 Asian",rs4633,research
morphine,Efficacy,P value  0.009,"Multiple groups, Netherlands: 62 Caucasian, 1 Asian",rs4633,research
morphine,Dosage,P value  0.009,"Multiple groups, Netherlands: 62 Caucasian, 1 Asian",rs4680,research
morphine,Efficacy,P value  0.009,"Multiple groups, Netherlands: 62 Caucasian, 1 Asian",rs4680,research
atazanavir,Metabolism/PK,P value  0.003,European,CYP3A5*1,research
atazanavir,Metabolism/PK,P value  0.003,European,CYP3A5*3,research
atazanavir,Metabolism/PK,P value  0.003,European,CYP3A5*6,research
atazanavir,Metabolism/PK,P value  0.003,European,CYP3A5*7,research
clozapine,Dosage,P value  0.0001,Unknown,CYP3A5*1,research
clozapine,Dosage,P value  0.0001,Unknown,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,European,CYP3A5*3,research
tacrolimus,Dosage,P value  0.005,European,CYP3A5*1,research
tacrolimus,Dosage,P value  0.005,European,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.001,European,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,European,CYP3A5*3,research
nimodipine,Efficacy,P value  0.008,Unknown,CYP3A5*1,research
nimodipine,Efficacy,P value  0.008,Unknown,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.0001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.00001,"Multiple groups, Caucasian, Mediterranean, Asian, Black",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.00001,"Multiple groups, Caucasian, Mediterranean, Asian, Black",CYP3A5*3,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*1,research
tacrolimus,Dosage,P value  0.01,East Asian,CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.009,"Multiple groups, 100% Caucasian for *3/*3 patients; 56% for *1/*1 or *1/*3, 44% 'other'.",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.009,"Multiple groups, 100% Caucasian for *3/*3 patients; 56% for *1/*1 or *1/*3, 44% 'other'.",CYP3A5*3,research
tacrolimus,Metabolism/PK,P value  0.002,"Multiple groups, White, Hispanic, Asian/Pacific Islander, Other",CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.002,"Multiple groups, White, Hispanic, Asian/Pacific Islander, Other",CYP3A5*3,research
midazolam,Metabolism/PK,P value  0.001,Unknown,CYP3A5*1,research
midazolam,Metabolism/PK,P value  0.001,Unknown,CYP3A5*3,research
naltrexone,Efficacy,P value  0.01,European,rs1799971,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.0007,Multiple groups,rs1800629,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.002,"Multiple groups, Not stated: studies in Belgium, Switzerland, Denmark, Czech, China and Greece.",rs1800629,research
atenolol,Efficacy,P value  1.79E-4,"Multiple groups, See Figure 1A for genetic ancestry data",rs9306160,research
tacrolimus,Dosage,P value  0.0001,European,CYP3A5*1,research
tacrolimus,Dosage,P value  0.0001,European,CYP3A5*3,research
fentanyl,Metabolism/PK,P value  0.01,Unknown,CYP2D6*1,research
fentanyl,Metabolism/PK,P value  0.01,Unknown,CYP2D6*9,research
warfarin,Dosage,P value  0.0001,East Asian,rs7294,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*1,research
tacrolimus,Metabolism/PK,P value  0.001,East Asian,CYP3A5*3,research
tacrolimus,Dosage,P value  0.002,Near Eastern,CYP3A5*1,research
tacrolimus,Dosage,P value  0.002,Near Eastern,CYP3A5*3,research
atenolol,Efficacy,P value  0.002,European,rs1042713,research
paroxetine,Efficacy,P value  0.005,East Asian,rs2973049,research
ticagrelor,Metabolism/PK,P value  1.32E-14,European,rs62471956,research
tacrolimus,Metabolism/PK,P value  1.18E-09,African American/Afro-Caribbean,rs41303343,research
ataluren,Efficacy,P value  0.0001,Unknown,rs77010898,research
cisplatin,Efficacy,P value  2.4E-5,Unknown,rs7608731,research
capecitabine,Efficacy,P value  0.001,East Asian,rs1042522,research
capecitabine,Efficacy,P value  0.001,East Asian,rs1042522,research
capecitabine,Efficacy,P value  0.001,East Asian,rs1042522,research
ivacaftor,Efficacy,P value  0.001,Unknown,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
ivacaftor,Efficacy,P value  0.001,Multiple groups,rs113993960,research
enalapril,Efficacy,P value  0.002,"Multiple groups, 80% White, remaining unspecified",rs1799752,research
enalapril,Efficacy,P value  0.009,"Multiple groups, 80% White, remaining unspecified",rs1799752,research
anastrozole,Metabolism/PK,P value  5.4e-8,Unknown,rs28845026,research
losartan,Efficacy,P value  0.001,East Asian,rs3825016,research
ara-CTP,Metabolism/PK,P value  0.0025,"Multiple groups, USA St Jude, specified 43 white, 13 black and 12 other.",rs11030918,research
cefotaxime,Metabolism/PK,P value  0.006,Unknown,rs11568482,research
interferons,Efficacy,P value  0.0039,East Asian,rs4796793,research
bevacizumab,Efficacy,P value  0.006,Unknown,rs45445694,research
bevacizumab,Efficacy,P value  0.006,"Multiple groups, Forty-five patients were Caucasian, 3 Asian, 3 African-American and 2 Hispanic",rs4073,research
sildenafil,Efficacy,P value  0.001,"Multiple groups, Brazil approximately half White half non-white",rs1570360,research
sildenafil,Efficacy,P value  0.008,"Multiple groups, Brazil approximately half White half non-white",rs1570360,research
ethanol,Efficacy,P value  0.01,"Multiple groups, The majority of study participants were Caucasian",rs1799971,research
opioids,Dosage,P value  0.003,"Multiple groups, Caucasian and Asian patients",rs1799971,research
opioids,Efficacy,P value  0.003,"Multiple groups, Caucasian and Asian patients",rs1799971,research
opioids,Dosage,P value  0.001,Multiple groups,rs1799971,research
opioids,Efficacy,P value  0.001,Multiple groups,rs1799971,research
opioids,Dosage,P value  0.005,Multiple groups,rs1799971,research
opioids,Efficacy,P value  0.005,Multiple groups,rs1799971,research
ivacaftor,Efficacy,P value  0.0001,"Multiple groups, Majority of patients were Caucasian and not of Hispanic/Latino origin",rs397508453,research
warfarin,Dosage,P value  5e-50,Unknown,rs9923231,research
warfarin,Dosage,P value  0.001,East Asian,rs9923231,research
antiepileptics,Efficacy,P value  0.009,Multiple groups,rs717620,research
lacidipine,Efficacy,P value  2.6E-4,European,rs2238032,research
calcium channel blockers,Efficacy,P value  5.1E-12,European,rs2238032,research
hmg coa reductase inhibitors,Efficacy,P value  1.22e-9,Multiple groups,rs2900478,research
hmg coa reductase inhibitors,Efficacy,P value  2.26e-6,Multiple groups,rs2900478,research
hmg coa reductase inhibitors,Efficacy,P value  3.54e-3,Multiple groups,rs2900478,research
letermovir,Metabolism/PK,P value  0.0057,"Multiple groups, Asian, Black, Other and White ethnicities",rs4149032,research
atazanavir,Dosage,P value  0.001,Unknown,rs4149056,research
fluvastatin,Metabolism/PK,P value  8.15e-8,European,rs4149056,research
Tumor necrosis factor alpha (TNF-alpha) inhibitors,Efficacy,P value  0.000,Unknown,rs6920220,research
trandolapril,Efficacy,P value  3.2e-5,"Multiple groups, USA",rs4742610,research
trandolapril,Efficacy,P value  0.0011,European,rs4742610,research
trandolapril,Efficacy,P value  0.0066,Latino,rs4742610,research
warfarin,Dosage,P value   1.82E-8,African American/Afro-Caribbean,rs7856096,research
buprenorphine,Efficacy,P value  0.006,"Multiple groups, European American - mainly White but some Latino/White.",rs529520,research
benazepril,Efficacy,P value  0.003,East Asian,rs1801131,research
methotrexate,Toxicity,P value  0.004,"Multiple groups, Mixed, Caucasian, Egyptian",rs1801133,research
methotrexate,Toxicity,P value  0.005,"Multiple groups, Caucasian, Egyptian, Mixed",rs1801133,research
Vitamin B-complex,Efficacy,P value  0.001,Unknown,rs1801133,research
fluorouracil,Efficacy,P value  0.006,Central/South Asian,rs1801133,research
warfarin,Dosage,P value  0.001,"Multiple groups, patients at Washington University Medical Center.  79 White;13 African-American.",rs1057910,research
warfarin,Dosage,P value  1.0E-4,Near Eastern,rs1057910,research
irbesartan,Metabolism/PK,P value  0.01,East Asian,rs1057910,research
carvedilol,Efficacy,P value  0.001,Multiple groups,rs1801252,research
metoprolol,Efficacy,P value  0.001,East Asian,rs1801253,research
rosuvastatin,Metabolism/PK,P value  0.01,Sub-Saharan African,rs3740066,research
efavirenz,Metabolism/PK,P value  1.9e-9,Unknown,rs3745274,research
isoniazid,Metabolism/PK,P value  0.005,Sub-Saharan African,rs2472677,research
